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2Abstract
Immune-mediated diseases (IMDs) can give rise to long standing painful
oral mucosal disease which adversely affect oral function and perhaps
lessens quality of life.
The present series of studies, retrospectively determine the clinical
presentation and long-term efficacy and safety of treatment of large
groups of patients with oral lichen planus, mucous membrane
pemphigoid, pemphigus vulgaris and orofacial granulomatosis. These
diseases are some of the challenging disorders to be managed by oral
medicine specialists.
It was found that patients with oral lichen planus (OLP) rarely have extra-
oral manifestations of LP. The symptoms of OLP can generally be
controlled with topical corticosteroids and/or tacrolimus. While tacrolimus
is not notably better than topical corticosteroids for the management of
OLP, it does not seem to increase any risk of malignant transformation.
Adverse side effects are uncommon with topical corticosteroids, while
21% of patients with OLP may have adverse side effects with tacrolimus,
particularly unpleasant taste.
In the present cohort of 49 patients with orofacial granulomatosis (OFG)
the onset of disease was characterised by facial swelling in 50% and the
long-term behaviour of OFG was characterised by the development of
further clinical manifestations with most patients developing orofacial
swelling and/or intra-oral ulceration. The response of OFG to therapy was
typically remitting and although a lessening of soft tissue swelling oral
ulceration could generally be achieved with topical and/or systemic
therapy. Complete remission of facial swelling occurred in 50% of patients
within 3 years of therapy but may be achieved quicker when intra-lesional
corticosteroids are used. Spontaneous remission was rare. Significant
adverse side effects to therapy were rare.
3In a cohort of 62 patients, mucous membrane pemphigoid typically
manifested as recurrent oral mucosal ulceration and/or desquamative
gingivitis and 32.3% patients had some extra-oral involvement.
Treatment generally lessened painful symptoms however gingival lesions
rarely resolved. Adverse side effects affected 50% of patients; however in
the majority of affected individuals these were minor.
In a cohort of 40 patients with pemphigus vulgaris the mouth was often
the initial site of involvement but other mucocutaneous sites could be
affected. Management necessitated topical and systemic therapy.
Adverse side effects occurred in 50% patients and were mainly
associated with systemic immunosuppressive agents (e.g. azathioprine).
The results of this present study indicate that the long-term treatment of
IMDs of the oral mucosal are challenging to both the patients and
clinicians. While many patients do experience an improvement in their
disease status, many do not. The precise impact of IMDs upon the quality
of life of affected individuals remains unclear.
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GENERAL INTRODUCTION
A wide range of disorders can give rise to oral mucosal disease,
particularly infection, malignant disease and immunologically-mediated
diseases. While infections generally give rise to transient oral symptoms
(e.g. painful ulceration) and potentially malignant disease is often
asymptomatic, immunologically-mediated diseases can be symptomatic
and long standing and thus can adversely impact upon a patient’s quality
of life. Some of these disorders are very common (e.g. recurrent
aphthous stomatitis and oral lichen planus) however there seems to be an
increase in the prevalence of other less common diseases such as
orofacial granulomatosis and pemphigus vulgaris.
Immunologically-mediated disorders comprise a group of disorders that
give rise to wide variety of cutaneous and/or oral lesions. The most
common oral mucosal lesions are ulceration/erosions and other clinical
manifestations (e.g. labial swelling of orofacial granulomatosis). Mucous
membrane pemphigoid and pemphigus vulgaris can also give rise to oral
vesicles and bullae, however this may rarely be seen in the mouth as
most break down before the patient is seen by the clinician.
Immunologically-mediated disorders can be difficult to diagnosis and
treat. They may share the similar clinical manifestations (e.g.
desquamative gingivitis and/or oral ulceration) and as a consequence
there may be a delay in the definitive diagnosis.
As noted above many of these disorders seem to be lifelong and can be
distressing to affected individuals and as a result adversely affect quality
of life (Hegarty et al., 2002). Also the disease can have an impact upon
the patient’s family (e.g. worry) and necessitate lifelong care and may
result in the loss of employment time due to attending clinics. Finally the
long-term clinical management could potentially place additional pressure
upon health care resources.
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The chronic nature of these disorders necessitates patients requiring
extended periods of treatment with different potent topical and/or
systemic medication which may be associated with adverse side effects.
Corticosteroids for example can give rise to short- and/or long-term
adverse side effects that, perhaps frustratingly, limit their prescription to
patients with severe or recalcitrant disease and those without controlled
diabetes mellitus or hypertension.
The long-term adverse outcomes of therapy of immunologically-mediated
diseases of the oral mucosa have rarely been reported and existing
reports, for example of oral lichen planus, do not detail the adverse
outcome of therapy (Ingafou et al., 2006). Certainly however the
treatment of immunologically mediated diseases can adversely affect
patients, for example 2 of 55 patients with oral pemphigus vulgaris may
have died as a consequence of adverse effects of therapy (Scully et al.,
1999). There are few systematic reviews of the therapy of
immunologically-mediated diseases and yet perhaps as a consequence
of increased longevity of life and changing attitudes towards medical care,
increasing numbers of patients are referred to oral medicine units for the
treatment of such diseases.
The overall aims of this work is to retrospectively determine the clinical
manifestations of large groups of patients with well defined oral mucosal
diseases; examine the outcome of therapy, and to detect the nature and
frequency of adverse effects of therapy. With such information it may be
possible to establish the optimum and safe treatment of such diseases. It
will also give insight into the likely course of disease and hence provide
patients with a greater understanding of their disease.
The study has focused upon 4 significant immunologically-mediated oral
mucosal disorders: oral lichen planus, orofacial granulomatosis, mucous
membrane pemphigoid and pemphigus vulgaris.
Chapter 1 General introduction
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Lichen planus (Chapter 2) is the most common cutaneous disorder that
can affect the oral mucosa and oral lichen planus (OLP) is one of the
most common chronic immunologically-mediated oral mucosal diseases.
It represents one of the most challenging disorders that oral medicine
physicians have to manage on a regular basis (Mignogna et al., 1998;
Gonzalez-Moles et al., 2003; Mignogna et al., 2005). The aims of this
chapter were to determine: the clinical outcomes of long-term therapy of
OLP and to report the frequency and nature of adverse side effects of
therapy and the malignant transformation rate of OLP.
Orofacial granulomatosis (OFG) (Chapter 3) is a chronic inflammatory
disease with the potential to adversely affect the quality of life of patients
by the persistent labial and/or facial swelling, painful oral ulcerations,
and/or occasional neurological manifestations (Wiesenfeld et al., 1985;
Somech et al., 2001; Leao et al., 2004). The aims of this chapter are to
describe the early and late clinical features and other clinical
characteristics of a large number of patients with OFG together with the
clinical outcomes of long-term therapy and the frequency and nature of
adverse side effects of therapy of OFG.
Mucous membrane pemphigoid (MMP) (Chapter 4) is a rare
mucocutaneous disorder which often affects oral mucosal surfaces. MMP
usually affects people in their middle to late life (Laskaris et al., 1982;
Silverman et al., 1986; Gallagher and Shklar, 1987). The aims of this
chapter are to describe the long-term outcomes of therapy in a
substantial cohort of MMP patients attending single clinical centre in
addition to the frequency and nature of adverse side effects of therapy of
MMP.
Pemphigus vulgaris (PV) (Chapter 4) although uncommon is the most
common and severe form of pemphigus and was considered a fatal
condition before the immunosuppressive therapy era. PV affects all ethnic
groups; however it frequently affects Ashkenazi Jewish (Gazit and
Loewenthal, 2005; Mimouni et al., 2008). It gives rise to vesiculobullous
Chapter 1 General introduction
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lesions of the skin and/or mucous membranes. The overall aims of this
chapter are to describe the long-term outcomes of therapy in a large
cohort of PV patients in addition to the frequency and nature of adverse
side effects of therapy of PV.
Chapter 2 Oral lichen planus
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2.1 INTRODUCTION
Oral lichen planus (OLP) is a common chronic mucocutaneous disorder
of middle to late life affecting approximately 0.1% to 4% of the population
(Scully et al., 1998; Xue et al., 2005) and is found more frequently in
women than men (Eisen, 2002; Mignogna et al., 2005) with a reported
ratio of around 2:1 (Xue et al., 2005) (Table 2.1). In a recent study
conducted to assess frequency of diagnostic biopsies from UK general
dental practitioners, 1.0% of the examined biopsies were lichen planus or
lichenoid reaction (Franklin and Jones, 2006). Although OLP in children is
uncommon (Laeijendecker et al., 2005) it has been reported (Sharma and
Maheshwari, 1999; Alam and Hamburger, 2001; Patel et al., 2005; Xue et
al., 2005) and the prognosis is suggested to be better than in adults
(Laeijendecker et al., 2005).
In contrast to cutaneous LP which is usually self-limiting, oral lichen is a
chronic disease and rarely disappears completely, although it may
change in appearance over time (Thorn et al., 1988; Eisen, 2002). In a
recent study, about 30% of the lesions resolved, but the authors noted
that the disease could re-emerge (Roosaar et al., 2006).
2.1.1 Prevalence of oral lichen planus
Lichen planus (LP) commonly affects the oral mucosa (Mignogna et al.,
1998) and OLP is one of the most common oral mucosal disorders
(Mignogna et al., 2005). It represents one of the principle and most
challenging disorders that oral medicine physicians treat on a regular
basis (Gonzalez-Moles et al., 2003). Many studies have reported the
prevalence and/or incidence of OLP; however, its true prevalence is
unknown as most data are of symptomatic patients referred to hospitals
or specialized dental units. OLP and other extra-oral involvement are
thought to be underreported since many patients are asymptomatic
(Mignogna et al., 1998; Chainani-Wu et al., 2001; Bidarra et al., 2008;
McCartan and Healy, 2008). However a critical review (McCartan and
Healy, 2008) concluded that the true prevalence of OLP is difficult to
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determine from published reports as most are methodologically
inadequate (e.g. lack of diagnostic clinical and histopathological criteria,
absence of histological confirmation and inclusion of lichenoid reactions).
Nevertheless on a day to day basis OLP remains one of the most
common disorders to be managed by specialist in oral medicine in the
world.
2.1.2 Clinical features of oral lichen planus
The clinical presentation of OLP differs from patient to patient and ranges
from asymptomatic reticular lesions (usually not detected by the patient)
to widespread painful erosive or ulcerative mucosal lesions. Six clinical
variants have been described: reticular, papular, plaque, atrophic, erosive
and bullous (Andreasen, 1968). Eisen combined these six types into
three groups; white striae, plaques, and papules representing
asymptomatic reticular type, and two symptomatic groups,
atrophic/erythematous and erosive, including ulcerations and bullae
(Eisen, 2002). Piboonniyom and co-workers (2005) have suggested OLP
be classified into three main variants: reticular/hyperkeratotic,
erosive/erythematous, and ulcerative forms (more details are discussed
below).
It is common to have more than one mucosal site involved at same time
(Ingafou et al., 2006) and it is not unusual to find more than one type in
the same patient where it is can classified according to the most severe
form. Bilateral buccal mucosal involvement is the most common
presentation of OLP followed by disease of the tongue, lower lip, and
gingivae (Gorsky et al., 1996; Xue et al., 2005). Unilateral lesions have
been reported in 1.8% and 5.2% in different OLP patient cohorts
(Andreasen, 1968; Eisen, 2002). OLP may affect any oral mucosal
surface; however it rarely affects lips, the palatal mucosa or floor of the
mouth (van der Waal, 2009). A recent study of 808 patients reported that
OLP affected the buccal mucosa (73%), tongue (44%) and gingivae
(33%) much more frequent than the floor of the mouth (4. 6%), labial
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mucosa (1. 8%), palate (1. 8%) or oropharynx (0. 7%) (Carbone et al.,
2009a).
Most patients with oral lichen planus who are referred to tertiary clinics
have mucosal pain and discomfort. A recent report (Ingafou et al., 2006)
found about 62.5% of a OLP cohort had oral soreness or discomfort
while another study estimated mouth discomfort to be present in 69.5% of
the patients (Brown et al., 1993).
2.1.3 Oral lichen planus forms
There are many classifications of OLP, however the most common one is
Andreasens’s classification with the six subtypes or forms; reticualr,
papular, palque, erosive, atrophic and bullous forms (Andreasen, 1968).
The reticular form is the most common variety of OLP and may more
prevalent among women. It usually presents as asymptomatic bilateral
white keratotic lines (Wickham’s striae) on the buccal mucosa (Dusek and
Frick, 1982; Xue et al., 2005).
The papular form usually presents as multiple, raised, small (<1 mm)
white lesions and is often found with other types (Dusek and Frick, 1982).
The plaque form presents as symptomatic multiple, raised, flat lesions on
the oral mucosa, usually on the tongue or buccal mucosa. The clinical
appearance of plaque OLP resembles multiple hyperkeratotic mucosal
lesions (Dusek and Frick, 1982; Edwards and Kelsch, 2002).
The erosive form may be more likely in older individuals and represents
the second most frequent type. It is usually painful, of long duration and
usually presents as slightly erythematous, depressed areas of the oral
mucosa with partial loss of the epidermis usually with surrounded
radiating keratotic lines which usually affect many oral mucosal surfaces
(Dusek and Frick, 1982; Xue et al., 2005).
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The atrophic form presents as multiple erythematous, thinning areas of
oral mucosa. White keratotic striae usually surround the atrophic areas.
As with the erosive form, it is usually painful and requires treatment to
decrease patient discomfort (Dusek and Frick, 1982; Edwards and
Kelsch, 2002).
In some reports “atrophic” disease is described as “erosive” and “erosive”
as ulcerative. Hence there can sometimes be confusion in the exact
description of disease. Nevertheless these aforementioned types are the
most common to give rise to painful symptoms.
The bullous form is rare and presents as circumscribed swellings which
may rupture due to mechanical trauma to leave an area of erosion
(Dusek and Frick, 1982).
Gingival involvement of OLP is common. Gingival lesions may present as
desquamative gingivitis or as keratotic reticular or plaque lesions.
Desquamative gingivitis is the term used to describe gingival atrophic
lesions caused by a group of disorders which includes lichen planus.
Patients may complain of mild to severe pain accompanying gingival
lesions. In one study of 700 OLP patients (Mignogna et al., 2005), 336
(48%) had gingival lesions. 0.1% to 10% of OLP patients can have
lesions solely affecting the gingivae (Scully and el-Kom, 1985; Xue et al.,
2005).
2.1.4 Extra-oral involvement
Extra-oral involvement in the course of LP is well documented. The skin,
nails, scalp, and mucosal surfaces of the oesophagus, pharynx, larynx,
conjunctiva, genitals, and bladder (albeit it rarely) can be involved in the
course of the disease (Tunca et al., 2004) however most of patients
usually have just one extra-oral site involvement (Bidarra et al., 2008). In
a recent study extra-oral involvement was reported to affect 40% of the
87 OLP patients (Bidarra et al., 2008).
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Cutaneous lichen planus can affect any part of the skin; however, it
commonly presents as pruritic areas on the flexor surfaces of forearms
and pre-tibial skin of the lower legs and may affect about 16% to 20% of
patients with OLP (Gorsky et al., 1996; Eisen, 1999; Bidarra et al., 2008).
The cutaneous lesions are usually self-limiting and remission takes place
after periods ranging from a few weeks to years often leaving areas of
hypermelanotic pigmentation. The classic form presents with pruritic
symmetrically distributed polygonal erythemamatous papuloplaques on
the legs, wrists, and back (Eisen, 1999; Sharma and Maheshwari, 1999).
Scalp involvement of LP is uncommon but can give rise to scarring
alopecia, termed lichen planopilaris (Eisen, 1999).
Nail involvement has been reported in 2% of OLP patients (Eisen, 1999).
The nail plates may become itchy, thin and atrophic, with rough, striated
ridging, fissuring and splitting of the nail edge. Subungual hyperkeratosis
and ptyergium may occur (Eisen, 1999; Yokozeki et al., 2005). Lichen
planus is uncommon in children; however, nail involvement is common in
those diagnosed with the condition. In one series, 11% of LP patient with
nail lesions were children (Tosti et al., 2001).
Oesophageal LP may cause pain and persistent dysphagia resulting from
esophagitis and stricture formation. This may be more common in
females and the actual frequency of oesophageal involvement is thought
to be underestimated (Abraham et al., 2000).
Genital lesions seem to be more common in women than men; in one
study 19% of women and 4.6% of men with OLP had genital disease
(Eisen, 1999). In women, white, reticulate, lacy lesions are the classical
finding and disease may be most likely in the posterior vulvar vestibule
(Buffon et al., 2009). Dysuria, dyspareunia, postcoital bleeding, mucosa
adherence, synechiae, and obliteration of vagina are possible
complications and can cause painful sexual intercourse (Moyal-Barracco
and Edwards, 2004; Buffon et al., 2009). Affected men usually have
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lichen planus-like lesions of the external genitalia, probably of the glans
penis.
2.1.5 Oral lichen planus-related disorders
2.1.5.1 Oral lichenoid contact lesions (OLCLs)
OLCLs are the result of dental restorations, especially amalgam, and can
be recognized by proximity to the restoration and by their unilateral and
limited distribution. Removing the restoration usually results in resolution
of the lesions within months (Issa et al., 2004). OLCLs have the same
histopathological characteristics as OLP (Al-Hashimi et al., 2007). There
have been occasional reports of other metallic and non-metallic dental
restoration materials giving rise to contact lesions (Ostman et al., 1996;
Tosti et al., 1997; Koch and Bahmer, 1999).
2.1.5.2 Oral lichenoid drug reactions (OLDRs)
OLDRs are caused by systemic drugs such as angiotensin-converting
enzyme inhibitors, sulphonylureas, and non-steroidal anti-inflammatory
drugs (NSAIDs) (Rice and Hamburger, 2002). As with OLCLs, the lesions
are clinically and histopathologically indistinguishable from OLP, it has
been suggested that basal epithelial cell cytoplasmic autoantibodies may
be detected (Lamey et al., 1995) and that the subepithelial infiltrate is
deeper and more diffuse within the connective tissue, and contains a
more mixed infiltrate of eosinophils and plasma cells (Rice and
Hamburger, 2002). It has been suggested that the lesions of OLDRs may
resolve after the medication is discontinued (Al-Hashimi et al., 2007) but
there are few reports to substantiate this suggestion.
2.1.5.3 Vulvovaginal gingival lichen planus
Concurrent involvement of the gingivae and genital mucosa, known as
vulvovaginal gingival or less common peno-gingival syndrome, is a rare,
or more likely underreported, variant of lichen planus. Patients may
complain of painful erosions and/or ulceration of the vulva, vagina, in
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addition to desquamative gingivitis (Eisen, 1994; Rogers and Eisen,
2003).
2.1.5.4 Oral lichenoid lesions of graft-versus-host disease
The oral mucosa may be involved in both acute and chronic graft-versus-
host disease (GvHD); however, it is more commonly observed in the
latter. The lichenoid lesions of GvHD can affect any site of oral mucosa
but the buccal mucosa may be the first and most commonly affected oral
site of chronic GvHD (Ferrara et al., 2009). The clinical and conventional
histopathological features of GvHD are generally similar to those of OLP
(Al-Hashimi et al., 2007).
2.1.5.5 Lichenoid dysplasia
Lichenoid dysplasia describes lesions that have histopathological features
of dysplasia and a band like lymphocytic infiltrate in the lamina propria
mimicking that of LP. Histopathologically, unlike OLP, lichenoid dysplasia
may have an intact basal cell layer, rounded epithelial ridges with
abnormal cytology (Fatahzadeh et al., 2004). It is unlikely however that
lichenoid dysplasia is the underlying cause of the malignant potential of
OLP as it is a rare entity.
2.1.6 Diagnosis of oral lichen planus
The diagnosis of OLP is based on clinical and histopathological
examination. Some authors consider the classical clinical features (e.g.
bilateral distribution of white patches) alone are adequate to provide a
diagnosis (Ingafou et al., 2006; Al-Hashimi et al., 2007; Pakfetrat et al.,
2009). A biopsy is recommended when the clinical presentation is
perhaps atypical and to exclude dysplasia or malignancy (van der Waal,
2009). However, other authors recommend that histopathological studies
should always be undertaken even if the classical clinical presentations
are present (Xue et al., 2005; Rad et al., 2009). Indeed van der Meij and
van der Waal (2003) reported a lack of correlation between clinical and
histopathological diagnosis of OLP and proposed revised diagnostic
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criteria for OLP and oral lichenoid lesions. In view of the suggested
malignant potential of OLP it would seem clinically sensible to have
histopathological confirmation of the diagnosis of OLP. This would thus
lessen any medicolegal repercussions if a patient ultimately develops an
oral squamous cell carcinoma.
Both immunofluorescence and immunohistochemical studies are not
useful in the diagnosis of OLP (van der Waal, 2009) although they are
indicated when there is a possibility of disease such lupus erythematosus,
pemphigus vulgaris or mucous membrane pemphigoid (Leao et al.,
2008).
2.1.7 Histopathological features of oral lichen planus
The histopathological features of OLP lesions comprise epithelial
changes of parakeratosis and acanthosis with Civatte bodies, liquefaction
degeneration, and eosinophilic deposits at the basement membrane. The
so called “saw-toothed” rete pegs may be more likely with cutaneous than
oral disease. When there is erosion or ulceration there will be loss of
epithelial depth or histopathological evidence of frank ulceration. One of
the characteristic features of LP is a dense band of cellular infiltrate
(mainly T lymphocytes as demonstrated by immunobiochemistry) in the
superficial layer of connective tissue (Kramer et al., 1978; Porter et al.,
1997).
However, van der Meij et al. (1999) reported that histopathological
assessment of OLP biopsy material could at times be subjective,
inadequately differentiating LP from other similar histopathological
process such as OLDRs and OLCLs and possibly be non-reproducible
(van der Meij et al., 1999). Similarly recently Rad and co-workers (2009)
found a lack of correlation between the WHO histopathological and
clinical diagnostic criteria. Despite these possible shortcomings
histopathology remains the most common method worldwide to confirm
the clinical diagnosis of OLP. Ultimately diagnosis requires the collation of
all aspects of the history, clinical presentation and results of any
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additional investigations. In addition the treatment of symptomatic OLP is
usually similar to that of allied disorders such as lupus erythematousis
affecting the oral mucosa.
2.1.8 Aetiology of oral lichen planus
Discussion of the aetiopathogenesis of OLP is out with the remit of this
review but certainly OLP has a strong immunological basis. As noted
above, the lesions are histopathologically characterized by a dense T
lymphocyte infiltrate, which may represent a cell-mediated immune-
response to an unknown antigen. The initial triggers for the T cell immune
response are still unknown, although a variety of mechanisms have been
postulated (Porter et al., 1997). It has been suggested OLP may be
induced by systemic drugs (oral lichenoid drug reactions) or dental
restorative materials (oral lichenoid contact lesions) as discussed above.
The role of Hepatitis C in the aetiology of OLP is a controversial issue.
Several studies reported association between OLP and hepatitis (Table
2.2). Hepatitis C infection was commonly detected in OLP patients in Italy
(Mignogna et al., 1998; Mignogna et al., 2000), Brazil (Grossmann et al.,
2009), Taiwan (Chung et al., 2004), and Japan (Nagao et al., 1995) but
not in the UK (Ingafou et al., 1998; Roy et al., 2000) or the Netherlands
(van der Meij and van der Waal, 2000). The high number of OLP patients
with hepatitis C in some groups may reflect the prevalence of hepatitis C
in these populations (Mignogna et al., 2000) or a true association
between the two disorders (Mignogna et al., 1998). In a recent study of a
large cohort of OLP patients in Italy, 21% of those who underwent hepatic
examination had liver abnormalities, most of who were ultimately found to
have hepatitis C infection (Carbone et al., 2009a).
An immunogenetic susceptibility to HCV-related OLP has been proposed
(Carrozzo et al., 2005) that may explain the geographic variation in an
association between HCV and OLP, but at present the precise
association between the two disorders remain unclear.
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2.1.9 Malignant transformation of oral lichen planus
The precise association of OLP with risk of oral squamous cell carcinoma
(OSCC) remains undetermined. However OSCC does not always arise at
the site of OLP (van der Waal, 2009), is not always associated with
erosive or ulcerative disease (Ingafou et al., 2006) and the risk can be
independent of risk factors such as tobacco use (Gandolfo et al., 2004).
Although the malignant potential of OLP remains a controversial issue it
would seem appropriate all patients with OLP are made aware of this
malignant potential, given appropriate advice about relevant lifestyle
change (e.g. avoidance of tobacco and alcohol) and are regularly
reviewed by competent clinicians.
There is little information as to the actual malignant transformation rate
and the behaviour and outcome of squamous cell carcinomas (OSCCs)
arising from OLP lesions. One report states that the site of the
malignancy is not restricted to that of the pre-existing OLP (van der Waal,
2009).
Malignant transformation has been reported in several studies (Table
2.3). It reported to range between 0% to 12.5% of OLP patients (Lodi et
al., 2005a; Gonzalez-Moles et al., 2008). The standardized incidence
ratio (i.e. the ratio of observed to expected instances) ranged between
2.6 (95% CI: 0.1 to 14.8) to 45.3 (95% CI: 21.2 to 87.3) (Roosaar et al.,
2006; Carbone et al., 2009a). However, in a long-term population-based
study, there was minimal increased risk of oral malignancy in patients
with oral lichen lesions (Roosaar et al., 2006).
2.1.10 Treatment
As OLP is likely to be lifelong disease the principle goal of treatment is to
lessen the painful symptoms (Chainani-Wo et al., 2001; Gonzalez-Moles
et al., 2002). Intervention is recommended when patients complain of
burning sensations and irritation which may interfere with eating and
speech and, consequently, their quality of life (Hegarty et al., 2002;
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Rozycki et al., 2002). Such patients are likely to have erosive or ulcerative
lesions.
Although many OLP patients are asymptomatic, follow up visits,
explanation, patient education, and oral hygiene instruction are important.
A review of the patient’s drug history may identify medications associated
with lichenoid reactions, such as angiotensin-converting enzyme
inhibitors, sulphonylureas and non-steroidal anti-inflammatories (Rice and
Hamburger, 2002) and it may be possible for these to be changed to
agents less likely to cause or worsen OLP.
A systematic review on oral lichenoid lesion healing after amalgam
restorations were replaced reported complete healing ranged from 37.5%
to 100%, with lesions in direct contact with the original amalgam showing
the greatest improvement (Issa et al., 2004). The same review noted a
wide range of patch test results: 16% to 91% of patients were positive to
patch testing for at least one mercury compound (Issa et al., 2004). The
authors concluded that a patch test is of limited value in diagnosing
lichenoid lesions; although other groups have suggested that patch
testing is important to support clinical decisions (Pigatto and Guzzi,
2005).
2.1.10.1 Therapeutic agents
A wide range of topical and systemic therapies have been evaluated or
suggested for treatment of OLP including topical corticosteroids (Voute et
al., 1993); ciclosporin (Eisen et al., 1990; Sieg et al., 1995); retinoids
(Laurberg et al., 1991); and systemic modalities such as corticosteroids
(Carbone et al., 2003), hydroxychloroquine (Eisen, 1993), mycophenolate
mofetil (Nousari et al., 1999), thalidomide (Camisa and Popovsky, 2000),
dapsone (Kumar et al., 1994), heparin (Stefanidou et al., 1999; Femiano
et al., 2003), photochemotherapy (Lundquist et al., 1995), and methylene
blue-mediated photodynamic therapy (Aghahosseini et al., 2006).
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However, there is little evidence of the efficacy and superiority of any of
these agents as they have in general not been evaluated in well-designed
randomised controlled clinical trials and most studies had small patient
cohorts (Zakrzewska et al., 2005).
A detailed discussion of the different agents used in the managing OLP is
not the scope of the present section; however, the most common
modalities and the new agents recently introduced or suggested over the
last few years are discussed. More details on treatment of OLP can be
found in Table 2.4
Topical corticosteroids
Topical corticosteroids represent the mainstay of treatment of OLP
(Carbone et al., 2003), while topical retinoids and calcineurin inhibitors
(e.g. tacrolimus and pimecrolimus) may be considered to be a second-
line therapies (Al-Hashimi et al., 2007).
There are numerous reports on the efficacy of topical corticosteroids in
the management of OLP, including a recent review by Thongprasom and
Dhanuthai (2008).
Among the many topical corticosteroids preparations and forms that have
been suggested as effective in treating OLP are fluocinolone acetonide
(Buajeeb et al., 2000; Thongprasom et al., 2003), clobetasol propionate
alone (Carbone et al., 2003) or in an adhesive denture paste (Lo Muzio et
al., 2001) and triamcinolone acetonide 0.1% (Endo et al., 2008).
The most commonly used formulations are ointment, cream, mouthwash,
and spray. A mouthwash (e.g. betamethasone sodium phosphate
dissolved in water) may be used if the patient has extensive mucosal
involvement, especially in areas where it is difficult to easily apply an
ointment or cream, or the medication may not be retained on the oral
mucosal lesions (Gonzalez-Moles et al., 2002). Similarly clobetasol as an
aqueous mouthwash may be effective (Gonzalez-Moles et al., 2003).
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Some clinicians prefer occlusive therapy with custom-made trays for
gingival disease as this may extend the contact time of the topical agents
(Lu et al., 1998; Gonzalez-Moles et al., 2003; Mignogna et al., 2005;
Endo et al., 2008).
In addition to being effective and non-costly, topical corticosteroids give
rise to fewer minor adverse side effects (ASEs) than systemic
corticosteroids (Carbone et al., 2003), although severe adverse side
effects ASEs can occasionally arise with potent agents such as clobetasol
(Gonzalez-Moles et al., 2002). The most common ASEs of topical
corticosteroids are superficial candidal infections particularly with the
more potent topical creams, ointments and mouthwashes. As a
consequence some clinicians recommend the use of antimycotic agents,
such as nystatin or miconazole when highly potent corticosteroids agents
are prescribed (Gonzalez-Moles et al., 2003; Carbone et al., 2009a;
Carbone et al., 2009b).
Other ASEs of topical potent agents have included mild moon face and
hirsutism. The former reduces when frequency of application is reduced,
while the latter can be managed by cosmetic depilation (Gonzalez-Moles
et al., 2003). Nevertheless as such ASEs can affect 13% of patients
(Gonzalez-Moles et al., 2003) there is a need to prescribe such agents
with caution and ensure patients are aware of common ASEs. Although
topical corticosteroids are the mainstay of therapy of OLP worldwide,
even potent agents do not cause complete resolution of painful symptoms
hence the need for alternative (e.g. calcineurin inhibitors) or adjuvant
therapies (e.g. systemic corticosteroids and/or systemic
immunosuppressants).
Intralesional corticosteroids
Intralesional corticosteroids has been suggested for many years to be a
potential means of managing persistent OLP lesions, however there are
few detailed studies to confirm this. A recent report did however observe
that intralesional triamcinolone acetonide injection (40 mg/ml) was an
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effective and safe means of managing ulcerative OLP that had not been
responsive to topical corticosteroids (Xia et al., 2006).
Systemic corticosteroids
Systemic corticosteroids (e.g. prednisolone or deflazacort) may be
employed for severe erosive/ulcerative OLP or when there is also non-
oral involvement (Carbone et al., 2003). Systemic corticosteroids are
usually prescribed to control acute flare ups (Lu et al., 1998). There is a
significant risk of ASEs if these are prescribed for long-term use.
Topical calcineurin inhibitors
T-cell activation is central to the pathogenesis of OLP (Lodi et al., 2005b),
hence blockage of calcineurin function might be expected to lessen the
severity of such disease.
Topical ciclosporin
Although it has been reported to be effective in the management of OLP
(Frances et al., 1988; Eisen et al., 1990; Harpenau et al., 1995), topical
ciclosporin appears to be less effective and more expensive than topical
corticosteroid in controlling OLP lesions (Yoke et al., 2006; Conrotto et
al., 2006). The details of the precise impact of topical ciclosporin in the
management of OLP are reviewed elsewhere (Al Johani et al., 2009).
Topical tacrolimus
There are many reports of the efficacy of tacrolimus in the management
of OLP. Effectiveness has been assessed via open-label prospective
studies (Kaliakatsou et al., 2002; Olivier et al., 2002; Lozada-Nur and
Sroussi, 2006), randomized trials (Corrocher et al., 2008; Radfar et al.,
2008), retrospective studies (Hodgson et al., 2003; Thomson et al.,
2004), case series (Morrison et al., 2002; Rozycki et al., 2002), and
described in several case reports (Lener et al., 2001; Shen et al., 2004;
Shichinohe et al., 2006).
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Initial studies were conducted in patients with symptomatic OLP who
were recalcitrant to topical corticosteroids or at risk of adverse side
effects from corticosteroids. Eleven of the 13 OLP patients who were
prescribed topical tacrolimus (mean duration of 6.5 months) had either
complete resolution or partial improvement of painful oral mucosal lesions
within four weeks from the start of the treatment although 2 patients had
no benefit (Rozycki et al., 2002). Both 0.1% and 0.3 % concentrations of
tacrolimus were able to induce complete healing of OLP lesions and
cause relief of painful symptoms while 0.03% formulation led to partial
response only (Rozycki et al., 2002). Symptomatic and clinical
improvement is observed usually within 2 weeks (Kaliakatsou et al., 2002).
Adverse side effects were uncommon and minimal but recurrences were
observed within one to two weeks of cessation of tacrolimus therapy
(Rozycki et al., 2002).
Hodgson and colleagues (2003) in a retrospective analysis of 50 OLP
patients with erosive/ulcerative OLP recalcitrant to topical corticosteroids
demonstrated the long-term (mean: 19.8 months) efficacy and safety of
0.1% topical tacrolimus. Most of the patients (94%) having either
complete or partial resolution of mucosal erosions. Most of the ASEs
were intra-oral burnings sensation and taste disturbance.
Topical tacrolimus was suggested for OLP patients who are recalcitrant to
topical corticosteroids, patients at risk of adverse side-effects from
systemic immunosuppressant agents or at risk of oral candidosis (Lener
et al., 2001; Lozada-Nur and Sroussi, 2006; Chaudhry et al., 2007).
Two randomized trials reported that tacrolimus was more effective than
triamcinolone (Laeijendecker et al., 2006) and clobetasol (Corrocher et
al., 2008) in controlling painful symptoms of erosive OLP. However,
Radfar and co-workers (2008) in a randomized, double-blind study found
no significant differences between tacrolimus and clobetasol in the
management of symptomatic OLP. In addition relapse is common after
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the drug was discontinued and can occur quickly (Olivier et al., 2002;
Morrison et al., 2002).
At present there remains little strong evidence to demonstrate that
tacrolimus is notably superior to topical corticosteroids for the treatment of
oral lichen planus. Moreover, available data should be evaluated with
caution as studies often employed dissimilar preparations and
concentrations of tacrolimus ranging from mouthwash (Olivier et al.,
2002) to paraffin- or mineral oil-based ointments (Kaliakatsou et al., 2002;
Morrison et al., 2002). Overall however, tacrolimus can be considered
effective in controlling the extent of mucosal lesions and the related
symptoms of OLP. It has few adverse side-effects but relapses may arise
after discontinuation of therapy. Therefore the maintenance of disease
remission necessitates continued intermittent use of topical tacrolimus,
the frequency of application being different from one patient to another
(Hodgson et al., 2003). Additional details on studies reporting the efficacy
of topical tacrolimus in OLP in Table 2.4.
Pimecrolimus
Pimecrolimus shares the same cellular binding protein (FKBP-12) as
tacrolimus and blocks the transcription of cytokines by inhibiting the
calcineurin pathway. There is very limited data of the potential of topical
pimecrolimus for the treatment of oral mucosal disease. Pimecrolimus
has been suggested to be effective in the management of symptoms and
erosions/ulcerations of OLP (Dissemond et al., 2004; Esquivel-Pedraza et
al., 2004; Scheer et al., 2006; Swift et al., 2005). A significant pain
reduction in erosive OLP is reported by patients treated with pimecrolimus
in comparison to placebo (Swift et al., 2005). Another study of 12 patients
found that 1% pimecrolimus cream was more effective in lessening
symptoms and signs of erosive OLP in comparison with vehicle only
(Passeron et al., 2007).
Twice daily application of a mixture of 1:1 of pimecrolimus 1% cream with
a hydrophilic adhesive gel base has been suggested to be safe and
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effective treatment of OLP (Dissemond et al., 2004; Swift et al., 2005)
with clinical improvement usually observed from 2 to 5 weeks (Esquivel-
Pedraza et al., 2004). The drug was well-tolerated with only transient
burning sensation arising in 2 of the 6 patients using pimecrolimus.
However, relapse was observed in all patients within 4 weeks of
cessation of therapy (Passeron et al., 2007).
A randomized clinical trial found that pimecrolimus 1% cream was no
better than topical triamcinolone acetonide in lessening the symptoms
and signs of OLP when applied 4 times daily for 2 months (Gorouhi et al.,
2007). Moreover, a transient oral burning sensation was reported by 10%
of patients who received pimecrolimus (Gorouhi et al., 2007). A recent
randomized vehicle-controlled small study showed that topical
pimecrolimus was effective in controlling pain due to OLP
erosions/ulceration during and up to 30 days after cessation of therapy
(Volz et al., 2008). Similar results were reported in other studies,
(Dissemond et al., 2004; Esquivel-Pedraza et al., 2004; Swift et al.,
2005). Pimecrolimus was also used effectively in association to
tacrolimus in a patient with cheilitis glandularis superimposed on OLP
(Erkek et al., 2007).
Topical pimecrolimus may thus be of some benefit, at least in the short-
term in the treatment of symptomatic OLP. However its relative
effectiveness and safety when compared to topical tacrolimus or
corticosteroids are not known. Further investigations are needed to
confirm its suggested prolonged long-term efficacy.
In 2004 the US Federal Drug Agency (FDA) reported 19 and 10 patients
who received topical tacrolimus and pimecrolimus respectively developed
malignant tumours. The 10 malignancies associated with topical
pimecrolimus included; non-Hodgkin’s lymphoma, paniculitis-like T-cell
lymphoma, granulomatous lymphadenitis with hyperplasia, squamous cell
carcinoma, intraductal papilloma of the nipple and basal cell carcinoma.
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Two of the 10 pimecrolimus-associated malignancies occurred at the
same site of local application.
In patients who received topical tacrolimus, 9 patients developed
lymphomas and 10 developed cutaneous malignancy (mainly squamous
cell carcinoma, sarcoma, and malignant melanoma). Most of the
cutaneous tumours (70%) developed in the same area of tacrolimus
application (Anonymous, 2004). Tacrolimus was the suspected causative
agent of oral squamous cell carcinoma (OSCC) of the tongue in a 56-
year-old woman who was prescribed tacrolimus (0.1% twice daily) to
control her OLP (Becker et al., 2006). The OSCC developed after 3 years
of topical tacrolimus commencement and 6 years following the diagnosis
of OLP. In addition another paper reported the development of genital
SCC in a 57-old male with a 2 years history of balanoposthitis. The
patient developed the tumour after 2.5 months of therapy with topical
tacrolimus which necessitate surgical intervention with skin graft
(Langeland and Engh, 2005). Both of these mucosal tumours developed
at sites of tacrolimus application. This data may suggest that tacrolimus
may be a promoter or accelerator of mucoucutaneous carcinogenesis
(Niwa et al., 2003; Langeland and Engh, 2005). However, this should be
considered with caution as histopathological description of the lesions
before tacrolimus application was not always provided and hence it is not
known whether or not the carcinogenetic process had already
commenced before the therapy (Berger et al., 2006; Qureshi and Fischer,
2006). A more recent case-control study did not find any increased risk of
lymphoma in atopic dermatitis patients treated with topical tacrolimus
and/or pimecrolimus (Arellano et al., 2007).
In January 2006, the US FDA approved the inclusion of a potential risk of
cancer in the labelling of tacrolimus and pimecrolimus cream, and
recommends the use of these agents as second-line therapies. In
addition, the FDA recommended refraining from using these treatments in
children under 2 years of age (Anonymous, 2006a).
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There remains little information of the carcinogenic potential of tacrolimus
or pimecrolimus, and the new recommendations from the European
Medicines Agency state that the benefits of these calcineurin inhibitors
outweigh the risks (Anonymous, 2006b). The European Medicines
Agency however recommends that intermittent use of the topical
tacrolimus with the lowest strength possible and only for short periods of
time. Certainly with regard to OLP, a clear diagnosis should be
established before the use of topical tacrolimus as early squamous cell
carcinoma may clinically mimic lichenoid lesions or develop in the context
of lichen planus (Lozada-Nur and Sroussi, 2006).
Retinoids
Although often mentioned in non-systematic reviews, there are few
reports of the benefit of retinoids. Twice daily application of topical
tazarotene gel 0.1% has been suggested to be effective in the
management of hyperkeratotic OLP (Petruzzi et al., 2002) although, as
this was likely to be asymptomatic the exact benefit to the patient is
unclear. In a randomized trial, topical isotretinoin was found effective in
managing atrophic and erosive oral lichen planus with dysplasia.
Transient mucosal soreness and sensitivity to hot foods has been
reported with isotretinoin topical therapy (Scardina et al., 2006).
Thalidomide
Thalidomide in a dose of 100 mg/day was found to be effective in
managing erosive lesions of OLP; however, when the dose was
increased to 200 mg/day, patients started to develop side effects such as
dizziness and skin rash (Camisa and Popovsky, 2000). Thalidomide
should be reserved for the most severe cases of OLP due to its adverse
side effects such as teratogenic effects, proximal myopathy and
neuropathy (Camisa and Popovsky, 2000; Macario-Barrel et al., 2003).
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Efalizumab
Efalizumab, an inhibitor of T cell interactions, is a recombinant humanized
IgG1 monoclonal antibody that binds to CD11a and is used primarily in
the treatment psoriasis (Joshi et al., 2006). Efalizumab (0.7 mg/kg/week
followed by 1 mg/kg/week) has been used successfully in the
management of patient who developed cutaneous LP and symptomatic
oral lesions and who did not respond to a short course of systemic
prednisone and topical tacrolimus. Both cutaneous and oral mucosal
lesions improvement was evident within 5 weeks and substantial
improvement was reported within 10 weeks (Cheng and Mann, 2006).
Heffernan and co-workers (2007) reported on four patients with erosive
OLP who had been prescribed subcutaneous efalizumab (initial dose;
0.7 mg/kg for a week followed by 1 mg/kg weekly for 11 weeks). All
patients’ oral mucosal lesions responded favourably to treatment. The
mean reduction in the total mucosal lesional surface area was 71.1%
(range; 57.3–96.8%) with improvement in the patient-centred outcomes of
82% and 69.3% in visual analogue scale and oral health impact profile-
14, respectively. One patient discontinued therapy as she developed
subacute cutaneous lupus erythematosus and another developed
urticaria and a staphylococcal abscess of an artificial hip joint.
Alefacept
Alefacept may lessen the severity of many disorders by inhibition of
activated T cells. It was approved by the US Food and Drug
Administration for the treatment of moderate to severe psoriasis. It
prevents T cell activation and initiates T cell apoptosis (Sugiyama et al.,
2008).
Intramuscularly injected alefacept (15 mg/week for 12 weeks) was used in
the management of two patients with widespread mucocutaneous LP,
that also affect the oral mucosa, who did not respond to a variety of
topical and systemic agents, including antihistamines, hydroxychloroquine
sulfate, topical tacrolimus, topical and systemic corticosteroids,
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azathioprine, ciclosporin, mycophenolate mofetil, griseofulvin, and
ultraviolet-B (Fivenson and Mathes, 2006). Neither of the 2 patients
developed ASEs and both were disease free after completing the
treatment protocol. There was no flare-up after discontinuation of therapy
up to 12 to 20 weeks (Fivenson and Mathes, 2006).
Other agents
A wide variety of other agents (alone or in combination with others) have
been proposed in the management of OLP. These include adalimumab
(Chao, 2009), etanercept (Yarom, 2007), hydroxychloroquine (Eisen,
1993), mycophenolate mofetil (Nousari et al., 1999; Dalmau et al., 2007),
dapsone (Kumar et al., 1994), rapamycin (Soria et al., 2009), levamisole
(Sun et al., 2007), heparin (Stefanidou et al., 1999; Femiano et al., 2003;
Femiano and Scully, 2006), photochemotherapy (Lundquist et al., 1995;
Guyot et al., 2007), aloe vera (Choonhakarn et al., 2007), Ignatia
(Mousavi et al., 2009), hyaluronic acid (Nolan et al., 2009), CO2 laser
(van der Hem et al., 2008), and methylene blue-mediated photodynamic
therapy (Aghahosseini et al., 2006).
2.1.10.2 Surgery
Surgery have a very limited role in the treatment of OLP, however palatal
grafts may be used to treat recalcitrant gingival lichen planus or lichenoid
lesions (Axell and Henriksen, 2007). In one case report a patient had
complete disappearance of gingival lesions after 3.5 years (Tamizi and
Moayedi, 1992).
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2.1.11 Clinical follow-up and outcome of oral lichen planus
2.1.11.1 Clinical follow-up
The review interval is a controversial issue in OLP patients and there are
no widely accepted guidelines available. Eisen (2002) and Al-Hashimi
and co-authors (2007) recommended regular follow-up of OLP patients to
detect any malignant transformation and to improve prognosis. Some oral
medicine units regularly review patients whom they believe are at higher
risk of malignancy; however, this observation is not based on evidence
but personal clinical experience. Carbone and co-workers (2009)
reviewed patients according to clinical presentation and treatment needs;
patients with white lesions (reticular, papular or plaque forms) were seen
twice a year for the first 2 years after diagnosis and then annually;
patients with red lesions (erosive or atrophic) were usually seen twice
annually and with active disease undergoing therapy were seen every 2
months until their disease stabilized.
However due to the limited number of oral medicine specialists and the
high cost of follow-up, there is doubt over exact frequency of visits to
improve prognosis. Some authors recommend involvement by general
dental practitioner in the long-term management of OLP patients (Ingafou
et al., 2006; Mattsson et al., 2002).
2.1.11.2 Outcome of oral lichen planus
OLP is chronic disorder (Chainani-Wu et al., 2001) and flare up of oral
lesions is common (Eisen, 2002; Roosaar et al., 2006). In a long-term
population-based study, one-third of the lesions had spontaneous
remission (Roosaar et al., 2006). In the Carbone et al. study (2009), most
of the 808 patients (76.6%) had the same clinical presentation as that
found in first visit of the study; 2.5% had complete healing for at least 12
months after presentation; and 6% of the study group reported worsening
of their disease. Fifteen per cent of the patients had resolution of
atrophic/erosive lesions which changed to reticular, plaque, or papular
lesions; while 6% had their white lesions (reticular, popular, or plaque)
altered to atrophic or erosive forms (Carbone et al., 2009a). In another
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large cohort (690 patients), only 13% had complete resolution of
symptoms and signs after a median of 35 months (Ingafou et al., 2006).
While there is considerable data concerning the clinical presentation of
OLP the long-term outcomes of patients receiving contemporary care of
OLP remains unknown. In addition the frequencies of adverse events with
therapy are not well detailed. Hence the aim of this chapter was to
describe the long-term outcomes of therapy and malignant transformation
rate in a large cohort of OLP patients attending a single clinical centre.
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2.2 AIMS
The aims of this chapter were to determine:
1. The clinical outcomes of long-term therapy of oral lichen planus in a
cohort of patients with oral lichen planus that had been treated with
corticosteroids and/or topical tacrolimus.
2. The frequency and nature of adverse side effects of therapy of oral
lichen planus in this cohort of patients.
3. The malignant transformation rate of oral lichen planus.
4. To compare clinical, haematological and serological outcome and
malignant transformation rate between patients who had treated
with and without topical tacrolimus.
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2.3 PATIENTS AND METHODS
2.3.1 Patients group
The study group consisted of 186 subjects managed by the Oral Medicine
Unit of UCL Eastman Dental Institute and UCLH Eastman Dental Hospital
UCLH NHS Trust between 1985 and 2006, found to have clinical and/or
histopathological features of oral lichen planus (OLP) based upon WHO
histopathological criteria (Kramer et al., 1978).
2.3.2 Methods
The medical chart of each patient was examined using multiple data
extraction forms for details of demographics, past medical and drug
histories, extra-oral and intra-oral clinical features and clinical progress
data. Details of diagnostic and monitoring investigations were also
systematically extracted. These included: histopathology, full blood cell
count, differential white cell count, hepatic and renal biochemistry and
details of the different topical and systemic therapies employed in the
management of each patient (Appendices 1-5).
In the second section of this study, patients were divided into two groups
according to wether they had received topical tacrolimus during the
course of their treatment.
Outcomes of therapies
Analyses were restricted to patients with OLP-related mucosal
ulceration/erosion and desquamative gingivitis. Three outcome analyses
were used in the present study:
1. Analysis 1 was relevant to patients on topical corticosteroids (group A)
and patients on topical tacrolimus (group B) as separate groups. The
presence of oral ulceration/erosion and/or desquamative gingivitis
between baseline and last clinical review for each group was used as
outcome measure.
2. Analysis 2 consisted of comparison between group A and group B. The
presence of symptoms (pain, soreness, or discomfort) and clinical signs
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(oral ulceration/erosion and/or desquamative gingivitis) in group A versus
group B at baseline and on last clinical review were used as outcome
measures.
3. Analysis 3 was restricted to group B. Serial measurements of disease
status during 6-months reviews were conducted and identified the most
common disease status (> 50% of reviews) during the observation period.
The disease status was considered separately for symptoms and signs.
The symptoms-related disease status was defined as a 3-point scoring
system: 0 (asymptomatic/mild pain), 1 (presence of moderate pain), 2
(presence of severe pain), as reported by the patients.
The sign-related disease status was defined as a 3-point scoring system: 0
(absence/or presence of erosive areas on <30% of oral mucosa surface), 1
(presence of erosive areas on 30-70% of oral mucosa surface), 2
(presence of erosive areas >70 of oral mucosa surface) as reported by the
clinician. The score was retrospectively collected for each clinical review on
the bases of clinical notes and photographs.
Malignant transformation rate
The rate of malignancy transformation was detected by recording the
number of patients who developed oral squamous cell carcinoma at least
6 months after the diagnosis of OLP.
Statistical analyses
The differences between females and males in relation to duration of oral
symptoms before attending to Oral Medicine clinics and duration of the
treatment were analyzed using Student’s t-test.
McNemar test was used to compare symptom and signs scores between
the two treatment groups (Group A and B). Descriptive and analytical
statistics were undertaken using the SPSS program (SPSS for Windows:
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(Statistical Package for the Social Sciences) software, version 12.0).
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2.4 RESULTS
2.4.1 Patient demographics
Age and gender
The mean age of the patients when they attended for first time in the oral
medicine unit was 54.7 years (SD 13.4, median 55.0), this being 54.0 for
males (SD 14.3), and 54.9 for females (SD 13.1). There was an age
range of 18.3 to 92 years. The onset of the clinical features of oral lichen
planus was usually in the fifth to seventh decades of life (Table 2.5).
There were a higher number of females (133; 71.5%) than males (53;
28.5%), with a female to male ratio of 2.5:1.
Ethnic group
The majority of patients were white British (90; 48.4 %) (Self-reported,
according to 2001 Census) (Office for National Statistics, 2003). The
second most common ethnic group who had OLP was Indian (32;
17.2%). Additional details of ethnic background of this cohort of patients
are provided in Table 2.6.
Marital status
Marital status was stated under four categories; married which included
married patients and patients with civil partnership; single, divorced and
widowed patients. One hundred and twenty one (65.1%) patients were
married or living with a partner. 37 (19.9%) were single, 13 (7.0%) were
widowed, 9 (4.8%) were divorced and the marital status was not reported
in the case note of 6 patients.
Tobacco use and Alcohol consumption
Forty eight (25.8%) of the patients were previous tobacco users and 20
(10.8%) were current users of tobacco. The mean number of self-reported
cigarettes per day was 15.3. One hundred and seventeen (62.9%) of the
group currently drank alcohol, the mean total weekly consumption being
11.9 units.
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Sources of referral to oral medicine
One hundred and three (55.4%) of the patients had been referred to the
oral medicine unit by general dental practitioners. Thirty five patients were
referred by oral maxillofacial or oral surgeons, 12 patients were referred
by general medical practitioners and the remaining patients were referred
by different medical and dental specialists as detailed in Table 2.7. All
patients had been referred for the diagnosis and/or management of their
oral lesions. The mean time from referral to initial attendance in oral
medicine was 0.29 years (SD 0.53).
2.4.2 Past medical and drug histories
2.3.2.1 Past medical history
A quarter of this cohort of patients had a history of allergic disease.
Eighteen (9.7%) patients were allergic to penicillin, two to aspirin and 19
were allergic to a variety of other agents. Fifty patients had history of
cardiovascular disease and 24 patients had respiratory diseases. Thyroid
dysfunction and other endocrine conditions were common among this
cohort of patients. Additional details of past medical history are provided
in Table 2.8.
2.3.2.2 Past drug history
The patients were receiving a wide range of medication at the time of
their clinical consultation in the Oral Medicine Unit. As expected from the
medical history, the most common drugs were anti-hypertensives,
endocrine and anti-asthmatic agents (Table 2.9).
Some of these agents were being used to control oral and/or
mucocutaneous lesions likely to be due to OLP. A wide range of topical
and/or systemic agents had been prescribed to the present cohort of
patients before attending the Oral Medicine clinic. Triamcinolone
acetonide (Adcortyl in Orabase) was prescribed to 28 patients,
hydrocortisone sodium succinate and chlorhexidine gluconate were
prescribed to 24 patients. Patients also were prescribed other
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preparations of topical corticosteroids, systemic corticosteroids,
antimicrobial and/or analgesic agents. Additional details on different
agents used to control the patients’ disease before attending Oral
Medicine clinics are summarised in Table 2.10.
2.4.3 Histopathological features
Histopathological examination of lesional tissues was undertaken for 158
(84.9%) patients. 127 (68.3%) had just one biopsy, 24 had two and 5 had
three, one patient had 4 and another had 7 biopsies. The
histopathological reports of the remaining 28 patients were not available
in their clinical notes. Additional details on the histopathological features
of the present cohort are provided in Table 2.11.
2.4.4 Clinical features
2.4.4.1 Presenting clinical signs and symptoms
Most patients complained of oral discomfort, soreness and pain or mouth
ulcerations (133; 71.5%). The buccal mucosa, tongue and the gingivae
were the most affected sites. Gingival involvement, ranging from redness
of the gingivae to painful ulcerated gums, was reported by 51.1% of the
patients. Asymptomatic white patches (4 detected by GDP, two by GP
and 4 by patients) were the cause of referral of 10 patients and three
patients were complaining of oral dryness in addition to oral pain or
ulceration. The patients had had oral symptoms from few weeks to more
than 22 years before attending Oral Medicine Unit. The average duration
of symptoms prior to clinical presentation in oral medicine was 31.9
months (SD 47.8).
2.4.4.2 Distribution of OLP lesions
Bilateral involvement of the oral mucosa and/or gingivae was observed in
132 patients and when it was unilateral, it was affecting the left side (11
patients) more than the right side (9 patients). The distribution of oral
lesions was not reported in the remaining 34 patients. The buccal mucosa
was the most commonly affected site (68.3%) followed by the gingivae
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(51.1%). Additional details of the intra-oral distribution of OLP lesions are
provided in Table 2.12.
2.4.4.3 Extra-oral involvement
In this cohort of patients, extra-oral involvement of possible LP was self-
reported by 25 patients (13.4%). Eleven patients had cutaneous disease
while 6 patients had vulva or vaginal involvement. Three patients had
both cutaneous and genital involvement. Four patients had scalp
involvement. One patient had widespread mucocutaneous lesions
affecting skin, scalp, nails and genitals. Seven of the patients with extra-
oral LP reported that the mouth was the first site of involvement while skin
or genital lesions preceded oral lesions in 5 patients. One patient had
simultaneous onset of oral and extra-oral disease. The temporal
relationship of the oral/extra-oral disease of the remaining 12 patients
was not recorded.
2.4.5 Duration of therapy
The duration of treatment of OLP provided by the Oral Medicine clinic
differed between patients and ranged from a few months to more than 20
years (until data collection ceased) with a mean of 4.2 SD (3.7) years.
Sixty four (34.4%) patients were followed-up for less than 2 years, 76
(40.9%) from 2 to 6 years, 32 (17.2%) from 6 to 10 years and 14 (7.5%)
patients were followed-up for more than 10 years.
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2.4.6 Analysis of outcome according to prescribed therapies
In the following section patients are divided into two groups (Group A or
B) according to whether they did or did not receive topical tacrolimus as
part of their therapy.
Patients not prescribed topical tacrolimus (Group A)
One hundred patients received topical treatment other than topical
tacrolimus. Only 4 of this group received systemic corticosteroids and/or
systemic immunosuppressant. Details of the different topical and
systemic agents used to control OLP in this group of patients are
provided in Table 2.13.
Patients prescribed topical tacrolimus (Group B)
The remaining 86 patients received topical tacrolimus treatment in
addition to other topical agents and 18.6% of this group had also received
systemic corticosteroids and/or systemic immunosuppressant in an
attempt to control their disease (Table 2.14). One or both topical
tacrolimus concentrations (0.03% and/or 0.1 %) had been prescribed to
all this group of patients. The mean duration of treatment with tacrolimus
was 2.2 years with a range of 2 weeks to more than 6 years.
2.4.6.1 Analysis 1: Presence of oral ulceration/erosions and
desquamative gingivitis at baseline vs. last clinical examination for
group A and group B separately
Patients on topical corticosteroids (Group A)
Among the forty three patients with oral mucosal ulceration/erosions
32.6% (14/43) had persisting lesions after therapy whereas complete
healing was observed in 29 patients (29/43; 67.4%).
Most of the patients with desquamative gingivitis (33/44; 75%) had
persisting gingival lesions after therapy, whereas in only 25% of cases
complete healing was observed (11/44) (Table 2.15).
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Patients prescribed topical tacrolimus (Group B)
Among the 52 patients with oral mucosal ulceration/erosions 44.2%
(23/52) had persisting lesions after therapy whereas complete healing
was observed in 29 patients (29/52; 55.8%).
Half of patients (20/41; 48.8%) with desquamative gingivitis had
persisting lesions after therapy, whereas in only 51.2% of cases complete
healing was observed (21/41) (Table 2.16).
2.3.6.2 Analysis 2: comparison between group A and group B
Symptoms
Most patients of group A had improvement of their painful symptoms with
almost 71% of individuals reported no pain after therapy. This percentage
was slightly lower in group B (49/86; 57%).
Clinical signs
Mucosal ulceration/erosion
Both groups of patients exhibited significant improvement in the
prevalence of oral mucosal ulceration. In group A, 43/100 (43%) initially
had mucosal ulceration/erosions and after treatment this was reduced to
32.6% (14/43) (P< 0.001). In group B, 52/86 (60.5%) initially had ulcers
and/or erosions and this reduced to 23/52 (44.2%) after treatment (P<
0.001).
Comparison between the 2 groups showed that patients in group B had
significantly more mucosal ulceration/erosion before therapy than group A
(P=0.03). However at the end of the observation period, there was no
statistical difference between the 2 groups in regard to their mucosal
ulcerations (P=0.33).
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Gingival involvement (desquamative gingivitis)
There was significant improvement in desquamative gingivitis only in
group B. In group A, 44/100 (44%) initially present with gingival
involvement and after treatment this was reduced to 33% (P=0.65). In
group B, 41% initially had gingival involvement and this reduced to 23.3%
after treatment (P= 0.006).
There was no significant difference between the 2 groups of patients in
their gingival involvement in the start or at the end of the study (P=0.72
and 0.09 respectively).
2.3.6.3 Analysis 3: First, last and serial measurements of group B (i.e
those receiving tacrolimus)
Symptoms before therapy vs. last review
Of the 15 patients who had disease symptoms status of 2 (severe pain) at
start of tacrolimus therapy, 12 (80%) reported a reduction of pain to
disease status 0 (11/12; 91.7%) or 1 (1/12; 8.3%). Three patients
reported persistence of disease status 2.
Of the 50 patients who had disease symptoms status 1 (moderate pain),
43 (86%) reported reduction to disease status 0. One patient had an
increase to disease status 2 and 6 patients reported persistence of
moderate pain.
Of the 16 patients who had disease symptoms status of 0 (no/mild pain)
at start of tacrolimus therapy, 15 (93.8%) reported stable disease (status
0) at the end of therapy. One patient reported disease status 1.
Serial measurements of symptoms
Analysis of patients’ symptoms calculated upon serial measurements of
symptoms during 6-month reviews shows absence of/mild pain (disease
status 0) was the most common disease status during therapy. It was
present in 66/81 (81.5%) patients. Disease status 1 and 2 were the most
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frequent disease status in 11/81 (13.6%) and 4/81(4.9%) patients
respectively.
Signs before therapy vs. last review
Of the 14 patients who had disease signs status of 2 (erosions affecting
>70% of oral mucosa) at the start of tacrolimus therapy, 11 (78.6%)
reported a reduction of disease status to status 0 (9/11; 81.8%) or 1
(2/11; 18.2%). 3 patients reported persistence of disease status 2.
Of the 57 patients who had disease signs status 1(erosions affecting 30-
70% of oral mucosa), 49 (86%) reported reduction to disease status 0.
One patient disease status increased to 2 and 7 patients reported
persistence of pre-therapy disease status.
Of the 10 patients who had disease signs status of 0 at start of tacrolimus
therapy, 9 (90%) reported stable disease at the end of the therapy. One
patient had an increase of disease status to 1.
Serial measurements of signs
Analysis of the response to topical tacrolimus calculated upon serial
measurements of disease signs status during 6-month reviews shows
that disease status 0 was the most common disease status (>50% of
reviews) it was reported in 65/81 (80.2%) patients. Disease status 1 and 2
were the most frequent in 12/81 (14.8%) and 4/81 (4.9%) patients
respectively.
2.4.7 Adverse side effects and malignant transformation
Twenty nine (15.6%) patients had adverse side effects (ASEs). In the
majority of instances, patients had only 1 ASE (19/29; 65.5%). Four
patients had 2 ASEs (4/29; 13.8%), 5 (17.2%) had 3 ASEs and 1 had 4
ASEs. Most adverse effects in this cohort of OLP patients were
associated with topical tacrolimus.
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Patients not prescribed topical tacrolimus (Group A)
Only two patients in this group had adverse side effects. One complained
of burning sensation, due to topical application of fluticasone propionate
0.05%, and one had worsening of his gastroesophageal reflux which
necessitated the cessation of betamethasone mouthwash.
Patients prescribed topical tacrolimus (Group B)
Twenty seven patients reported adverse side affects. Eighteen patients
(20.9%) complained that the topical tacrolimus gave rise to oral side
effects that included local burning (3 patients), tingling sensation (6), a
peppery taste (3), other taste disturbances (2), a stinging sensation (2) or
local irritation (2).
All 5 patients in this group who had systemic azathioprine developed side
effects including cutaneous rash (1 patient), fever (1), nausea (2)
vomiting (3), dizziness (1) and headache (1).
In one patient (who also had type I diabetes mellitus) fluticasone
propionate spray caused an elevation of plasma glucose. Other side
effects had been reported such as diarrhoea, angular cheilitis, dryness of
the mouth, panic-anxiety, tiredness, shaking, bladder irritation and
haematuria. Additional details on adverse side effects of different
therapies used in this cohort of patients in Table 2.17.
Malignant transformation
One patient (72.4 year old male) who did not receive topical tacrolimus
developed reactive atypia while another patient on topical tacrolimus
developed oral squamous cell carcinoma (48 year old female).
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2.5 DISCUSSION
Oral lichen planus (OLP) is a common oral mucosal disorder that
adversely affects the patients’ quality of life (Tabolli et al., 2009). Although
OLP is common, there still controversy surrounding its diagnostic criteria,
association with hepatitis, and potential for malignant transformation. In
addition, there is no consensus on long-term management or strong
evidence on the most effective therapy. The aim of the present chapter
has been to determine the outcomes and safety of current OLP
management in one tertiary centre.
The demographics of the present patient cohort confirmed recent reports
from Italy (Mignogna et al., 1998; Carbone et al., 2009a), USA (Chainani-
Wu et al., 2001; Eisen, 2002), UK (Ingafou et al., 2006), Iran (Pakfetrat et
al., 2009), and China (Xue et al., 2005) that OLP is primarily a disease
affecting middle to late age females. Although OLP is most commonly
diagnosed in fifth and sixth decades of life, it can affect younger people
(Sharma and Maheshwari, 1999; Nnoruka, 2007; Woo et al., 2007;
Mathew et al., 2008) as demonstrated in the present group of patients.
The mean duration of symptoms before patients attended oral medicine
was 31.9 months, suggesting perhaps that misdiagnosis or delay in
referral may be a frequent occurrence. The referral delay may indicate
that some patients were managed by general dental practitioners (GDPs),
general medical practitioners, or medical specialist (e.g., dermatologist).
Some GDPs may be familiar with OLP, as it is one of the most common
mucocutaneous disease affecting the mouth, and may have prescribed
topical agents such as benzydamine hydrochloride or topical
corticosteroids to control symptoms, especially if the disease was mild
(López-Jornet et al., 2009). However, as a substantial number of this
cohort presented initially with only gingival lesions, it could be surmised
that many GDPs assumed that the clinical condition represented plaque-
related gingivitis, hence underlying the delayed referral (Mignogna et al.,
2005).
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The oral clinical features of OLP have been described in detail in several
large cohorts (Mignogna et al., 1998; Chainani-Wu et al., 2001; Eisen,
2002; Xue et al., 2005; Ingafou et al., 2006; Carbone et al., 2009a;
Pakfetrat et al., 2009). In the present study, OLP gave rise to multiple
areas of erosions/ulceration usually with a lichenoid background
characterised by red and white lesions and the presence of the classical
Wickham’s striae. The lesions most commonly affected buccal mucosa,
gingivae, and tongue as previously reported (Pakfetrat et al., 2009). The
tongue was more commonly affected than the gingivae in some studies
(Gorsky et al., 1996; Xue et al., 2005; Ingafou et al., 2006).
A recent study reported 12% of patients had extra-oral involvement
(Carbone et al., 2009a). Twenty-five (13.4%) patients of the present
cohort had a history of clinical and/or histopathological evidence of extra-
oral OLP. Most of the patients presented with only one extra-oral site
involvement in agreement with others (Bidarra et al., 2008), with the skin
the most commonly affected site (19; 10.2%), similar to the results of
Chainani-Wu et al. (2001) and Carbone et al. (2009), who reported skin
involvement in 11.4% and 7.8%, respectively. This small number of
patients with cutaneous involvement may reflect a referral bias, as
patients with predominately skin lesions will be referred to a
dermatologist, and those referred to oral medicine specialist have mainly
oral mucosal involvement. The genitalia, especially in women, is another
site which may be affected and underreported by cohort from dental
tertiary units (Eisen, 1994; Bidarra et al., 2008).
LP may affect the oral mucosa before, after, or simultaneously with extra-
oral involvement. Although all three situations were reported in the current
cohort, OLP commonly preceded the appearance at other
mucocutaneous sites as reported previously (Ingafou et al., 2006;
Pakfetrat et al., 2009), but of course this may simply reflect a bias of
patients with oral disease being referred to an oral medicine unit.
Chapter 2 Oral lichen planus
59
In summary, the clinical picture of OLP in this cohort of patients was
dominated by oral erosions/ulceration, desquamative gingivitis, and less
frequently by associated mucocutaneous involvement.
Both diabetes mellitus and hypertension have been suggested to be
associated with lichen planus (Grinspan et al., 1966; Lamey et al., 1990).
In present cohort, 21 (11.3%) and 42 (22.6%) patients had diabetes or
hypertension, respectively. In 2005/2006, the prevalence of diabetes
mellitus and hypertension was estimated to affect 3.6% and 12.0% of the
UK population, respectively (UK-Quality and Outcomes Framework for
GP databases). Therefore, the prevalence of both disorders is
considerably higher in our cohort patients. However, the age group of the
present cohort may account for these observations.
There are no widely accepted guidelines for treating OLP. A systematic
review in the Cochrane database (Chan et al., 2000) concluded that there
is weak evidence to support any agent over a placebo. The authors
recommend that large, well designed placebo-controlled randomised trials
were necessary determine the efficacy of different therapeutic agents to
assist clinicians in identifying appropriate medications to treat OLP.
Although patients were prescribed different topical and/or systemic
agents before attending to Oral Medicine clinics they still complained of
pain and active disease. The failure may be due to wrong diagnosis,
failure to use the appropriate agent or dosage or it could reflect the
severity of the disease.
A wide variety of preparations, forms, and concentrations of topical
corticosteroids were employed in present cohort of patients depending on
disease severity, clinical presentation, and/or patient’s preference (as
they used these agents for extended periods). Most patients were initially
managed with topical corticosteroids, the conventional OLP treatment
(Donovan et al., 2005), which reduced the symptoms of most (71%)
patients in group A (patients not received topical tacrolimus) who received
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these agents. However, the remaining patients (86 patients) required
topical tacrolimus and/or systemic agents to control symptoms.
Topical tacrolimus has been reported to be effective in the management
of OLP (Kaliakatsou et al., 2002; Olivier et al., 2002; Hodgson et al.,
2003; Thomson et al., 2004; Lozada-Nur and Sroussi, 2006; Radfar et al.,
2008; Corrocher et al., 2008). However, there are little substantial data on
the long-term benefits.
The results of the present study demonstrate that topical corticosteroids,
particularly the high potent agents, and topical tacrolimus are effective to
the same degree in managing symptomatic OLP. Both agents induce
lessening of symptoms and oral mucosal lesions. However,
corticosteroids may be more acceptable than topical tacrolimus as many
patients who receive the latter complained of local adverse side effects.
Recently 2 randomized controlled studies have been conducted to
investigate the efficacy of topical tacrolimus in comparison with 2 different
preparations of topical corticosteroids in the management of OLP. The
studies assessed the efficacy of 0.1% topical tacrolimus ointment in
comparison with 0.1% triamcinolone acetonide ointment 4 times daily (40
patients over a 6-week period) (Laeijendecker et al., 2006) and
clobetasol 0.05% (30 patients over a 6-week period) (Radfar et al., 2008)
in the management of OLP. The first study found that topical tacrolimus
was more effective, in short-term than triamcinolone acetonide. While the
later found no difference between clobetasol and tacrolimus. This result
may partially explain as clobetasol is more potent than triamcinolone
acetonide. At the end of observation period of the present study, there
was no statistically significant difference in symptoms between the two
groups. This might reflect the fact that patients on tacrolimus presented
initially with more severe oral mucosal erosions and ulcerations.
Topical tacrolimus resulted in rapid pain control in some patients (data not
shown), suggesting that there is some short-term benefit as reported
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previously (Laeijendecker et al., 2006). Thus it may be considered for
patients’ recalcitrant to corticosteroid treatment to control painful
symptoms. Both the US Food and Drug Administration and The European
Medicines Agency recommend intermittent, short-term (i.e., 2 week) use
of topical tacrolimus. In the present cohort tacrolimus was used to control
the pain quickly and to manage flare-ups and the patient then reverted to
the first line treatment, topical corticosteroids.
OLP is a chronic disorder with periods of remission and relapse (Xue et
al., 2005; Roosaar et al., 2006) and spontaneous remission is rare
(Bidarra et al., 2008). A substantial number of present patients still had
oral mucosal lesions, mainly white or atrophic lesions, at the end of the
data collection period. However, persistence of these lesions does not
necessarily correlate with symptoms and considered improvement from
the original status (Carbone et al., 2009a). Erosion and ulceration are
commonly resolved with treatment; while other lesions, such as the
lichenoid and white lesions, are more persistent and perhaps unlikely to
resolve with any topical and/or systemic agents.
Most of the patients who experienced ASEs were prescribed topical
tacrolimus (18 patients). Topical tacrolimus is associated with a number
of local ASEs (Corrocher et al., 2008) however most of these are
transient and resolve when the patient stops the medication or have
resolution of their mucosal erosions. Patients reported tingling, peppery
taste and taste disturbance, stinging sensation, and irritation. There were
minimal ASEs reported by patients receiving topical corticosteroids, and
included burning sensation and worsening of gastroesophegeal reflux
developed in 2 patients reflecting the high safety profile of these agents.
The malignant potential of OLP is an area of controversy (Lodi et al.,
2005a). In the present study after a mean observation period of 2.2 years,
one patient developed neoplasia in the 86 patients treated with tacrolimus
while none of the 100 patients receiving other therapies developed any
oral tumors in pre-existing OLP lesions. However both dysplasia and
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neoplasia, which developed in patients who received tacrolimus therapy,
developed in sites other than the original site of the biopsy thus it, cannot
be concluded that the tacrolimus was the cause of malignant
transformation. Although the atrophic and erosive forms of OLP have
been reported to present a higher malignancy risk compared with other
forms of the disease, (Markopoulos et al., 1997), a recent report (Carbone
et al., 2009a) found that atrophic and erosive lesions are not at higher risk
than other OLP forms and the presumed malignant potential is not
affected by the type of the therapeutic agents used in the management of
OLP. Although these authors did not investigate the risk of topical
tacrolimus these observations may give weight to the notion that
tacrolimus is not a significant co-factor in the malignant transformation
risk of OLP.
The main limitation of the present study is its retrospective design and
associated methodological inadequacies, including differences in
reporting clinical features and outcomes, and variations in diagnostic and
monitoring procedures.
There is a need to uniformly define terms such as relapse, flare-up, and
resolution therapeutic response and to conduct well-designed, controlled
randomized studies. A standardized method of reporting signs and
symptoms during routine clinical reviews is important to obtain maximum
benefit of patient’s observations as this represents a useful source of
information for evaluating long-term outcomes and the efficacy of different
therapies. Clinicians should include clear information on dosage, form
and preparation, and duration of the therapeutic agents used in different
treatment stages in each patient chart.
Patient records should also contain all clinical, histopathological,
serological, haematological test results. A clear clinical charting of the
mucosal lesions utilizing the appropriate scoring systems, at least one of
the available invalidated systems used in previous published papers. The
present study showed the need of establishing a simple, widely accepted
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standardized scoring system to record the oral lesions of immune-
mediated disorders, including OLP, which will help researchers and
practitioners better evaluate a patient’s condition and needs and to
evaluate the efficacy of different agents used in the management of oral
mucosal lesions.
In addition, establishment of national and international registers (although
there are some in some countries) for rare diseases will help us to
understand various aspects of these disorders including the most
effective treatment options.
2.6 CONCLUSION
The results of this study indicate that symptomatic OLP remains difficult
to manage. Tacrolimus is not superior to topical corticosteroids, and
malignant transformation is rare with topical corticosteroids and/or
tacrolimus.
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Table 2.1 Example of some studies that reported patients with oral lichen planus*
GenderAuthor
year
No. of
patients
Age (range)
years F M
F:M
ratio
Gingivae Skin Genitalia
Carbone et al.,
2009a
808 Men (58.3)
and women
(61.4)
(45.9-74.7)
493 315 1.6:1 33% 63 24
Bermejo-Fenoll
et al., 2009
550 56.4 (42.8-70) 442 128 3.5:1 - - -
Pakfetrat et al.,
2009
420 41.6 (13-75) 273 147 1.9:1 - 15.5% -
Camacho-Alonso
et al., 2007
213 NR** (14-90) 170 43 4:1 82
(38.4%)
0 0
Ingafou et al.,
2006
690 52 (16-83) 439 251 1.8:1 145 - 11
Xue et al.,
2005
674 50.4 (10-78 444 230 1.9:1 205 77
(11.4%)
-
Mignogna et al.,
2005
700 NR (18-83) 420 280 1.5:1 336
(48%)
- -
Eisen,
2002
723 NR (13-82) 544 179 3.1:1 401 - -
Chainani-Wu et al.,
2001
229 55 (NR) 154 75 2.1:1 - 26(11.4%)
-
* Cohorts of >200patients in last 10 years. ** NR: Not reported
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Table 2.2 Studies reporting the prevalence of Hepatitis C virus in patients with lichen planus
Study Year Country Study group (LP) Control group
Patients
Total Pts with OLP
HCV
seriopositive No Origin
HCV
seriopositive
Stojanovic et al., 2008 Slovenia 173 71 2 218 Dermatology patients 0
Michele et al., 2007 Italy 79 79 9 466 Acute trauma (orthopaedic) 25
Amer et al., 2007 Egypt 30 NR 21 30 Dermatology patients 1
Ali and Suresh 2007 Saudi Arabia 40 40 0 40 Dental patients 0
Yarom et al., 2007 Israel 62 62 3 65 Other oral mucosal lesions 1
225452 Volunteer blood donors 240
Das et al., 2006 India 104 NR 2 150 HIV-I and II and HCV
negative?
0
Laeijendecker et al., 2005 Netherlands 100 100 0 100 Psoriasis vulgaris 0
Rahnama et al., 2005 Iran 66 NR 1 140 Blood donors 3
Asaad and Samadani 2005 Saudi Arabia 114 7 30 65 Volunteers from relatives 3
Karavelioglu et al., 2004 Turkey 41 NR 2 18360 Blood donors 459
Ghodsi et al., 2004 Iran 146 NR 7 319375 Blood donors 309
Harman et al., 2004 Turkey 128 52 8 128 Healthy persons 1
Bokor-Bratic, 2004 Serbia 48 48 0 60 Dental patients 0
Chung et al., 2004 Taiwan 32 32 14 1034 Community-based sample 287
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Table 2.2 (Cont.) Studies reporting the prevalence of Hepatitis C virus in patients with lichen planus
Study Year Country Study group (LP) Control group
Patients
Total Pts with OLP
HCV
seriopositive
No Origin HCV
seriopositive
Lodi et al., 2004 Italy 303 303 58 278 Dental patients 9
Denli et al., 2004 Turkey 140 NR 7 280 Dermatosis other than LP 4
Gimenez-Garcia and
Perez-Castrillon
2003 Spain 101 53 9 99 Dermatology patients 2
Klanrit et al., 2003 Thailand 60 60 4 60 Dental healthcare workers 0
Garg et al., 2002 Nepal 64 29 0 43 Unknown 0
Daramola et al., 2002 Nigeria 57 NR 9 24 A. Dermatology patients 6
24 B. Healthy subjects 0
Figueiredo et al., 2002 Brazil 68 68 6 726 Sao Paulo residents 14
Beaird et al., 2001 USA 24 NR 4 20 Dermatology patients 1
Erkek et al., 2001 Turkey 54 7 7 54 Dermatology patients 2
Kirtak et al., 2000 Turkey 73 27 5 73 Dermatology patients 1
Ibrahim et al., 1999 Egypt 43 NR 9 30 Dermatology patients 3
Tucker et al., 1999 UK 45 13 0 32 Dermatology patients 1
Chuang et al., 1999 USA 22 NR 12 40 Psoriasis patients 10
149756 Volunteer blood donors 255
Mignogna et al., 1998 Italy 263 263 76 100 Dental patients 3
Ingafou et al., 1998 UK 55 0 0 110 Dental healthcare worker 0
Ilter et al., 1998 Turkey 1998 75 0 75 Dermatology patients 0
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Table 2.2 (Cont.) Studies reporting the prevalence of Hepatitis C virus in patients with lichen planus
Study Year Country Study group (LP) Control group
Patients
Total Pts with OLP
HCV
seriopositive No Origin
HCV
seriopositive
Bagan et al., 1998 Spain 100 100 23 100 Healthy individuals 5
Dupin et al., 1997 France 102 102 8 306 Surgical patients 14
Imhof et al., 1997 Germany 84 45 13 87 Dermatology patients 1
Sanchez-perez et al., 1996 Spain 78 56 16 82 Dermatology patients 2
Carrozzo et al., 1996 Italy 70 70 19 70 Unrelated oral keratosis 3
Tanei et al., 1995 Japan 45 37 17 45 Surgical patients 3
Gimenez-arnau 1995 Spain 25 NR 11 18 NR 1
Bellman et al., 1995 USA 30 NR 7 41 Dermatology patients 2
Cribier et al., 1994 France 52 4 2 112 Dermatology patients 3
Santander et al., 1994 Spain 50 NR 19 27 Dermatology patients 1
Narayan et al., 1998 India 75 NR 2 30 Healthy controls 0
Chuang et al., 1999 USA 22 NR 12 40 Psoriasis patients 10
149756 Volunteer blood donors 255
*Modified from Lodi et al., 2004 and Shengyuan et al., 2009
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Table 2.3 Studies reporting the malignant potential and systemic disorders that may
be associated with OLP
Authors
year
Patients
No.
Malignancy Liver disease Diabetes Hypertension
Carbone et al.,
2009a
808 15 (1.9%) patients
(3 men and 12
women; mean age;
67 [range; 57.7-
67.3 years])
More than 164
(20%) patients
had liver
abnormalities
137 were
hepatitis C
positive
1 12
Bermejo-Fenoll
et al., 2009
550 5 (0.9%) 17% had
positive hepatitis
C markers
NR NR
Fang et al.,
2009
2119 23 (1.1%) (mean
age; 52 years; 12
women and 11
men).
NR NR NR
Pakfetrat et al.,
2009
420 Dysplasia (7.1%),
OSCC (0.07%)
(2 males, 1 female)
NR NR NR
Ingafou et al.,
2006
690 OSCC (12 pts) and
carcinoma in situ
(1 pt)
NR NR NR
Xue et al.,
2005
674 4 (0.6%) NR 78
(11.6%)
NR
Mignogna et al.,
2005
700 21 (3%) NR NR NR
Eisen,
2002
723 6 (0.8%) 4 patients had
hepatitis C
5% 21%
Chainani-Wu et al.,
2001
229 4 (1.7%) Hepatitis C in
14/31 tested
patients
10 43
Bagán-Sebastián
et al.,1992
205 - 40 patients had
chronic liver
disease
27 -
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Table 2.4 Studies reporting the efficacy of different therapeutic agents in the management of oral lichen planus
Agent Study/Year Dose Study type No of
Pt’s
Results Adverse side effects
Clobetasol propionate
(0.025 or 0.05%) +
miconazole gel + 0.12%
chlorhexidine mouth rinse
Carbone et al.,
2009
Twice a day for 2 months Randomized
controlled trial
25 No difference
between the
2
formulations
No ASEs.
Clobetasol ointment +
miconazole + 0.12%
chlorhexidine ±
prednisone
Carbone et al.,
2003
Clobetasol 1-2 times/day
Prednisone (50 mg/day)
Comparative
study
49 Effective All ASEs associated with systemic
prednisone and including: elevation
of blood pressure, epigastric pain,
and water retention.
Clobetasol propionate
ointment (different
preperations)
Lo Muzio et al.,
2001
2-3 times/day Randomized 24/54 Effective Pseudomembranous candidiasis.
Clobetasol ointment
(0.05%)/ fluocinonide
ointment (0.05%) +
miconazole gel and 0.12%
chlorhexidine mouthwashe
Carbone et al.,
1999
- Placebo-
controlled,
comparative
60 Effective None.
Fluocinolone acetonide
(0.1% solution and/or
orabase)
Thongprasom et al.,
2003
1-3 times/day Retrospective 97 Effective Oral candidiasis.
Fluticasone propionate
spray/
betamethasone sodium
phosphate mouthrinse
Hegarty et al.,
2002
4 times/day Randomize,
crossover
48 Effective All ASEs associated with fluticasone
spray and including: nausea,
swollen mouth, bad taste and smell,
difficulty in spray application, dry
mouth, sore throat, red, painful
tongue and pseudomembranous
candidosis.
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Table 2.4 (Cont.) Studies reporting the efficacy of different therapeutic agents in the management of oral lichen planus
Agent Study/Year Dose Study type No of
Pt’s
Results Adverse side effects
Fluocinonide gel (0.05%)/
fluocinonide ointment in
Orabase (0.05%)/
clobetasol gel (0.05%)/
clobetasol ointment in
orabase (0.05%)
Chainani-Wu et al.,
2001
1-4 times/day Retrospective,
descriptive
229 Effective Oral candidiasis.
Fluocinolone acetonide
(0.1% gel or oral base)
Buajeeb et al.,
2000
4 times/day Randomized 48 Effective No significant ASEs.
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Table 2.4 (Cont.) Studies reporting the efficacy of different therapeutic agents in the management of oral lichen planus
Agent Study/Year Dose Study type No of
Pt’s
Results Adverse side effects
Volz et al.,
2008
Twice/day
Pimecrolimus 1% cream
Randomized
controlled
20 Effective Burning sensations and slight
paraesthesia in 5/10 patients
Dissemond,
2008
Twice/day
Pimecrolimus adhesive
ointment (0.5%) (1:1 of 1%
cream and a hydrophilic
adhesive gel base)
Case report 1 Effective None
Erkek et al., 2007 Pimecrolimus 1% cream Case report 1 Effective
(used for
remission
maintenance
Not reported
Gorouhi et al.,
2007
4 times/day
Pimecrolimus 1% cream
Randomized 40 Effective Transient burning sensation in 2
patients
Passeron et al.,
2007
Twice/day
Pimecrolimus 1% cream
Randomized
controlled
12 Effective Transient burning sensation in 2
patients
Scheer et al.,
2006
Twice/day
Pimecrolimus 1% cream
Case series 5 Effective Difficult application
Swift et al., 2005 Twice/day
Pimecrolimus 1% cream
Randomized
controlled
20 Effective Transient burning sensation in 1
patient
Dissemond et al.,
2004
Twice/day
Pimecrolimus 1% cream
Case report 1 Effective Transient burning sensation
Topical pimecrolimus
Esquivel-Pedraza et
al., 2004
2-5 times/day
Pimecrolimus 1% cream
Case series 3 Effective None
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Table 2.4 (Cont.) Studies reporting the efficacy of different therapeutic agents in the management of oral lichen planus
Agent Study/Year Dose Study type No of
Pt’s
Results Adverse side effects
Corrocher et al.,
2008
0.1% ointment
4 times/day
Controlled,
randomized,
32 Effective Transient (4-5 days) worsening of
burning sensation in 9/16 patients.
Radfar et al.,2008 1-4 times/day Controlled,
randomized
30 Effective -
Tavassol et al.,
2008
0.1% ointment twice daily Case series 11 Effective Rare and minor (not specified)
Erkek et al., 2007 - Case report 1 Effective -
Chaudhry et al.,
2007
0.1% ointment twice daily Case report 1 Effective -
Rabanal et al., 2007 0.1 % ointment twice daily Case report 1 Effective -
Becker et al., 2006 0.1% ointment twice daily Case report 1 Effective Development of squamous cell
carcinoma at the same site of
application of tacrolimus.
Lozada-Nur et al,
2006
0.1% tacrolimus in Orabase,
3 times/day for 14 days
Case series 10 Effective Recurrent headache (1 patient),
transient burning sensation (1).
Shichinohe et al.,
2006
0.1% tacrolimus, twice daily Case report 2 Effective None.
Laeijendecker et al.,
2006
0.1% ointment, 4 times/day
for 6 weeks.
Randomized
controlled
40 Effective Temporary burning/stinging
sensation in 8/20.
Riano Arguelles et
al., 2006
0.1% tacrolimus once daily Case report 1 Effective -
Topical tacrolimus
Donovan et al.,
2005
0.1% tacrolimus Case report 1 Effective -
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Table 2.4 (Cont.) Studies reporting the efficacy of different therapeutic agents in the management of oral lichen planus
Agent Study/Year Dose Study type No of
Pt’s
Results Adverse side effects
Fricain et al.,
2005
1% tacrolimus, twice/day
for 8 weeks
Case report 1 Effective Mucosal pigmentation.
Byrd et al.,
2004
0.03% and/or 0.1% tacrolimus Retrospective 37 Effective Local irritation (4 patients), burning
(5), tingling sensation (3), and
dysgeusia (2).
Shen and Pedvis-
Leftick, 2004
0.1% ointment twice/day
for 9 months
Case report 1 Effective Temporary brown discoloration of
oral mucosa.
Thomson et al.,
2004
0.1% tacrolimus in Orabase,
1-2 times/day
Retrospective 23 Effective Parasthesia and burning sensation
(6), dysguesia (1), dysguesia and
nausea (1).
Hodgson et al.,
2003
0.1% tacrolimus in paraffin
ointment twice/day
Retrospective 50 Effective Burning sensation (8), dysgeusia
(5), and headache (2).
Olivier et al.,
2002
Tacrolimus mouthwash (0.1
mg/100 mL of distilled water).
4 times/day for 6 months
Case series 8 Effective Transient burning sensation (3), dry
mouth (2).
Kaliakatsou et al.,
2002
0.1% tacrolimus in a paraffin
ointment base
Case series 17 Effective Tingling and burning sensation,
altered taste sensation, slight
nausea, mild headache and
constipation.
Morrison et al.,
2002
Tacrolimus 0.1% ointment or
in mineral oil. 2-3 times/day for
3 months
Case series 6 Effective None
Rozycki et al.,
2002
Tacrolimus ointment (0.03%,
0.1%, and 0.3%).
Retrospective 13 Effective Burning sensation (1 patient), sore
throat (1).
Lener et al.,
2001
0.1% Tacrolimus, twice/day
for 3 months
Case report 1 Effective -
Topical tacrolimus
Vente et al.,
1999
0·1% ointment, twice/day
for 4 weeks
Case series 4 Effective Burning sensation.
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Table 2.4 (Cont.) Studies reporting the efficacy of different therapeutic agents in the management of oral lichen planus
Agent Study/Year Dose Study type No of
Pt’s
Results Adverse side effects
Rapamycin Soria et al.,
2009
Topical rapamycin (1 mg/ml)
twice a day for 3 months
Open
prospective
7 Effective Local discomfort and detectable
blood sirolimus levels.
Hyaluronic acid 0.2% Nolan et al.,
2009
- Randomized,
placebo-
controlled,
double blind trial
124 Effective -
Topical isotretinoin (0.05%
and 0.18% concentrations)
Scardina et al.,
2006
Twice/day Randomized 70 Effective Transit increase in soreness, pain
and sensitivity to hot foods
Sulodexide Femiano and Scully,
2006
Oral sulodexide (250 units)
1-2 times/day
Open trial 12 Effective Dizziness, vomiting, and hot
flushes.
Intralesional triamcinolone
acetonide
Xia et al.,
2006
0.5 ml (40 mg/ml) Controlled,
short-term
45 Effective None.
Methylene blue-mediated
photodynamic therapy
Aghahosseini et al.,
2006
Patients gargle with 5%
methylene blue solution in
water for 5 minutes and after
10 minutes mucosal lesions
irradiated by laser light
(lambda = 632 nm, light
exposure dose = 120 J/cm2).
Open label 13 Effective Mild burning sensation.
Tazarotene gel 0.1% Petruzzi et al.,
2002
Twice/day Randomize,
controlled
12 Effective Transit burning sensation and taste
abnormalities.
Prednisone ±
azathioprine
Chainani-Wu et al.,
2001
Prednisone
40-80 mg/day
Azathioprine
50-100 mg/day
Retrospective,
descriptive
229 Effective Insomnia, mood swings, fatigue and
water retention, headaches,
nausea, dizziness, diarrhea,
increase in urinary frequency and
increased appetite.
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Table 2.5 Age of 186 oral lichen planus patients
Age Male Female Frequency %
10-19 2 0 2 1.1
20-29 1 4 5 2.7
30-39 5 13 18 9.7
40-49 10 30 40 21.5
50-59 21 37 58 31.2
60-69 7 31 38 20.4
70-79 6 15 21 11.3
80-89 0 1 1 0.5
90-99 1 2 3 1.6
Total 53 133 186 100
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Table 2.6 Ethnicity of patients with oral lichen planus
Ethnic group Frequency %
White British 90 48.4
Other White 9 4.8
Mixed-White and Asian 2 1.1
Asian-Indian 32 17.2
Asian-Pakistani 4 2.2
Asian-Bangladeshi 4 2.2
Chinese 1 0.5
Asian-other Asian 10 5.4
Black-Caribbean 1 0.5
Black-African 2 1.1
Black-other Black 1 0.5
Other ethnic group 11 5.9
Unknown 19 10.2
Total 186 100
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Table 2.7 Referral pattern of oral lichen planus patients
Source of referral Frequency %
General dental practitioners 103 55.4
Oral maxillofacial/oral surgeons 35 18.8
General medical practitioners 12 6.5
Dermatology 6 3.2
Periodontology 8 4.3
Restorative dentistry 2 1.1
Prosthodontics 2 1.1
Otolaryngology 2 1.1
Others 7 3.7
Unknown 9 4.8
Total 186 100
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Table 2.8 Past medical history at first visit to oral medicine clinic of 186 patients
with oral lichen planus
Condition No. %
Penicillin 18 9.7
Aspirin 2 1.1
Hay fever 9 4.8
Allergy
Others 19 10.2
Hypertension 42 22.6
Angina 3 1.6
Cardiovascular
Others 9 4.8
Asthma 16 8.6
Bronchietasis 1 0.5
Chronic obstructive pulmonary disease 2 1.1
Pneumonia 3 1.6
Respiratory
Sinus problems 3 1.6
Anaemia 10 5.4
Thalassemia 3 1.6
Haematological
Thrombocytopenia 1 0.5
Diabetes mellitus 21 11.3Endocrine
Thyroid dysfunction 18 9.7
Coeliac disease 3 1.6
Hepatitis (type unknown) 9 4.8
Jaundice (cause unknown) 6 3.2
Gastric ulceration 5 2.7
Ulcerative colitis 2 1.1
Barrett’s oesophagitis 1 0.5
Constipation 1 0.5
Diverticulitis 3 1.6
Haemorrhoids 2 1.1
Hernia (inguinal) 8 4.3
Irritable Bowel Syndrome 4 2.2
Duodenal ulcer 2 1.1
Perianal irritation 1 0.5
Gastro-oesophageal reflux disease 3 1.6
Oesophegeal varices 1 0.5
Gastrointestinal
tract
Others 2 1.1
Renal disease 4 2.2Genito-urinary
Urinary tract disease 5 2.7
Visual 13 7.0
Hearing 7 3.8
Epilepsy 2 1.1Central nervous
system Stroke 2 1.1
Mental health Psychiatric problems (varies) 11 5.9
Others Acne, acoustic neuroma, alopecia, arthritis, back pain, breast cancer, carpal
tunnel syndrome, cerebrovascular accident, cervical cancer,
hypercholesterolemia, cystitis, dermatitis, dry skin and “skin lesions”,
eczema, fibroid, “frozen shoulder”, gout, knee pain, lichen sclerosus, limited
scleroderma (CREST syndrome), lumber spondylosis, migraine, migraine-
like disease, oesophageal varices, osteoarthritis, osteoporosis, polymyalgia
rhumatica, primary billary cirrhosis, prolapsed bowel, psoriasis, radiotherapy
for prostate cancer, Reynaud’s syndrome, rheumatoid arthritis, rheumatic
fever, sarcoidosis, sciatica, Sjogren's syndrome, vasculitis, vitiligo, vulvo-
vaginal dryness, wart-like lesions.
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Table 2.9 Past drug history of patients with oral lichen planus
Drug group Drug name No.
Calcium-channel blockers
Amlodipine 8
Nifedipine 3
Verapamil HCL 1
Diltiazem hydrochloride 1
Felodipine 1
Beta-adrenoceptor blocking drugs
Propranolol 3
Atenolol 13
Sotalol 1
Potassium-channel activators
Nicorandil 2
Diuretics
Bendroflumethiazide 7
Frusmide 2
Amiloride 1
Spironolactone 1
Indapamide 1
Angiotensin converting enzyme inhibitors
Losartan potassium 2
Ramipril 2
Valsartan 1
Enalapril 5
Others
Digoxin (cardiac glycosides) 1
Co-amilofruse 1
Simvastatin 11
Atorvastatin 5
Pravastatin 1
Isosorbide mononitrate 2
Isosorbide dinitrate 2
Glyceryl trinitrate 3
Valsartan 1
Salmeterol (long-acting beta 2 adrenergic receptor
agonist)
1
Candesartan cilexetil (angiotensin-II receptor antagonists) 1
Irbesartan (angiotensin-II receptor antagonists) 1
Navispare® (amiloride with thiazides) 1
Clopidogrel (antiplatelet) 1
Candesartan (angiotensin-II receptor antagonists) a 1
Cardiovascular
Prazosin (alpha-adrenoceptor blocking) 1
Beclomethasone dipropionate (corticosteroids) 1
Salbutamol (selective beta 2 agonists) 10
Salmeterol (selective beta 2 agonists) 1
Terbutaline sulphate 1
Respiratory
Ipratropium (anticholinergic drug) 3
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Table 2.9 (Cont.) Past drug history of patients with oral lichen planus
Drug group Drug name No.
Thyroid hormones
Thyroxin 18
Levothyroxine sodium 1
Antidiabetic
Insulin 6
Metformin 10
Glibenclamide 2
Gliclaside 3
Glipizide 1
Rosiglitazone 2
Vitamin D
Adcal-D3 2
Calcichew 3
Endocrine
Other
Hormone replacement therapy
14
Rantidine (H2-receptor antagonists) 5
Cimetidine (H2-receptor antagonists) 2
Sulfasalazine (aminosalicylates) 1
Lansoprazole (proton pump inhibitors) 4
Omeprazole (proton pump inhibitors) 10
Salazopyrin (aminosalicylates) 1
Mesalazine 1
Loperamide hydrochloride 2
Gaviscon (compound alginates) 2
Gastrointestinal
Ursodeoxycholic acid (drugs affecting biliary composition
and flow)
1
Temazepam (benzodiazepines) 1
Flurazepam (benzodiazepines) 1
Diazepam (benzodiazepines) 1
Prothiaden (tricyclic antidepressants) 1
Fluoxetine (antidepressant) 1
Carbamazepine (antiepileptic drugs) 2
Phenytoin (antiepileptic drugs) 1
Nortriptyline (tricyclic antidepressants) 1
Amitriptyline (tricyclic antidepressants) 3
Venlafaxin (antidepressants) 1
Central nervous
system
Clomipramine hydrochloride (tricyclic antidepressants) 1
Topical
Betamethasone 1
Clobetasol propionate 1
Fluticansone propionate (flixonase spray) 3
Betamethasone esters 3
Mometasone furoate 1
Fluocinolone acetonide 1
Corticosteroids
Systemic
Prednisolone 4
Ferrous sulphate 3
Folic Acid 1
Iron supplements 11
Ferrous gluconate 1
Vitamin B-12 1
Vitamin E 1
Vitamin K 1
Vitamins, nutrition
and blood
Pharmaton (multivitamins and minerals) 1
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Table 2.9 (Cont.) Past drug history of patients with oral lichen planus
Drug group Drug name No.
Alendronic acid 4Bone metabolism
Etidronate disodium 1
Aspirin 17
Feverfew (migraine) 1
Co-codamol (headache) 1
Acetaminophen (paracetamol) 6
Coproxamol (paracetamol and dextropropoxythene) 1
Co-dydramol (paracetamol and dihydrocodeine tartrate) 1
Diclofenac sodium (NSAIDs) 2
Napratec (NSAIDs) 1
Ibuprofen (NSAIDs) 5
Etoricoxib (NSAIDs) 1
Arthrotec® (diclofenac with misoprostol, NSAIDs) 2
Voltarol gel patch® (topical NSAIDs) 1
Coproxamol (compound analgesic preparations) 1
Tramadol hydrochloride (opioid analgesics) 1
Hydroxychloroquine (antimalarials) 1
Terbinafine hydrochloride (antifungal) 1
Aciclovir (antiviral drugs) 1
Oxytetracycline (antibacterial) 1
Clotrimazole (antifungal) 1
Biotène Oralbalance® (dry mouth treatment) 1
SST tablets (dry mouth treatment) 1
Salivix® (dry mouth treatment) 1
Betahistine dihydrochloride (used in nausea and vertigo) 1
Allopurinol (anti-gout) 2
Premique® (conjugated oestrogens with progestogen) 1
Hypromellose (ocular lubricants) 1
Cosopt® Eyedrops (treatment of glaucoma) 1
Lacrilube ointment 1
Hydroxyzine hydrochloride (antihistamines) 1
Others
Oxybutynin (anticholinergic agent for urinary and bladder) 1
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Table 2.10 Different therapeutic agents prescribed to patients to manage OLP
lesions before attending the Oral Medicine clinics
Drug group Drug name
No of
patients
Topical
Triamcinolone acetonide in 0.1% carmellose paste
(Adcortyl in Orabase)
28
Hydrocortisone sodium succinate (Corlan pellets) 24
Betamethasone sodium phosphate (Betnesol) 19
Beclomethasone (Bectoid) 11
Fluticasone propionate (Flixonase spray) 9
Clobetasol propionate (Dermovate) 1
Tri-adcortyl (Triamcinolone, nystatin, neomycin,
gramicidin)
1
Prednisol mouthwash 1
Other topical corticosteroids 7
Systemic
Prednisolone 9
Corticosteroids
Intralesional corticosteroids 1
Anti-viral
Aciclovir 1
Antibiotics
Metronidazole 5
Others (not specified) 5
Anti-fungal
Miconazole 4
Nystatin 5
Amphotericin B 1
Fluconazole 5
Anti-infective
agents
Others (not specified) 6
Ciclosporin (mouthwash) 2Calcinurin
inhibitors Topical tacrolimus (protopic) 1
Azathioprine 2
Bonjela® 2
Chlorhexidine gluconate 24
Benzydamine hydrochloride (Difflam) 16
Hydrogen peroxide 1
Others
Laser ablation 1
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Table 2.11 Histopathological features of 158 biopsies of patients
with oral lichen planus
Histopathological features Total
Thickening of basement membrane 29
Irregular/hyperplasia of rete ridges 13
Pigmentary incontinence 11
Positive direct immunofluorescent (fibinogen) 17
Positive direct immunofluorescent (C3) 2
Apoptosis 18
Cytoid bodies 6
Civatte (colloid) bodies 12
Increase mitosis 1
Cell atypia 4
Dysplasia (mild) 2
Fungal infection 13
Bacterial infection 1
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Table 2.12 Distribution of oral lichen planus lesions
Site Frequency %
General distribution
Bilateral 132 71.0
Right 9 4.8
Left 11 6.0
Unknown 34 18.3
Buccal mucosa 127 68.3
Right 114 61.3
Left 109 58.6
Labial mucosa 6 3.2
Upper 3 1.6
Lower 5 2.7
Tongue 71 38.2
Dorsum 24 13.0
Lateral border 49 26.3
Ventral surface 13 7.0
Gingivae/desquamative gingivitis 95 51.1
Soft Palate 3 1.6
Hard Palate 8 4.3
Floor of the mouth 5 2.7
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Table 2.13 Different therapeutic agents used to control oral mucosal lesions in
group A (patients not prescribed topical tacrolimus)
Agent Frequency %
Topical agent
Fluticasone propionate- 0.05% cream (Cutivate) 23 23
Clobetasol propionate- 0.05% cream (Dermovate) 8 8
Fluticasone propionate,400 mcg in 15 mL of water as mouthwash 6 6
Fluticasone propionate,50 mcg per puff-(Flixonase) 61 61
Fluticasone propionate- 125 mcg per puff-(Flixotide Evohaler) 7 7
Prednsole mouthwash 3 3
Betamethasone mouthwash 58 58
Beclomethasone dipropionate 50, 100 or 250mcg per puff-
(Bectoide)
2 2
Triamcinolone acetonide in 0.1% carmellose paste 32 32
Hydrocortisone hemisuccinate pellets 5 5
Mometasone furoate 0.1% cream 1 1
Intralesional triamcinolone acetonide 1 1
Ciclosporin mouthwash 3 3
Systemic agent
Prednisolone 2 2
Azathioprine 1 1
Mycophenolate Mofetil 1 1
Pentoxifylline 1 1
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Table 2.14 Different therapeutic agents used to control oral mucosal lesions in
group B (patients prescribed topical tacrolimus)
Agent Frequency %
Topical agent
Fluticasone propionate- 0.05% cream (Cutivate) 54 62.8
Clobetasol propionate- 0.05% cream (Dermovate) 26 30.2
Fluticasone propionate,400 mcg in 15 mL of water as mouthwash 18 21.0
Fluticasone propionate,50 mcg per puff-(Flixonase) 54 62.8
Fluticasone propionate- 125 mcg per puff-(Flixotide Evohaler) 6 7.0
Betamethasone mouthwash 59 68.6
Beclomethasone dipropionate 50, 100 and 250 mcg per puff-
(Bectoide) 3
3.5
Triamcinolone acetonide in 0.1% carmellose paste 25 29.1
Hydrocortisone hemisuccinate pellets 7 8.1
Intralesional triamcinolone acetonide 1 1.2
Tacrolimus 0.03% 38 44.2
Tacrolimus 0.1% 75 87.2
Ciclosporin mouthwash 7 8.1
Systemic agent
Prednisolone 8 9.3
Deflazacort 10 11.6
Azathioprine 6 7.0
Mycophenolate Mofetil 3 3.5
Isotretinoin 1 1.2
Tacrolimus 1 1.2
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Table 2.15 Clinical features of group A (patients not prescribed topical
tacrolimus) at initial and last visit to Oral Medicine
Before therapy After therapy
14 (32.6%) with oral mucosal
ulceration/erosion
43 patients with oral mucosal
ulceration/erosion
29 (67.4%) without oral mucosal
ulceration/erosion
33 (75.0%) with desquamative
gingivitis
44 patients with desquamative
gingivitis
11 (25.0%) without desquamative
gingivitis
Table 2.16 Clinical features of group B (patients prescribed topical tacrolimus)
at initial and last visit to Oral Medicine clinic
Before therapy After therapy
23 (44.2%) with oral mucosal
ulceration/erosion
52 patients with oral mucosal
ulceration/erosion
29 (55.8%) without oral mucosal
ulceration/erosion
20 (48.8%) with desquamative
gingivitis
41 patients with desquamative
gingivitis
21 (51.2%) without desquamative
gingivitis
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Table 2.17 Clinically apparent and patient-reported drugs reactions
Drugs involved Adverse Drug Reaction Frequency
Systemic agents
Mycophenolate mofetil Bladder irritation and haematuria 1
Nausea 2
Vomiting 3
Rash 1
Fever 1
Headache 1
Dizziness 1
Azathioprine
Malaise 1
Systemic tacrolimus Diarrhoea 1
Nausea 1
Topical agents
Betamethasone
(Betnesol) Worsening gastric reflux 1
Clobetasol propionate
(Dermovate)
Burning sensation 1
Rash 1
Pseudomembranous candidosis 1
Nausea 1
Fluticasone
propionate (Cutivate)
Burning and local stinging 1
Prednesol mouthwash Mouth dryness 1
Local tingling 6
Burning sensation 3
Peppery taste 3
Stinging sensation 2
Taste disturbance 2
Local irritation 2
Indigestion 2
Nausea and vomiting 1
Topical tacrolimus
Tiredness and anxiety 1
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3.1 INTRODUCTION
Orofacial granulomatosis (OFG) is an uncommon disorder characterised by
recurrent or persistent swelling of the orofacial tissues. In addition, ulceration
and a variety of other oral mucosal and facial anomalies can occur. The term
granulomatosis reflects the chronic inflammatory nature of OFG which is
often characterized by the presence of granulomas in sub-epithelial stroma
(Wiesenfeld et al., 1985; Leao et al., 2004). The concept of OFG was initially
introduced by Wiesenfeld and co-workers in 1985, with the aim of
encompassing into a single entity those patients whose oro-facial
clinicopathological features resembled Crohn’s disease but who did not have
characteristic gastrointestinal findings of the inflammatory bowel disease
(Wiesenfeld et al., 1985). However, further to Crohn’s disease, OFG shows
several similarities also with other inflammatory and granulomatous
disorders that can affect the head and neck area. Chronic orofacial swelling,
with or without ulceration and inflammation of intraoral tissues can be found
in sarcoidosis. Orofacial granulomatosis is believed to be aetiopathologically
distinct from these disorders as their major distinctive clinical signs,
symptoms and/or laboratory changes are typically lacking in patients with
OFG. Diagnosis of OFG should be considered only when laboratory,
histopathological, clinical and radiological investigations have ruled out the
presence of the aforementioned disorders.
When the swelling/inflammatory process akin to OFG only involves the lips
the term cheilitis granulomatosa (Miescher’s cheilitis) has been applied
(Miescher, 1945). However, this is more likely to be a paucisymptomatic
form of OFG rather than a separate entity. In addition, relapsing craniofacial
neurological and neuro-vegetative manifestations have been described in
patients with OFG (Greene and Rogers, 1989). These occur more
commonly, but not exclusively, when chronic orofacial swelling is associated
with lingua plicata. This triad of signs has been labelled as Melkersson-
Rosenthal syndrome. Historically, Melkersson (1928) described a 35 years
old patient presented with facial palsy and orofacial swelling. Later,
Rosenthal (1932) reported a patient with same clinical features in addition to
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fissured tongue which known later as Melkersson-Rosenthal syndrome
(MRS). However, MRS may simply represent a subtype of OFG, where
orofacial swelling and intraoral mucosal changes are associated with
neurological manifestations and frequently, but not always, tongue fissuring.
Orofacial granulomatosis has the potential to cause significant adverse
effects upon patient well-being. The swelling of the lips and/or face may be
cosmetically unacceptable and may rarely cause difficulties of speech and
drooling. The intra-oral ulceration is painful, giving rise to dysphagia and
dysarthria and poor dietary intake (Leao et al., 2004).
There is still confusion about OFG, as some authors use the term to
describe a spectrum of OFG-like disorders including Melkersson-Rosenthal
syndrome, cheilitis granulomatosa, oral Crohn’s disease, and sarcoidosis
(Pryce and King, 1990; Rogers, 1996; Kolokotronis et al., 1997); however,
others restricted it to patients without systemic disease (i.e. Crohn’s and
sarcoidosis) (Grave et al., 2009; Al Johani et al., 2010). Recently
(Tilakaratne et al., 2008) coined the term idiopathic OFG to exclude those
patients with systemic disease and recommended re-diagnosing patients
who subsequently develop intestinal involvement.
Both OFG and the oral manifestations of Crohn’s disease are similar and the
histopathological features are indistinguishable. The exact relationship
between the two conditions remains unclear. However, Sanderson and co-
workers (2005) suggested that OFG is different from Crohn’s disease as the
aetiology for OFG is most likely related to dietary habits and diet modification
is more likely to benefit children with OFG than those with Crohn’s. In
addition, the inflammatory response in the intestinal mucosa differs between
the two disease processes as the intestinal mucosa of OFG patients seems
to have more granulomas than that from Crohn’s disease (Sanderson et al.,
2005).
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3.1.1 Epidemiology
As OFG is an uncommon disorder, epidemiological data are sparse.
However, clinical experience from centres where OFG patients are more
frequently referred suggests that the incidence of OFG is increasing (Rees,
1999; Leao et al., 2004). OFG may develop at any age and there is no
gender or racial predilection (Alawi, 2005; Lourenco et al., 2008) (Table 3.1).
However the clinical experience of colleagues in London (SR Porter, C
Scully and T Hodgson) suggests that OFG tends to arise in early adulthood.
Nevertheless, as OFG is uncommon in childhood, children with features of
possible OFG should be investigated for intestinal Crohn's disease (Khouri et
al., 2005).
3.1.2 Clinical features
The clinical manifestations of OFG are similar to those of the orofacial
features of Crohn’s disease and other granulomatous disorders. The clinical
features and differential diagnosis of OFG is summarized in Tables 3.2 and
3.3. The clinical features of OFG can be divided into intra-oral and
facial/extra-oral.
Intra-oral manifestations
Oral mucosal ulceration, cobblestoning, gingival enlargement
(granulomatous gingivitis) and mucosal tags are the most frequent intra-oral
manifestations of OFG. Other features may also present including lip
fissures (midline and/or angular), labial dryness and erythema. Recently
Shakeel et al (2009) reported a patient with tonsillar enlargement as a result
of OFG.
Two types of oral ulcers can arise, both of which are recurrent: linear and
deep with surrounding raised borders, commonly affecting buccal and/or
labial vestibule, and aphthous-like flat round-shaped ulcers that can arise on
any non-keratinised surface. Intra-oral ulceration can be associated with
painful symptoms and significantly impair quality of life of patients (Somech
et al., 2001).
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Oral mucosal swelling typically affects the buccal mucosa give rise to
notable thickening and folds, sometimes termed cobblestoning. The labial
mucosa may occasional be similarly affected.
Gingival enlargement in OFG is not uncommon and indeed the most
common affected site in a cohort of 12 cinnamon induced OFG patients
(Endo and Rees, 2007). In another study (Lourenco et al., 2008), five of the
29 (17%) patients had gingival involvement. This presented clinically as
erythema, oedema of interdental papillae, diffuse gingival infiltration,
granular hyperplasia, or gingival enlargement which may associated with
bleeding, periodontal fistulae or tooth mobility (Endo and Rees, 2007;
Lourenco et al., 2008). Gingival involvement may be localized or generalized,
but is commonly affect the anterior mandibular and/or maxillary gingivae
which may extend from the free gingival margin on to the non-keratinised
mucosa (Wiesenfeld et al. 1985; Lourenco et al., 2008). The gingival
inflammation is different from plaque-induced or non-specific gingivitis as it
clinically appears more granular.
Tongue fissuring can be present and this sometimes, but not always,
associated with increases in the risk of neurological manifestations (Greene
and Rogers, 1989). Fissures may be large with multiple grooves or single
and central (Worsaae et al., 1982; Greene and Rogers, 1989). The fissures
may be deep and can occasionally result in an accumulation of food debris,
which may lead to bad taste (dysgeusia), malodour, and burning sensation.
Facial/extra-oral manifestations
Labial/facial swelling represents possibly the major clinical feature OFG and
can affect any soft tissues of the head and neck area. Although enlargement
of the lip(s) is described to be the most common finding (Wiesenfeld et al.,
1985; Sanderson et al., 2005), swelling of the periorbital, zygomatic and
mental areas, as well as the maxillary site, can occur (Mignogna et al.,
2003). A few case reports have described isolated eyelid involvement
(Pierre-Filho Pde et al., 2004; Cocuroccia et al., 2005; Akarsu et al., 2005).
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Cervical lymph node enlargements can occasionally occur (James and
Ferguson, 1986).
Facial swelling can be widely variable, multiform, and temporary, making
early diagnosis of OFG difficult. The swelling can progress through different
stages (i) initially, it is soft, non-pitting and recurrent, resembling
angioedema, with involved tissues returning to their original size between
acute episodes; (ii) eventually, recurrences are followed by a mild, soft
permanent increase in size; (iii) finally, the swelling becomes persistent firm,
rubbery and/or fibrous (Kauzman et al., 2006). The labial enlargement can
affect upper and/or lower lips (Odukoya, 1994; Mignogna et al., 2003). The
lips may become dry, and median cheilitis and/or angular cheilitis may
develop leading to development of deep vertical cracks which may be painful
and bleed during lip movement (Leao et al., 2004). Angular/median cheilitis
can be secondarily infected by fungi (candida) and/or bacteria (Leao et al.,
2004).
Several neurological manifestations have been described in patients with
OFG. A lower motor neurone palsy of the facial nerve can arise in 20-33% of
the affected individuals (Zimmer et al., 1992; Worsaae et al., 1982). This
may arise months to years before or after tissue swelling (Vistnes and
Karnahan, 1971) and can be unilateral or bilateral and partial or complete.
Palsy usually resolves with complete recovery; although, some patients may
have residual facial weakness (Alexander and James, 1972; Pino Rivero et
al., 2005; Khandpur et al., 2006).
The facial palsy may be accompanied by changes in taste, hearing, or
earache (Cockerham et al., 2000). The glossopharyngeal and vagus nerves
have occasionally been affected (Khandpur et al., 2006). Other reported
neurological manifestations include hyperhidrosis, hypogeusia, glossodynia,
acroparesthesia, hyperacusia, lacrimation, sweating, migraine-like
headache, and blepharospasm (Hornstein, 1973; Stosiek et al., 1992).
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Gastrointestinal
The inclusion of gastrointestinal features as part of OFG is controversial.
Some clinicians consider the absence of symptoms and signs of
gastrointestinal (usually lower bowel) disease to be a key factor of the
diagnosis of OFG, although others seem to have a contrasting view. As a
consequence the exact relationship between OFG and inflammatory bowel
disease is unclear.
There are contradicting results of the frequency of gastrointestinal (GI)
involvement in OFG patients as different reports used different methods to
investigate the intestinal involvement and there are few detailed studies that
have formally investigated GI involvement. However, GI symptoms may not
be uncommon in OFG patients. A recent prospective study from Sweden
with a follow-up period of 6 to 8 years highlighted the risk of intestinal
Crohn’s development in younger (9 to 16 years old) OFG patients, as four of
the eight patients later developed the condition (Saalman et al., 2009). All
affected patients developed GI symptoms within 6 months of the diagnosis of
OFG.
Most of published papers on OFG reported no intestinal involvement, and
historically OFG was not thought to have any GI involvement and if patients
developed GI symptoms they were rediagnosed as having Crohn’s disease
even before intestinal biopsy. However, some patients may develop
asymptomatic intestinal inflammation that differs from that of Crohn’s
disease (Sanderson et al., 2005). Intestinal involvement in OFG patients who
present without gut symptoms ranges between 37% (using rigid
sigmoidoscopy and barium studies) to 54% (using ileocolonoscopy and
histopathological studies) (Scully et al., 1982; Sanderson et al., 2005). In a
detailed study of gastrointestinal involvement in OFG without GI symptoms,
histopathological intestinal abnormalities were evident in 19 of 35 OFG
patients. Non-caseating granulomas were found in 68.4% of those patients
with intestinal abnormalities in the colon, ileum, or both (Sanderson et al.,
2005).
Chapter 3 Orofacial granulomatosis
96
The risk of developing intestinal involvement in OFG may be greater in
children and younger adults (Sanderson et al., 2005). In a study by van der
Waal and co-workers (2002) only two of 13 patients with cheilitis
granulomatosa (mean age; 32.8 years) developed Crohn's disease within
5 years. Gastrointestinal examinations are not presently recommended
unless there is likely GI disease as suggested by the development of
diarrhoea, cramps, perianal fissures or abscesses, poor childhood growth
and/or weight loss (Khouri et al., 2005; Ojha et al., 2007).
3.1.3 Aetiopathogenesis
The cause of OFG is unknown and some groups have labelled OFG an
idiopathic disorder (Tilakaratne et al., 2008). Current evidence indicates that,
after the exclusion of individuals presenting chronic/recurrent orofacial
swelling as a result of systemic granulomatous disorders, deep fungal
infections, C1 esterase inhibitor deficiency, foreign body, contact, or delayed
hypersensitivity reaction, no specific aetiologic agent for OFG has presently
been established.
OFG is presently thought to be multifactorial disorder. Several mechanisms
have been suggested, such as immunity, infection, and genetic
predisposition (Patton et al., 1985; Lim et al., 1997; Sciubba and Said-Al-
Naief, 2003).
3.1.3.1 Genetic
The role of genetic factors has been suggested by reports of hereditary
cases of OFG associated with neurological manifestations. A potential
“susceptibility gene” located at 9p11 has been proposed. An increased
frequency of HLA-B16 and HLA-Cw3 in OFG patients and their first kin has
also been found (Ronnblom et al., 1986; Goto et al., 1999; Cabrera-Gomez
et al., 2005) while another observed a significant increase in A3, B7 and
DR2 alleles in OFG patients compared with the general population in
Scotland (Gibson and Wray, 2000).
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3.1.3.2 Hypersensitivity
It has been suggested that some OFG patients are atopic and allergic to
food or other antigens (James et al., 1986). Food additives such as benzoic
acid, cinnamonaldehyde, carmoisine, sunset yellow, chocolates and
monosodium glutamate (Sweatman et al., 1986; Oliver et al., 1991; Wray et
al., 2000; Taibjee et al., 2004; Saalman et al., 2009); metals such as gold
(Lazarov et al., 2003), cobalt (Pryce and King , 1990) and amalgam/
mercury restorations (Guttman-Yassky et al., 2003; Lazarov et al., 2003;
Khamaysi et al., 2006) have been reported as causative agents in OFG
patients.
OFG may thus represent a delayed hypersensitivity-type response with
granulomas forming as a consequence of cytokine release in the response
to these unknown antigens (Lim et al., 1997).
However there are no detailed studies of the precise long-term effectiveness
of diets or lifestyles that exclude these aforementioned agents and indeed
not all patients with OFG have demonstrable hypersensitivity to these, or
other agents.
3.1.3.3 Infection
The role of mycobacterial species (Mycobacterium tuberculosis and
paratuberculosis) and other infectious agents (Saccharomyces cerevisiae,
Candida albicans, Borrelia burgdorferi, Toxoplasma, Treponema, herpes
simplex virus, and Streptococcus mutans) has been investigated but remain
no consistent findings (Riggio et al., 1997; Gibson et al., 2000; Muellegger et
al., 2000; Handa et al., 2003; Savage et al., 2004).
3.1.3.4 Immunity
OFG certainly represents a granulomatous inflammatory response to an
unknown antigen (Sanderson et al., 2005). There are strong parallels with
gastrointestinal Crohn’s disease as levels of CD4-T cells, IFN-γ, IL-10, and
IL-12 are raised in the OFG patients. In addition, chemokines; RANTES and
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MIP-1α and chemokine receptors; CCR5 and CXCR3 expression levels are
elevated in OFG patients, suggesting a Th1 immune response, as observed
in intestinal Crohn’s disease (Freysdottir et al., 2007). While these findings
may point towards a commonality of aetiopathogenesis between OFG and
Crohn’s disease these do not explain the different clinical presentations of
each disorder.
3.1.4 Histopathology
Histopathological examination of early OFG lesions usually shows oedema,
lymphoedema, and paravascular and perivascular mononuclear infiltrates.
Non-caseating granulomas are usually evident when clinical disease is well
established. The granulomas are scattered throughout the lesion and within
the lymphatic vessels. The granuloma is composed of lymphocytes and
epithelioid histiocytes, dilated lymphatic vessels, and fibrosis may be found
late in the disease process (Hornstein, 1973; Allen et al., 1990; Hornstein,
1997; van der Waal et al., 2001; El-Hakim and Chauvin, 2004; Kruse-Losler
et al., 2005; Cockerham et al., 2005; Sanderson et al., 2005; Lourenco et al.,
2008). The presence of perilymphatic granulomas, granulomatous
lymphangitis, and lymphedema has been considered to be pathognomonic
of this disease (Cockerham et al., 2000). However in the early stages of
OFG, typical granulomas may not be present (Lourenco et al., 2008), and
even in the late disease process some patients may not have granulomas
(Wiesenfeld et al., 1985; Hegarty et al., 2003; Endo and Rees, 2007). This
lack of reliable presence of granulomas can thus complicate definitive
diagnosis of OFG.
3.1.5 Management
Patients with OFG may consult several groups of clinicians and undergo a
number of testing procedures before the appropriate diagnosis is made.
Furthermore, patients may be followed for long periods to facilitate early
diagnosis and management of other systemic involvement, such as intestinal
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Crohn’s disease, that may develop (Mignogna et al., 2001; Shakeel et al.,
2009).
In general, management of orofacial manifestations in OFG and Crohn’s
disease is the same. However, the status of oral mucosa in Crohn’s disease
may correlate with the activity of intestinal disease (Ojha et al., 2007; William
et al., 2007) and may respond to systemic treatment of intestinal Crohn’s.
For example, Bogenrieder et al. (2003) described a patient with oral
manifestations of Crohn’s who responded well to treatment of intestinal
symptoms with mesalazine (3 g daily) and oral prednisolone (initial dose, 60
mg/day).
In general, although OFG and Crohn’s are considered to be different
disorders; there is overlap in the management of the orofacial features of
both.
3.1.5.1 Therapeutic agents
The management of OFG generally remains symptomatic and is directed
towards lessening or resolving the facial swelling and associated intra-oral
ulceration. However, this typically remains difficult and is often unsatisfactory
(Sciubba and Said-Al-Naief, 2003). As there are no systematic reviews nor
large-scale, well-planned randomised control studies, treatment is mainly
based upon data from case reports, case series studies and clinician
experience. At the present no single therapy has proven to be universally
effective for OFG and the possible potential of novel therapeutic strategies,
such as specific anti-TNF- agents, remains unknown. Different approaches,
utilizing a wide range of topical and/or systemic agents have been used on
the basis of disease extent, severity and typology of lesions. These
therapeutic strategies include elimination diet, antiseptics, non-steroidal anti-
inflammatory drugs, antibiotics (Stein and Mancini, 1999) antihistamines
(Allen et al., 1990) topical, intralesional and systemic corticosteroids,
(Tyldesley, 1979; Wiesenfeld et al., 1985; Kolokotronis et al., 1997),
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antilepromatous agents (Ridder et al., 2001) and anti-TNF-α agents (Tables
3.4, 3.5 and 3.6).
As indicated previously some patients may have an identifiable precipitant
such as a food stuff in particular food additives. Perhaps just under 40% of
patients have clinical benefit following avoidance of a likely precipitant alone
(Sweatman et al., 1986; Oliver et al., 1991; Wray et al., 2000). Labial
swelling and other signs may subside within about 5 months (Lazarov et al.,
2003). Resolution of OFG following removal of amalgam restorations has
been reported (Guttman-Yassky et al., 2003).
Cutaneous patch testing has been suggested to aid the identification of
patients who may respond to an elimination diet (Armstrong et al., 1997) but
there can be considerable variation in the ability to identify a likely precipitant
as the clinical skills of the attending clinicians may vary. Such investigations
are also labour-intensive, time consuming and ultimately expensive.
If the causative agent(s) cannot be identified or any elimination protocol has
failed then the use of therapeutic agents is inevitable.
Management of intraoral lesions
Many topical regimens (such as antibacterials, topical corticosteroids and
tacrolimus) have been used for the management of intraoral manifestations
of OFG. Good oral hygiene has been reported to potentially lessen the
severity of ulceration of OFG and hence topical anti-microbial agents such
as chlorhexidine gluconate may be of some benefit in mild disease (Sciubba
and Said-Al-Naief, 2003).
The mucosal ulceration may lessen with a range of topical corticosteroids
and topical calcineurin inhibitors (e.g. tacrolimus). Mignogna and co-workers
(2003) reported good response of intraoral lesions to topical clobetasol
(0.05% ointment) with orabase. Mucosal tags and gingival lesions
disappeared after use of 0.05% topical clobetasol ointment mixed with
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orabase (1:1) (twice/day, 2-4 weeks) (Mignogna et al., 2001), employing
custom-made trays for the gingival lesions.
However, hydrocortisone hemisuccinate pellets, triamcinolone acetonide,
betamethasone sodium phosphate, dexamethasone mouth rinses and
fluticasone propionate aqueous spray have been suggested to be ineffective
or of transient benefit in lessening oral ulceration of some patients (Hegarty
et al., 2003). In general intraoral lesions rarely necessitate systemic therapy
with systemic corticosteroids, immunosuppressants or anti-TNF-α agents.
Management of orofacial swelling
The labial swelling of OFG is difficult to resolve (Fdez-Freire et al., 2005). In
particular if there has been a considerable time lag from initial onset to
presenting at specialty clinic, the lip swelling can be rubbery or fibrous in
consistency and difficult to resolve.
Mild labial swelling may be managed with topical corticosteroids while
moderate to severe swelling respond to intralesional corticosteroids. Other
management modalities include immunosuppressive therapies, surgery, and
psychological support.
Topical agents
Topical corticosteroids and tacrolimus applied onto the involved lip(s) have
been reported to be effective in reducing swelling and lip fissuration (Casson
et al., 2000). However, this approach is likely to be effective only in patients
with mild disease (Hegarty et al., 2003). The precise efficacy and safety of
facial application of such agents have not been detailed.
Topical tacrolimus has been suggested to have a role in lessening the labial
swelling of granulomatous cheilitis, OFG and Crohn’s disease (Hegarty et
al., 2003; Kovich and Cohen, 2004) and as with topical corticosteroids are
likely to only be useful when lip swelling is mild. Topical tacrolimus has been
used successfully, without any systemic absorption, in three young patients
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with Crohn’s disease (Casson et al., 2000). It resulted in lessening of labial
swelling and fissures following 4 to 6 weeks of application (0.5 mg/g in
Orabase). However, there is a need for additional studies to determine
whether topical tacrolimus is consistently effective in lessening other lesions
of OFG.
Intralesional corticosteroids
Intralesional injections of corticosteroids have been long advocated for
lessening or resolving the oro-facial swelling of OFG (Sakuntabhai et al.,
1993; Kolokotronis et al., 1997; Camacho-Alonsoet et al., 2004), particularly
if the disease is recognized in its early stage and the tissues are not fibrotic.
In a recent study (Lourenco et al., 2008), intralesional corticosteroids with
dapsone (100 mg/day) with/without systemic corticosteroids were used in the
management of 5 patients with lip and gingival swelling. All patients had
either partial or complete resolution of their lesions. In another study,
intralesional triamcinolone (1 cm3 every other week for 6 weeks) has been
found to be effective either alone or in combination with clofazimine (100 mg/
every 2 days) or with systemic betamethasone (4 mg/day) (Camacho-
Alonsoet et al., 2004).
Aside from resolving tissue swelling within 2-4 weeks intralesional therapy
may decrease the rate of recurrence and increase the disease-free period in
upto 80% of patients (Sakuntabhai et al., 1993). Nevertheless, there are no
studies of the long-term efficacy of this therapeutic approach.
Two different techniques of intralesional therapy have been described on the
basis of different corticosteroid formulation. Sakuntabhai and co-workers
(1993) performed intralesional therapy using the 10 mg/ml formulation of
triamcinolone acetonide. This was effective in reversing existing swelling or
reducing further lip enlargement for about 10 months. In instances of
recurrence, the regimen was repeated. However, the low concentration of
medication necessiate the injection of high volume of triamcinolone (3 to 10
ml) giving rise to pain and a transient increase in swelling. As a
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consequence, regional nerve block anesthesia is required. Other group has
used high concentration triamcinolone (10 mg/ml) injected via a tuberculin
syringe on a weekly basis for 2-3 weeks (each session consisting of topical
anesthetic application then 0.1 ml of triamcinolone to be injected in each of
3-4 sites of each swollen lip) (El-Hakim and Chauvin, 2004). This protocol
led to good long-term results (up to 5 years in some instances) and was
generally painless.
As an alternative to trimacinolone 10 mg/ml, a small volume of a delayed-
release high-concentrated triamcinolone formulation (40 mg/ml) was recently
used in a cohort of 7 patients and found to be an effective means of
decreasing labial swelling of OFG for 8 to 30 months following one cycle of
therapy (Mignogna et al., 2004). In addition this strategy may be useful for
the treatment of orofacial manifestations of Crohn’s disease (Mignogna et
al., 2008).
Systemic corticosteroids
There are several reports upon the effectiveness of moderate doses (0.5-1
mg/kg/day) of systemic corticosteroid therapy (usually oral prednisolone or
deflazacort) in the treatment of swelling of OFG (Sciubba and Said-Al-Naief,
2003; El-Hakim and Chauvin, 2004; Mergulhao et al., 2005; Kauzman et al.,
2006; Lourenco et al., 2008). However, because of the recurrent/chronic
nature of OFG, extended periods of therapy are inevitable thus increasing
the risk of corticosteroid-induced adverse side effects. Intravenous
methylprednisolone (1000 mg/day) alone (Kesler et al., 1998) or in
combination with systemic prednisolone (Saito et al., 1994) has been
effectively used to control synchronous neurological manifestations (e.g.
facial palsy) and facial swelling in some OFG patients.
Clofazimine
The anti-leprotic clofazimine has been used in combination with, or as an
alternative to, systemic corticosteroids for the treatment of OFG (Podmore
and Burrows, 1986; van der Waal et al., 2002; Sciubba and Said-Al-Naief,
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2003; Camacho-Alonso et al., 2004; Fdez-Freire et al., 2005; Shakeel et al.,
2009). However, the duration of clofazimine therapy to induce and maintain
clinical remission/improvement is unknown. Mahler and co-workers reported
resolution of peri-oral and lingual swelling after two weeks of treatment with
clofazimine (Mahler et al., 1995). Sussman and co-workers used clofazimine
(100 mg 4 times weekly) for 3-11 months in 10 OFG patients and obtained
complete and partial remission in five (50%) and three (33%) patients
respectively. Two patients did not respond to treatment. Histopathological
studies of lesional tissue after treatment with clofazimine have demonstrated
a decrease or disappearance of granulomas (Sussman et al., 1992).
Anti-TNF- strategies
As TNF- is considered a major determinant of granuloma formation in
several disorders, anti-TNF- therapies have been tested as potential
therapeutic agents. Medications with anti-TNF- activity include thalidomide
and novel monoclonal antibodies such as infliximab and adalimumab. The
largest experience comes from the treatment of Crohn’s disease but also
patients with idiopathic OFG have been recently studied. Low-dose
thalidomide (25-100 mg/day) has been found to lessen the labial and facial
swelling of OFG (Safa et al., 1995; Odeka and Miller, 1997; Weinstein et al.,
1999; Medeiros et al., 2002; Hegarty et al., 2003). Clinical benefits seem to
be rapid, leading to a quick reduction or remission of labial swelling within
weeks (Hegarty et al., 2003). Nevertheless, in view of the significant risk of
teratogenesis, sensory (and motor) neuropathies and occasional cutaneous
adverse effects, the use of thalidomide must be carefully considered.
Regular clinical monitoring is essential (particularly a 6-month assessment of
sensory nerve action potentials) (Odeka and Miller, 1997; Hegarty et al.,
2003; Thomas et al., 2003) and patients receiving thalidomide must always
be informed and instructed to follow strict contraceptive measures. Although
thalidomide itself is a low cost agent, the clinical monitoring is complex and
expensive, and patients must be reminded of the significant adverse effects
of therapy.
Chapter 3 Orofacial granulomatosis
105
The murine/human anti-TNF-α monoclonal antibody infliximab is an effective
therapy for intestinal Crohn’s disease (Targan et al., 1997; Baert et al., 1999)
and has been reported to lessen the orofacial lesions of Crohn’s disease
(with/without azathioprine) (Mahadevan and Sandborn, 2001; Ottaviani et al.,
2003; Cardoso et al., 2006). There have been a small number of reports that
infliximab may be effective for the treatment of OFG (Barry et al., 2005;
Peitsch et al., 2007). Adalimumab, a recombinant human anti-TNF-
antibody, has been reported to be of potential benefit for the treatment of
OFG (Gaya et al., 2006) but such agents are costly and not without risk of
significant adverse side effects.
Other agents
A wide variety of other agents (alone or in combination with others) have
been proposed in the management of OFG. These include methotrexate
(Tonkovic-Capin et al., 2006), sulphasalazine (500 mg/day) (Clayden et al.,
1997), lymecycline (Pigozzi et al., 2004), dapsone (van der Kooi et al., 2005;
Thomas et al., 2003; Lourenco et al., 2008), prednisolone with diclofenac
(Gerressen et al., 2005), minocycline (Stein and Mancini, 1999) or 5-
aminosalicylic acid (Girlich et al., 2002; Saalman et al., 2009), metronidazole
(Miralles et al., 1995; Coskun et al., 2004), hydroxychloroquine (van der
Waal et al., 2002), and combination of metronidazole, methylprednisolone
and mesalamine (Dummer et al., 1999).
3.1.5.2 Surgery
Surgery for persistent or recalcitrant disease has been proposed but there
are few reports of outcomes. Cheiloplasty, alone (Glickman et al., 1992;
Ellitsgaard et al., 1993; Kruse-Losler et al., 2005) or in combination with
corticosteroids (intralesional triamcinolone acetonide) (Krutchkoff and
James, 1978; van der Waal et al., 2002), has been suggested to correct
facial swelling and maintain clinical remission. The basic surgical procedure
consists of excising transversely a variable amount of labial mucosa,
submucosa and orbicularis oris muscle on the basis of the degree of lip
swelling (also known as Conway method) (Kruse-Losler et al., 2005). More
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rarely, when severe gigantic macrocheilia is present, lip reduction can be
performed combining the transversal Conway method with a central sagittal
wedge excision (Kruse-Losler et al., 2005). In instances of severe facial
swelling and asymmetry, facial liposuction (suction lipectomy) has been
undertaken (Tan et al., 2006). Surgery is likely to be of greatest benefit if
performed when the swelling is quiescent or stable (Worsaae et al., 1982;
van der Waal et al., 2002) as post-surgical inflammation process may cause
a further increase or recurrence of swelling. It has been suggested surgical
treatment to be deferred until a patient has been free of active disease for
about 8 to 12 months (Kruse-Losler et al., 2005). Temporary post-operative
lip swelling and paraesthesia commonly arise following cheiloplasty but
these may settle 4 to 6 weeks (Oliver and Scott, 2002). Although labial
swelling may recur or persist long-term benefit for up to 8 years has been
reported (Ellitsgaard et al., 1993; Oliver and Scott, 2002). Some clinicians
have suggested surgery be combined with intralesional corticosteroids and
long-term systemic tetracycline therapy (Camacho et al., 2001). Four
patients with gingival enlargement as part of OFG process had gingivoplasty
with dapsone, intralesional corticosteroids with/without systemic
corticosteroids and achieved either partial or complete resolution of gingival
and lip(s) swelling (Lourenco et al., 2008).
3.1.5.3 Psychological support
The labial and facial swelling of OFG can be distressing to patients,
particularly when they are children or young adults. Affected individuals can
be embarrassed and can become socially isolated. Accordingly, social
support and psychological counselling are important, particularly short-term,
in management of individuals distressed by their disease (Clayden et al.,
1997).
Chapter 3 Orofacial granulomatosis
107
3.1.6 Clinical outcome and prognosis
The precise clinical outcome of patients with OFG is not known. Gradual
improvement (Mignogna et al., 2001) and spontaneous resolution have been
rarely reported but this may take many years (Lourenco et al., 2008). The
majority of patients seem to have chronic relapsing clinical picture which is
variably controlled by medical therapy. In general however the treatment
remains usually satisfactory and recurrence of labial swelling may occur (van
der Waal et al., 2002).
While there is considerable increase in the published reports concerning the
clinical presentation and management of OFG in the last few years, the long-
term outcomes of OFG remain largely unknown. Hence the aim of this
chapter is to describe the long-term outcomes of therapy in a large
homogeneous cohort of OFG patients attending a single Oral Medicine unit.
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3.2 AIMS
The aims of this chapter were to:
1. Detail description of the early and late clinical features and other clinical
characteristics of a substantial cohort of patients with orofacial
granulomatosis resident in England, UK.
2. The clinical outcomes of long-term therapy of orofacial granulomatosis.
3. The frequency and nature of adverse side effects of therapy of orofacial
granulomatosis.
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3.3 PATIENTS AND METHODS
3.3.1 Patients group
The study group comprised 49 patients managed by the Oral Medicine Unit
of UCL Eastman Dental Institute and UCLH Eastman Dental Hospital, with
clinical and usually histopathological features consistent with the diagnosis
of orofacial granulomatosis (OFG). The patients had been under the care of
the clinicians of the unit between 1985 and 2007.
3.3.2 Methods
The case record of each patient was examined using multiple data extraction
forms for details of demographics, past medical and drug histories, extra-
and intra-oral clinical features and clinical progress data. Incisional biopsy
was performed wherever possible and relevant histopathology obtained.
Haematology and serology data were evaluated in some of the studied
patients as they were required for (i) diagnostic purposes, (ii) to evaluate
potential gastrointestinal involvement and (iii) to monitor therapy. These
include full blood cell count, differential white cell count, hepatic and renal
biochemistry, erythrocyte sedimentation rate (ESR), C-reactive protein
(CRP) and serum angiotensin converting enzyme (SACE) levels. The
number of patients tested varied from 16 to 34 on the basis of which types of
investigations were undertaken. The details of diagnostic and monitoring
investigations were systematically extracted using a preformed data
extraction sheets (Appendices 1-5). Analyses were performed with regard to
the total number of investigations, the total number of patients tested, and
any association with pharmacological therapies.
Inclusion criteria:
1. Intra-oral and/or extra-oral clinical features suggestive of OFG.
2. Histopathological evidence of non-caseating granulomas.
3. Exclusion of other granulomatous disease on the basis of clinical,
histopathological and laboratory investigations (Mignogna et al., 2003;
Leao et al., 2004).
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All patients met at least criteria (i) and (iii). Patients who developed intestinal
inflammation of Crohn’s disease after the onset of orofacial manifestations
were re-categorized as having oral Crohn’s disease and were thus excluded
from the study.
Clinical outcome
Disease onset was evaluated on the basis of patients’ history, referral letter
and/or first clinical examination at the Oral Medicine clinic. Long-term clinical
manifestations occurring during the course of the disease were evaluated on
the basis of clinicians’ descriptions in the clinical notes and photographs
taken during clinical reviews. The impact of therapies on the behavior of
clinical manifestations was not considered.
The outcome of therapy was evaluated separately for both intra-oral
ulceration and soft tissue (labial) swelling on the basis of observation at 6
monthly reviews recorded in clinical notes. The therapeutic effectiveness
was estimated using a 4-point scoring system: 0 (initial status), -1
(worsening), +1 (partial resolution), +2 (complete resolution). Initial status
defined the size of oro-facial swelling and number/size of intra-oral ulceration
at pre-therapy stage. Partial resolution was defined as partial dimensional
reduction of swelling in case of facial manifestations and partial resolution of
intra-oral ulcerative disease. Complete resolution was defined as complete
return to normal dimension/shape of affected facial tissues and complete
resolution of intra-oral ulcerative disease. Worsening was defined as
dimensional increase of any facial swelling and/or an increase in number
and/or size of intra-oral ulcerative disease. Evaluation of response was
based on clinicians’ judgments during clinical examination, upon clinical
photographs, and the patients’ opinions as reported in clinical notes.
Analysis of treatment outcome was based on (i) the comparison between
disease status before therapy and last review in 2007, and (ii) the serial
measurements of disease status at 6-month reviews. The Kaplan Meier
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cumulative incidence curve was constructed to assess the proportions of
patients having a complete resolution of labial swelling over time.
Statistical analyses
Descriptive and analytical statistics were undertaken using the SPSS
program (SPSS for Windows: (Statistical Package for the Social Sciences)
software, version 12.0.
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3.4 RESULTS
3.4.1 Patient demographics
Age and gender
The mean age of the patients at the time of diagnosis or referral to the oral
medicine unit was 32.4 years (SD 19.1), with age range of 7.4 to 72.1 years.
The mean age at OFG diagnosis was statistically significant lower in males
(23.3 years) than females (43.6 years) (P=0.00). The onset of the clinical
features of disease was thus usually in the second decade of life. There
were a slightly higher number of males (27; 55.0%) than females (22;
45.0%), with a male to female ratio of 1.2:1 (Table 3.7).
Ethnic group
The majority of patients were white British (36; 73.5%) (self-reported,
according to 2001 UK Census) (Office for National Statistics, 2003). In
present cohort there were 6 (12.2%) white other than British, 4 (8.2%) Black
African and 3 (6.1%) Asian.
Marital status
Marital status was stated under four categories; married which included
married patients and patients in a civil partnership; single, divorced and
widowed patients. 29 (59.2%) were single, 17 (34.7%) were married or living
with a partner, 1(2.0%) was widowed, 1 (2.0%) was divorced and the marital
status was not reported in the case note of one patient.
Tobacco use and alcohol consumption
Nine (18.4%) of the patients were previous tobacco users and 8 (16.3%)
were current users of tobacco. The mean number of self- reported cigarettes
per day by the present tobacco users was 8.6. Twenty five (51.0%) of the
group currently drank alcohol. The mean total weekly consumption by the
present alcohol users was 9.9 units.
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Sources of referral to oral medicine
Twenty three (46.9 %) of the patients had been referred to the Oral Medicine
unit by specialists in Oral and Maxillofacial Surgery (OMFS) from within and
outside London. Fifteen (30.6%) patients were referred by general dental
practitioners. Four (8.2%) patients were referred by periodontist and the
remaining patients were referred by their general medical practitioner,
medical or a dental specialist (Table 3.8). The patients had been referred to
Oral Medicine clinics for the diagnosis and/or management of variety of
orofacial lesions such as labial swelling or intra-oral mucosal ulcers.
3.4.2 Past medical history
The patients had a history of a wide variety of common medical conditions,
the most common of which were: allergies, respiratory, and gastrointestinal
diseases. A variety of allergic diseases were reported by the 14 (28.6%)
patients of whom 2 (4.0%) were allergic to penicillin, one to plaster (sticky-
plaster, e.g. band-aid) and 11 were allergic to a variety of other allergens.
Eight (16.0%) patients had a history of asthma and 10 (20.4%) had central
nervous system diseases. Gastrointestinal symptoms and/or serological
abnormalities necessitated referral to a gastroenterology unit where
endoscopic investigations failed to show any intestinal Crohn’s disease.
More details about the past medical history of this cohort of OFG patients in
table 3.19.
3.4.3 Clinical signs and symptoms at presentation and at disease onset
3.4.3.1 Duration of oral symptoms at first visit
The duration of oral symptoms before clinical diagnosis varied from 4 to 192
months, with a mean of 44 months (SD 44.6).
3.4.3.2 Clinical signs and symptoms at presentation
Thirty seven patients (37/49; 75.5%) had labial swelling at the time of initial
specialist examination. Both lips were affected in 9 (18.4%) patients while 9
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and 19 patients had swelling of upper and lower lips respectively. Eighteen
patients (36.7%) had oral ulcer at time of initial examination. Seventeen of
the 18 patients (94.4%) had superficial aphthous-like ulcers while 2 patients
(4.1%) had linear, deep ulcers of the vestibular fold areas. Ten patients
(20.4%) had cervical lymphadenopathy, this usually comprising multiple
small (<1 cm diameter) rubbery mobile nodes of the anterior and/or posterior
triangle of the neck. Additional details about presenting clinical features are
provided in Table 3.10.
3.4.3.3 Clinical features at disease onset
Five major patterns of disease onset were identified in the present cohort of
patients. These include: facial swelling only (Group 1), facial swelling with
other manifestations (Group 2), oral ulceration only (Group 3), other intra-
oral manifestations without facial swelling (e.g. gingival hyperplasia) (Group
4), and neurological manifestations only (e.g. facial palsy) (Group 5) (see
Table 3.11 and Figure 3.1). The most commonly reported abnormality at
disease onset was recurrent oro-facial swelling, reported by 26 (53.1%)
patients (groups 1 and 2). Twenty-five patients (51.0%) had swelling of one
or both lips, and 1 patient (2.1%) reported bilateral malar swelling. Fifteen
(Group 1) of these 26 patients, reported oro-facial swelling to be their only
initial manifestation (upper and/or lower lip in 14 and malar area in 1) while in
the other 11 patients (Group 2) the swelling of the lips co-existed with other
extra- and/or intra-oral manifestations including angular cheilitis (1 patient),
perioral erythema (1), fissuring plus angular cheilitis plus mucosal
cobblestoning and tags (1), swelling of the cheek (1), mucosal cobblestoning
and gingival enlargement (1), intra-oral ulceration (4), gingival enlargement
(1) and lip fissuring (1). Lymph node swelling was never found to be the only
presenting manifestation of OFG.
Oral mucosal ulceration as the only presenting sign were reported by 14
patients (28.6%) (Group 3) consisting of either superficial aphthous-like
ulcers or linear, deep ulcers of the vestibular fold areas. However, intra-oral
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ulcers were associated with other oro-facial and/or intra-oral manifestations
at disease onset in a further 4 patients.
In patients with other intra-oral manifestations (Group 4), gingival
enlargement was the presenting sign of OFG in four patients (8.2%), one of
whom had also cobblestoning while the other had cervical lymph nodes
swelling. One patient (2.1%) reported swelling of the tongue as the probable
initial feature of OFG.
Mucosal cobblestoning was never reported as the only presenting sign of
OFG. However it was associated with gingival enlargement (probably
unrelated to plaque) in 1 patient (2.1%) and with multiple orofacial and intra-
oral manifestations in 2 patients (4.1%).
Mucosal tags were never the sole presenting sign of disease but were
associated with oro-facial swelling and other intra-oral manifestations in one
patient (1/49; 2.1%).
One or more episodes of facial nerve palsy, at disease onset, were reported
by three patients (6.1%) and one (2.1%) patient had chronic paroxysmal
haemicrania as presenting manifestation of OFG (Group 5).
3.4.4 Histopathology
Details of histopathological examination of lesional tissue were available for
37 patients (75.5%). In the remaining cases (12; 24.5%) biopsy was refused
by the patient, undertaken in other hospitals/units (and the results
unavailable for review) or considered not necessary by the attending
specialist. Non-caseating granulomas were observed in only 43.2% of the
examined specimens (16/37). The granulomas were usually small, loose and
poorly defined consisting of epithelioid histiocytes surrounded usually by
lymphocytes. Moreover, multinucleate giant cells were present and were
sometimes of the Langhans’s type.
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Features of oedema of the corion with dilated lymphatic and blood vessels
and unspecific inflammatory infiltrate were observed in all specimens,
regardless of the presence or absence of granulomas.
3.4.5 Haematological and serological assessments
Table 3.12 shows the abnormal findings with regards to the total number of
investigations and the type of therapy (topical or combined therapy). Overall
12.2% (mean value; range 0-41.4%) of the total number of investigations
showed abnormal results and these were mainly associated with combined
therapy.
Table 3.13 shows the abnormal findings with regards to the total number of
patients and the type of therapy (topical or combined therapy). Overall 20%
(mean value; range 0.0-42.1%) of the total number of patients showed
abnormal results and these were mainly associated with combined therapy.
Most of the abnormal results consisted of mild reduction/elevation with
respect to normal values and were thus considered of little clinical
significance.
3.4.6 Long-term clinical features
The majority of patients (42/49; 85.7%) developed a variety of different
additional features of OFG following its initial manifestation (Table 3.11 and
Figure 3.1).
Ten out of the 15 patients (66.7%) with OFG who initially presented with
facial swelling only (Group 1), developed other manifestations during the
course of the disease including intra-oral ulceration only (1 patient), intra-oral
ulceration and cobblestoning (2), labial swelling (2), labial swelling and
ulceration (1), labial swelling with cobblestoning and tags (1), perioral
erythema (1), cervical lymph node swelling (1) and cervical
lymphadenopathy with cobblestoning and mucosal ulceration (1).
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Eight of the 11 patients (72.7%) who initially had facial swelling co-existing
with other clinical features (group 2) developed further signs of OFG
including labial/buccal swelling (3 patients), labial swelling with
cobblestoning and cervical lymphadenopathy (1), intra-oral erythema, tags
and cobblestoning, hyperplasia of palatal mucosa and cervical
lymphadenopathy (1), perioral erythema plus gingival hyperplasia or
cobblestoning (2) or gingival enlargement only (1).
Thirteen of the 14 (92.9%) patients who had only intra-oral ulceration at
disease onset (group 3) eventually developed facial swelling only (4), or
swelling associated with cobblestoning (3), angular cheilitis (1),
lymphadenopathy with or without tags (2), cobblestoning with tags (1), tags
with perioral erythema and lymphadenopathy (1) or with angular cheilitis and
lymphadenopathy, labial abscess and tags (1). In only one patient, intra-oral
ulceration was followed by cobblestoning without any labial/facial swelling.
Within group 4, the patient with tongue swelling at disease onset eventually
developed gingival enlargement. The patients presenting initially with
gingival enlargement at disease onset without facial swelling (4/49)
developed intra-oral erythema and tags (1 patient), or labial swelling (1) and
labial swelling plus cobblestoning (2).
All four patients with neurological manifestations only at disease onset
(Group 5), later developed labial swelling alone (1 patient), labial swelling
plus mucosal cobblestoning (1), labial swelling with gingival hyperplasia,
cobblestoning and tags (1) and labial and buccal swelling plus perioral
erythema (1).
Twenty of the 23 (87%) patients who had intra-oral (groups 3 and 4) or
neurological (group 5) manifestations only at disease onset (individuals
presenting without facial swelling) had swelling of one or more facial areas
during the following years of clinical monitoring. Similarly, among those
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patients who only had facial swelling at disease onset (15 patients), the
majority (10/15; 66.7%) eventually developed intra-oral manifestations.
In total, 47 of the 49 patients (95.9%) developed facial swelling along the
course of their disease whilst mucosal ulceration occurred only in 24 (49%).
The lips were affected in 46 of the 47 patients with facial swelling (98%).
Labial enlargement affected lips in 20 patients (43.4%), the lower lip only in
19 (41.3%) cases, and the upper lip in 7 (15.2%) patients. Full-blown
symptomatic OFG (intra-oral ulceration and facial swelling) occurred in 23
patients (46.9%) during the disease course.
3.4.7 Therapies provided
A wide variety of different topical and systemic agents had been provided in
an attempt to control the extra-and intra-oral manifestations in this group of
OFG patients (Table 3.14 and Figure 3-2). Patients with oral lesions alone
were almost always managed initially with topical corticosteroids and/or
tacrolimus. However, if the signs failed to reduce with topical agents alone
intralesional corticosteroids with/without systemic agents were prescribed.
Overall 45 of 49 (91.8%) needed medical treatment whilst 4 experienced
spontaneous remission. Twenty four patients out of 45 (53.3%) were
managed with topical therapy only, while 21 (46.7%) received combined
therapy (topical plus systemic and/or intra-lesional). Different topical and/or
systemic agents were used during the long-term management of OFG
because of (i) development of new manifestations, (ii) lack of response, or
(iii) adverse side effects. Further details about the total number of topical and
systemic agents employed in the management of this cohort of patients can
be found in Table 3.15.
The duration of treatment of OFG (from commencement of therapy until end
of data collection) differed greatly among patients (1 to 15 years; median
1.8).
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Details of treatment outcome after a minimum of 3, 5 and 10 years of
therapy were available for 38 (77.6%), 26 (53.1%), and 9 patients (18.4%)
respectively.
3.4.8 Clinical outcome
3.4.8.1 Clinical outcome of oro-facial swelling
i Disease status before therapy and at last clinical consultation
Complete resolution 22 (46.8%)
Partial resolution 18 (38.3%)
Same status 6 (12.8%)
Oro-facial
swelling 47
Worsening 1 (2.0%)
Figure 3.3 Status of patients with regards to oro-facial swelling before (left
side) and after therapy (right side).
Forty seven of the 49 (95.9%) OFG patients in this cohort had orofacial
swelling and 44 needed medical therapy to control their disease. Analysis of
the overall outcome (based on the comparison between disease status
before therapy and last review in 2007) indicated 19 (40.4%) patients had
complete resolution of disease while 18 (38.3%) had partial resolution. The
disease status on last review was the same as that observed at the
commencement of treatment of only 6 (12.8%) patients. Only one patient
(2.1%) had a worsening of disease. Three patients (6.4%) presented with
complete resolution at their last review but were classified as being
spontaneous remission cases as resolution was not associated with any
ongoing therapy.
The 19 patients with complete resolution of the swelling were managed with
topical agents only in 8 cases and with combined therapy (topical and
systemic/intralesional therapy) in 11 cases. The 18 patients with partial
resolution of the swelling were managed with topical agents only in 4 cases
and with combined therapy in 14 cases. The 6 patients whose disease status
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on last review was the same as that observed at the commencement of
treatment were managed with topical agents only in 5 cases and with
combined therapy in 1 case. The patient who had worsening of the disease
was managed with topical therapy only.
ii Serial measurement of disease status
Complete resolution 17 (36.2%)
Partial resolution 17 (36.2%)
Same status 12 (25.5%)
Oro-facial
swelling 47
Worsening 1 (2.0%)
Figure 3.4 Serial measurement of oro-facial swelling before (left side) and
during therapy (right side).
Analysis of the typical progress during the treatment (calculated upon serial
measurements of disease status during 6-month reviews) showed a typical
remitting behaviour. It permitted classification of patients into distinct 4
groups on the basis of the most common (>50%) disease status during
reviews: complete resolution (17 patients; 36.2%), partial resolution (17
patients; 36.2%), worsening (1 patient; 2.0%), and same disease status as
that before therapy (12 patients; 25.5%).
The 17 patients who showed complete resolution in the majority (50%) of
reviews had been treated with combined therapy in 9 cases, and with topical
agents only 5 cases. Three patients had spontaneous resolution.
The 17 patients who showed partial resolution in the majority (>50%) of
reviews during therapy were managed with topical agents only in 5 cases
and with combined topical/systemic agents in 12 cases.
The 12 patients whose disease status was mainly the same as that at initial
pre-therapy were managed with topical therapy (8 patients) or combined
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topical and systemic agents (4 patients). The patient with worsening disease
status was managed with topical agents only.
A sub-analysis of three patients treated with systemic thalidomide showed
that the most frequent disease status during therapy was equally distributed
between complete resolution (1 patient), partial resolution (1 patient), and
initial status (1 patient).
Kaplan Meier plot analysis of 46 patients with labial swelling showed that 23
(50%) of them had complete resolution of the swelling within 3 years of
treatment (median time to complete resolution was 36 months). Also, about
25% of patients had complete resolution of swelling within the first year of
therapy. However, there were still 6 patients who did not have complete
resolution of swelling during the follow-up period (Figure 3.5).
3.4.8.2 Clinical outcome of intra-oral mucosal ulceration
i Disease status before therapy and at last clinical consultation
Complete resolution 7 (29.2%)
Partial resolution 10 (41.7%)
Same status 6 (25.0%)
Intra-oral
ulceration 28
Worsening 1 (4.2%)
Figure 3.6 Status of patients with regards to intra-oral ulceration before (left
side) and after therapy (right side).
Twenty four (24/49; 49%) patients had symptomatic intra-oral ulceration
which required medical therapy. Analysis of the overall outcome (based on
the comparison between disease status before therapy and the last review in
2007) demonstrated that complete resolution occur in 7 patients (29.2%),
while partial resolution in 10 (41.7%). The disease status on last review was
the same as that observed at treatment start in 6 (25%) patients, and in only
one patient (4.2%) had the disease worsened.
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The 7 patients who showed complete resolution of intra-oral ulceration were
managed with topical agents only in 5 cases and combined topical/systemic
agents in 2 instances.
The 10 patients who showed partial resolution of intra-oral ulceration were
managed with topical agents only in 4 cases and combined therapies in 6
cases.
The 6 patients whose disease status on last review was the same as that
observed at the commencement of treatment were managed with topical
agents only in 4 cases and with combined therapy in 2 cases. The patient
who had worsening of the disease was managed with topical therapy only.
ii Serial measurement of disease status
Complete resolution 5 (20.8%)
Partial resolution 10 (41.7%)
Same status 8 (33.3%)
Intra-oral
ulceration 24
Worsening 1 (4.2%)
Figure 3.7 Serial measurement of intra-oral ulceration before (left side) and
during therapy (right side).
Analysis of the typical progress during the treatment (calculated upon serial
measurement of disease status during 6-month reviews) was undertaken
based on the aforementioned classification. One group of 5 patients (20.8%)
had complete resolution of intra-oral ulceration in the majority (>50%) of
reviews. Another 10 (41.7%) patients showed partial resolution in the
majority of reviews. Disease status was the same as the initial pre-therapy
status during >50% of the reviews in a third group of 8 patients (33.3%).
Only one patient (4.2%) showed a worsening of disease status in the
majority of reviews.
Chapter 3 Orofacial granulomatosis
123
The 5 patients who presented complete resolution in the majority (>50%) of
reviews were managed with topical agents only (3 patients) and topical and
systemic therapies (2 patients). The 10 patients who showed partial
resolution in the majority (>50%) of reviews during therapy were managed
with topical agents only in (5 patients) and combined topical/systemic agents
in 5 cases. The 8 patients whose disease status was mainly the same as
initial pre-therapy status were managed with topical therapy only in 5 cases
and combined topical and systemic agents in the remaining 3 cases. The
patient with worsening disease status was managed with topical agents only.
3.4.9 Adverse drug reactions
Six patients had adverse side effects (ASEs) such as gastrointestinal upset,
nausea, vomiting, diarrhoea, cutaneous rash or sensory neuropathy. Five
patients had one ASE and one had three ASEs. All patients who developed
an ASE were on systemic agents, mainly long-term azathioprine or
thalidomide.
Azathioprine was prescribed to 7 patients; adverse side effects developed in
3 patients and included skin rash (1 patient), nausea and headache (1), and
cardiac arrhythmia (1).
Thalidomide was prescribed to 7 patients; adverse effects developed in 4
patients and included skin rash (3 patients) and fatigue (1).
Systemic prednisolone was prescribed to 13 patients; it caused
gastrointestinal upset in one patient. Gastrointestinal upset developed in the
only patient was on systemic tacrolimus. Oral candidosis was the most
common adverse side effect from topical therapy.
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3.5 DISCUSSION
Oro-facial granulomatosis (OFG) is a chronic inflammatory disease with the
potential to adversely affect the quality of life of patients by virtue of
persistent labial and/or facial swelling, painful oral ulcerations, and in
occasionally neurological manifestations (Somech et al., 2001).
There are few detailed studies with large groups of patients on the clinical
onset and long-term behaviour of this disorder and little is known regarding
the long-term effects of different therapies. The present chapter attempted to
clarify these issues by virtue of a retrospective analysis of a group of patients
with OFG who were managed at a single centre over more than 20 years.
The study represents the largest homogenous group of individuals
diagnosed with only OFG reported in the past two decades, as individuals
with likely Crohn’s and sarcoidosis were excluded. As the majority of
previous clinical studies (Wiesenfeld et al., 1985; Patton et al., 1985; James
et al., 1986; Williams et al., 1991) of OFG-like diseases included patients
with Crohn’s disease and those with hypersensitivity reactions and their
findings should be interpreted with caution as these disorders may behave
and respond to therapy differently from OFG.
With regards to epidemiological findings, our cohort had a ratio of males to
females of 1.2:1, which agrees with the majority of previous reports
(Wiesenfeld et al., 1985; Plauth et al., 1991; Williams et al., 1991; Sanderson
et al., 2005; White et al., 2006). These studies also suggest that OFG may
develop at any age and only one study reported that young individuals are
more frequently affected than adults (James et al., 1986). Our results are in
accordance with the latter as we found that more than half of patients (26/49;
53.1%) in our cohort were younger than 30 years of age and about two-
thirds (32/49; 65.3%) were ≤ than 40 at diagnosis. These were mainly males,
which is difficult to explain as there was no significant difference in the
symptoms or signs of OFG between genders (data not shown).
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Caucasians were the most common reported ethnic group (85.7%) with
Asian, and Black-Africans representing 14.3% of our patients. This ethnical
distribution parallels that of general population of London as indicated by the
2001 consensus (Office for National Statistics, 2003) and indeed OFG had
been reported in patients from many parts of the world (Odukoya, 1994;
Mignogna et al., 2003; Guttman-Yassky et al., 2003 ; van de Scheur et al.,
2003; Sciubba and Said-Al-Naief, 2003; Lazarov et al., 2003; Khouri et al.,
2005; Gaya et al., 2006; Kauzman et al., 2006; Endo and Rees, 2007;
Shams et al., 2007).
Labial swelling is traditionally indicated as the most common clinical feature
of OFG. It is also reported as being the most frequent manifestation at
disease presentation (Alawi, 2005) and with agreement with previous reports
(Wiesenfeld et al., 1985; Plauth et al., 1991; Mignogna et al., 2003;
Sanderson et al., 2005) OFG in the present cohort of patients typically gave
rise to recurrent/persistent painless facial (mainly of the lips) swelling
(95.9%) and long-standing painful ulceration (49%) during the course of the
disease.
However, few authors have reported that clinicians should not focus solely
on labial swelling as patients with OFG can in fact present with multiple,
temporary and multi-focal clinical features affecting intra-oral mucosa,
gingivae, facial tissues and the craniofacial nervous system (Wiesenfeld
et al., 1985; Mignogna et al, 2003). Moreover they have been reported to
develop at different time points in the duration of disease (Mignogna et al.,
2003). Little is known about clinical onset and early manifestations of OFG.
The few data available suggest that early OFG can cause clinical
manifestations other than lip swelling (e.g. atypical onset) that can include
gingival hyperplasia, transient facial palsy or daily persistent headache and
swelling of other areas of the face (Rozen, 2001; Mignogna et al., 2003).
Mignogna et al (2003) reported that about half of their 19 OFG patients
(9/19) had a disease onset characterized by the absence of labial swelling
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and occurrence of facial palsy, intra-oral manifestations and swelling of facial
areas other than the lips. However 7 of these 9 patients eventually
developed labial swelling. Zimmer et al (1992) reported that labial swelling
was the initial disease manifestation in only 43% of their 42 patients but this
percentage increased to 74% during the course of the disease. Moreover,
the overall number of clinical manifestations increased during the years as
the percentage of patients with facial swelling increased from 26% to 50%
and those with facial palsy from 19% to 33% (Zimmer et al., 1992). In partial
agreement with these findings, the present study identified five patterns of
disease onset (Figure 3.1) with orofacial swelling (53.1%) and oral ulceration
(28.6%) being the most common initial manifestations. Most patients (85.7%)
developed further facial and/or intra-oral manifestations over the years. This
confirms the concept that the clinical behaviour of OFG is multiform,
progressive and highly variable, and that perhaps each patient's disease has
a unique pattern of duration and presentation (Mignogna et al, 2003).
Gingival inflammation and/or enlargement unrelated to plaque or a drug
were observed in 26.5% of the present group of patients and is generally
similar to that reported in previous group of UK residents (Wiesenfeld et al.,
1985) but twice as common as that reported in a group of patients’ residents
in Italy (Mignogna et al., 2003).
Cervical lymphadenopathy has not been frequently described in association
with OFG, but was found in 10 (20.4%) of the present patients. It can cause
facial/submandibular swelling and may reflect, at least in some individuals,
granulomatous lymphadenitis, as observed in the mesenteric lymph node of
Crohn’s disease (Geboes et al., 1986).
Neurologic manifestations are reported to affect up to 33% of patients with
OFG (Wiesenfeld et al., 1985; Zimmer et al., 1992; Mignogna et al., 2003;
Kanerva et al., 2008) and were observed in 4 patients of present cohort
(8.2%). They all occurred at early stage of disease and never as subsequent
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clinical manifestation, suggesting that patients who do not present neurologic
involvement at early stage are unlikely to develop it afterward.
OFG does not seem to be associated with any significant haematological
abnormalities or serological evidence of systemic inflammation (CRP, ESR),
other granulomatous disorders (e.g. SACE) or gastroenterological
involvement (e.g., iron or folic acid anaemia). All these parameters were
normal in this group of patients which in part reflects inclusion criteria
applied. These findings appear consistent with previous report (Sanderson et
al., 2005) which found no consistent haematological and/or serological
abnormalities in OFG patients.
OFG is considered to be a granulomatous disorder (Wiesenfeld et al., 1985);
however, few studies have determined the exact frequency of granulomas in
a large cohort of homogenous OFG patients (Sanderson et al., 2005). In the
present study, histopathological results were available for 37 patients
(75.5%). In general, the reports revealed a range of features and typical non-
caseating granulomas were observed in only 43.2% of the specimens, which
is similar to the prevalence (46.4%) reported before by Williams et al (1991).
Other studies reported that granulomas were found in 81% to 100 % of
affected patients (Wiesenfeld et al., 1985; Harty et al., 2005; Sanderson et
al., 2005). It should be noted that two of them included patients with oral
Crohn’s disease (Wiesenfeld et al., 1985; Harty et al., 2005). As reported
earlier, (Wiesenfeld et al., 1985; Sanderson et al., 2005), other
histopathological features such as oedema of the corium with dilated
lymphatic and blood vessels and unspecific inflammatory infiltrate can
characterize OFG and these were found in the histopathological lesional
tissues examined in present study.
The analysis of OFG treatment described in the present study showed that
combined therapy (topical and intra-lesional corticosteroids or systemic
agents) was more frequently associated with partial/complete control of the
facial manifestations of OFG than topical therapy alone. Even though the
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behaviour of OFG was typically remittent, almost half of the patients showed
complete resolution of facial swelling at last review. About one-third of the
patients responded only partially to therapy and in 12.8 % of cases the
treatment could only prevent further increase in facial swelling. Resistance to
therapy with worsening of the disease was extremely uncommon (1/49;
2.0%).
Comparison of long-term clinical outcomes (as recorded at last review) with
serial outcomes recorded during 6-month reviews demonstrated that facial
swelling of OFG tends to improve slowly over time as long as therapy is
provided. The percentage of patients with complete resolution of swelling
increased from 36.2% during the course of therapy to 46.8% at last review
where as the percentage of patients with no significant improvement
decreased from 25.5% to 12.8%. This means that a considerable number of
patients who had not benefited from treatment in the short to medium term
eventually showed partial or complete resolution in the long-term.
With regards to the time needed to achieve clinical effectiveness, the results
of the present study suggest that OFG responds slowly to treatment with
50% of the patients achieving complete resolution of the orofacial swelling
within 3 years of treatment and only 25% of them doing so within the first
year of therapy (Figure 3.5). However a sub-analysis of clinical outcome data
suggests that intra-lesional corticosteroids are usually effective in the first
weeks of treatment (data not shown). Intra-oral ulceration was typically less
responsive to treatment than facial swelling. Only one-third of patients
achieved complete resolution of intra-oral ulceration whilst in the majority of
cases treatment led to obtain partial resolution only (41.7%) or prevent
further worsening (25%) of the mucosal disease.
The aims of OFG management were to lessen and hopefully resolve intra-
oral painful lesions, oro-facial swelling and other features of the diseases
(e.g. lip fissures, angular cheilitis, etc). Ulceration of the oral mucosa,
mucosal tags and cobblestoning were usually managed with topical
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corticosteroids (Mignogna et al., 2003) and only rarely were they severe
enough to require systemic therapies. Mild oro-facial swelling was managed
with topical corticosteroid (e.g. Fluticasone propionate 0.05% cream
prescribed to 23 patients) and/or tacrolimus (Tacrolimus 0.1% prescribed to
22 patients). Mild swellings that were non-responsive to topical agents and
moderate to severe swellings were usually managed with short courses (1-2
weeks) of moderate doses of systemic corticosteroids (25-50 mg of
prednisolone) and, when required, with intra-lesional corticosteroids
injections, long-term systemic immunosuppressants (e.g. azathioprine), or
anti-TNF-α agents (e.g. thalidomide).
Despite the wide range and long-time use of topical and/or systemic
therapies employed in the management of this cohort of OFG patients, no
consistent haematological and/or serological abnormalities were observed. A
few patients undergoing long-term topical therapy developed oral candidosis
which was managed by appropriate antimycotic agents such as nystatin. The
other clinical adverse drug reactions were minor and were mostly observed
in patients on systemic therapy.
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3.6 CONCLUSION
The results of this study show that OFG is a rare disease of young adults
whose ethnicity reflects that of the general population living in the same
area. Onset of OFG is characterised by facial swelling in only half of the
patients whilst in the other half early disease causes intra-oral or
neurological manifestations only. Lip/facial swelling is the most common
clinical manifestation of OFG leading the patients to seek medical attention.
Among intra-oral manifestations, the prevalence of cobblestoning, gingival
enlargement and mucosal changes exceeds that of oral ulceration. The long-
term behaviour of OFG is subsequently characterised by development of
further clinical manifestations with most patients (95.9%) developing, at any
time during the course of the disease, orofacial swelling and, less frequently
(49 %), intra-oral ulceration. A careful differential diagnosis is mandatory as
OFG and related disorders have different aetiologies and different
treatments and clinicians should consider the variable, progressive and
multiform nature of OFG when they attempt early diagnosis and long-term
management.
A wide range of topical, intralesional, and systemic agents can be used to
control signs and symptoms. The response of OFG to therapy is typically
remitting but some improvement of tissue swelling and oral ulceration can be
achieved in 78.8% and 70% of patients respectively. Complete remission of
facial swelling is possible in about 50% of patients within 3 years of therapy
but may be achieved quicker when intra-lesional corticosteroids are used.
Intra-oral ulceration is usually less responsive. Significant adverse side
effects are rarely observed and spontaneous remission may occur in few
patients.
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Table3.1 Demographic and clinical presentation of some of the published studies on the orofacial granulomatosis*
First author/
year
No of
pts Female Male
Age
(range) Diagnosis
Clinical presentation (No. or % of
patients when available) Comment
Al Johani
2009
49 22 27 32.4
(7.4-72.1)
OFG Oro-facial swelling, angular cheilitis,
perioral erythema, fissuring, mucosal
cobblestoning, tags, gingival
enlargement, ulceration, lymph node
swelling, facial nerve palsy, chronic
paroxysmal hemicrania
-
Kanerva
2008
35 23 12 20
(3-61)
MRS Facial palsy (20), triad of symptoms
(11), edema (33), lingua plicata (13)
-
White
2006
25 11 14 30
(9-69)
OFG NA** 9 pts had had minor
changes in the gut
including aphthous
ulcerations and
granulomas present in
histopathological
specimens
Sanderson
2005
35 18 17 24
(6-74)
OFG (no GI
symptoms)
Lip swelling present in (95%),
Buccal and gingival inflammation,
Cobblestoning (49%),
Fissuring (37%),
Aphthous-like ulceration (15%),
Deep linear-type ulcers (12%)
-
Mignogna
2003
19 NA NA NA OFG 10 patients had recurrent lips swelling (6
lower; 4 upper).
Transient unilateral facial nerve palsy
(2), gingival hyperplasia (2), palatal
erythema (1), recurrent swelling of the:
peri-orbital area (2), chin (1), zygomatic
area (1) and cheeks (1)
-
*Studies with more than 15 patients published between 1985 and 2009. **NA, not available.
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Table 3.1 (Cont.) Demographic and clinical presentation of some of the published studies on the orofacial granulomatosis*
First author/
year
No of
pts
Female Male Age
(range)
Diagnosis Clinical presentation (No. or %
of patients when available) Comment
Gibson 2000 16 8 8 Male; 30
female; 32
range
(9-58)
OFG
(excluding
Crohn’s and
other systemic
disorders)
NA** -
Armstrong
1997
48 26 22 24
(9-70)
OFG
(excluding
Crohn’s and
sarcoidosis)
Facial swelling (12)
Lip swelling (41)
Mucosal oedema/ gingivitis (9)
Vertical lip fissuring (7)
Angular cheilitis (6)
Oral ulceration (11)
Facial nerve palsy (4)
Granuloma found in 41
lesional biopsies
Williams 1991 29 13 13 30
(6-78)
OFG including
Crohn’s disease
patients
Labial swelling (19)
Both lips (9)
Upper lip (6)
Lower lip (4)
Cobblestoning (11)
Linear ulceration (11)
Localized swelling (5)
Mucosal tags (2)
28 of the 29 biopsies
were reviewed.
Granuloma were
present in 13
patients
James 1986 75 39 36 15
(4-64)
13 patients had
Crohn’s
disease, 5 had
abdominal
symptoms and
one diagnosed
with sarcoidosis
NA The clinical atopy
prevalence among OFG
patients alone or in
association with Crohn’s
disease is highly
significant than control
group
*Studies with more than 15 patients published between 1985 and 2009. **NA, not available.
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Table 3.1 (Cont.) Demographic and clinical presentation of some of the published studies on the orofacial granulomatosis*
First author/
year
No of
pts
Female Male Age
(range)
Diagnosis Clinical presentation (No. or %
of patients when available) Comment
Haworth 1986 16 NA** NA NA OFG without
Crohn’s and
sarcoidosis
NA Food or flavouring
provoking the disorder.
Wiesenfeld
1985
60 30 30 20
(3-61)
OFG (including
MRS and CG.
Six had
confirmed GI
Crohn's and 9
had evidence
suggestive of
Crohn's disease,
2 patients had
sarcoidosis
Facial swelling (28),
Labial swelling (41); upper (27),
lower (30),
Intra-oral mucosal oedema (14),
tags (12), gingival lesions (13),
angular cheilitis (11), oral
ulceration (19), geographic
tongue (3), fissured tongue (1)
Facial nerve palsy (8)
47/58 had granuloma.
Patton 1985 80 NA NA NA OFG (including
MRS)
Oral Crohn’s
Urticarial rash
with porridge
and allergic
patients
NA 14 of the 80 patients
had food or flavouring
intolerance to
cinnamaldehyde,
carvone and/or
piperitone.
Scully 1982 19 10 9 15
(3-40)
OFG (Crohn’?) Lip/facial swelling (16)
Aphthous-like ulceration (6)
Deep linear-type ulcers (2)
Fissured tongue (1)
Mucosal tags or cobblestoning
(10)
Angular cheilitis (7)
Facial palsy (1)
Granulomas present in
14 cases.
- 7 patients had
nutritional deficiency
and intestinal disease
(on rectal biopsy).
*Studies with more than 15 patients published between 1985 and 2009. **NA, not available.
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Table 3.2 Clinical features and differential diagnosis of orofacial granulomatosis
Disorder
Aetiology and
pathogenesis Extra-oral/ facial manifestations
Intra-oral
manifestations Histopathology Comments
OFG Largely unknown.
OFG is thought to
be multifactorial
disorder. Several
mechanisms have
been suggested,
such as immunity,
infection, and
genetic
predisposition. It
may represent a
generalized GI
inflammatory
response to an
unknown antigen.
- Swelling: mainly the lip but other
facial areas possibly affected. Initially,
soft and recurrent, then progressive
and finally persistent and firm.
- Erythema can accompany the
swelling
- Patients may have facial palsy
(lower motor neuron); other cranial
nerves may be involved. Other
neurological manifestations (e.g.
headache, lacrimation, etc) may
present.
- Cervical lymph nodes can be
enlarged in some patients.
- Oral ulcerations
(linear and/or
aphthous-like ulcers)
- Cobblestoning
- Mucosal tags
- Gingival
enlargement
- Tongue fissures
- Angular cheilitis
Non-caseating
epitheloid granulomas
with/ without multi-
nucleated giant cells
can be found but not
in all lesional biopsies
(especially early
stages).
Oedema of the
superficial corium with
lymphangie-ctasia and
aggregates of
lymphocyte is
observed (early
stages).
Some patients may
have intestinal
inflammation that differs
from that of Crohn’s
disease.
Crohn's
disease
Largely unknown.
Evidence of
dysfunction of
innate immune
system causing
inappropriate (often
excessive)
response to
indigenous flora
and other luminal
antigens.
-Identical to OFG except cranial
nerve involvement and other
neurological manifestations
-Similar to OFG - Similar to OFG - Patients need to have
proven intestinal
involvement to be
diagnosed with oral
Crohn’s disease.
- Serology shows the
typical abnormalities of
CD and can help
identifying patients with
still undiagnosed
asymptomatic gut
disease (FBC, Vit. B12,
iron and ferritin, CRP,
ERS, albumin, ASCA).
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Table 3.2 (Cont.) Clinical features and differential diagnosis of orofacial granulomatosis
Disorder Aetiology andpathogenesis Extra-oral/ facial manifestations
Intra-oral
manifestations Histopathology Comments
Sarcoidosis Unknown.
Infection,
environmental
agents, genetic
predisposition and
immunological
factors have been
suggested.
- Lip swelling, usually progressive
and persistent, followed by slow
spontaneous resolution in 60% of
cases.
- Salivary gland swelling
- Lymph nodes enlargement
- Facial nerve palsy
- Heerfordt syndrome (combination of
fever, parotid enlargement, anterior
uveitis, and facial nerve palsy).
- Yellowish-brown papules and lupus
pernio affecting the skin of the face.
- Submucosal diffuse
swelling or focal firm
nodules, papular
eruptions or
superficial ulceration.
Usually progressive
and persistent,
followed by slow
spontaneous
resolution in 60% of
cases.
- Dry mouth
- Non-caseating,
epithelioid-cell
granulomas
surrounded by
lymphocytes,
-Basophilic
calcification
(Schaumann bodies)
and stellate inclusion
(asteroid bodies) can
be found.
Orofacial involvement is
usually a manifestation
of widespread
multiorgan disease and
can be the initial
manifestations of the
disease in about 50%
of patients.
- Serology (elevated
ACE level), chest
radiograph (bilateral
hilar adenopathy) and
Gallium 67 scanning
can support diagnosis.
Tuberculo-
sis (TB)
Mycobacterium
tuberculosis or
other related
species (M. bovis,
M. africanum, M.
microti, and M.
canettii)
- Cervical lymphadenopathy
- Salivary gland swelling
- Chronic progressive swelling of the
lip due to submucosal nodular
infiltration
- Swelling of the face due to
tuberculous osteomyelitis.
- Superficial non-
healing, indurated
ulcer with irregular
borders.
- Mucosal swelling
due to submucosal
nodular infiltration.
-Bone lesion
(osteomyelitis).
Caseating,
granulomas with
central necrosis.
Ziehl-Neelsen or other
acid-fast stains (e.g.
Fite method) can
demonstrate
mycobacteria
infection.
- TB can affect the
head and neck area in
both its primary and
secondary form.
- Collection of sputum
for culture and DNA
analysis, chest
radiography, tuberculin
skin testing and the
new serological INF-
gamma assay can
support diagnosis.
Chapter 3 Orofacial granulomatosis
136
Table 3.2 (Cont.) Clinical features and differential diagnosis of orofacial granulomatosis
Disorder Aetiology andpathogenesis Extra-oral/ facial manifestations
Intra-oral
manifestations Histopathology Comments
Delayed
hypersens-
itivity
reactions
(DHSR)
Type IV DHSR.
Antigens include
food (e.g.
chocolate),
additives (e.g.
benzoate), and
dental materials
(e.g. gold).
Lip and/or facial swelling.
Usually recurrent but chronic
permanent enlargement possible.
-Intra-oral mucosal
swelling
No distinctive features - Patch testing usually
helps in diagnosing the
causative agent.
- Allergen removal (e.g.
dietary modification)
leads to improvement/
remission of clinical
features.
Acquired
and
hereditary
forms of
angiodema
- C1 esterase
inhibitor (C1-inh)
deficiency
syndrome can be
hereditary or
acquired.
- Hereditary type is
a rare autosomal
dominant condition.
- Acquired forms
are generally
triggered by
autoimmune or
neoplastic
disorders
- Orofacial swelling: always recurrent
but never progressive or permanent.
- Episodes are triggered by minor
trauma, drugs, emotional stress or
infection.
- Recurrent intra-oral
mucosal swelling.
Non-specific
inflammatory changes.
No granulomas.
Gastrointestinal
symptoms (e.g.
nausea, vomiting, or
diarrhoea) are typically
associated.
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Table 3.3 Diagnostic investigations and criteria of orofacial granulomatosis$
Investigations Results
Full blood cell count Should be normal
Haemoglobin Should be normal
Serum angiotensin I converting enzyme levels* Should be normal
C-1 esterase inhibitor levels** Should be normal
Serum iron and transferrin Should be normal
Tuberculin skin test (when clinically justified) Should be negative
Chest radiography (when clinically justified) Should be normal
Gastrointestinal (GI) endoscopy/histopathology*** Should be normal. If
inflammatory changes are
present, Crohn’s disease
should be excluded
Histopathology I : dilated lymphatics, oedema of the
corium, slight fibrosis, with/without multiple non-caseating
granulomas with Langhan's giant cell and lymphocytes
Should be present****
Histopathology II : PAS reaction and Ziehl-Neelsen stain
(when clinically justified)
Should be negative
Polarised light microscopy: identification of birefringent
foreign-body material (when clinically justified)
Should be negative
$ Modified from Mignogna et al., 2003
* To be performed when there are clinical features compatible with a potential diagnosis of
sarcoidosis.
** To be performed when oro-facial swelling is recurrent and oedematous without signs
of persistent tissue fibrosis.
*** To be performed when clinical or laboratory features rise the suspect of GI
inflammatory disease.
**** Absence of histopathological features does not exclude OFG diagnosis if
clinical features are compatible.
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Table 3.4 Reported therapeutic regimes for the treatment of OFG and related
agents
Drug First author Year Drug Comments
Mignogna 2002 Clobetasol 0.05% ointment
mixed 1:1 with orabase
Good response with
intraoral lesions
Hegarty 2002 Betamethasone sodium
phosphate mouthrinse
Good response with
intra-oral ulcers.
Hegarty 2002 Fluticasone propionate
aqueous spray
Benzydamine hydrochloride
mouthwash
little effect
Topical
corticosteroids
van der Waal 2002 Triamcinolone in orobase/
clobetasol in orobase
Moderate to good
results and effective in
long-term
Lourenco 2008 Intralesional triamcinolone Good improvement in
4/5 patients
Barry 2005 Intralesional triamcinolone
(30 mg)
Some effect
van der Kooi 2005 Intralesional corticosteroids Partial improvement
Mignogna 2004 Intralesional triamcinolone
(40 mg/ml)
Effective with long
disease-free period
El-Hakim 2004 Intralesional triamcinolone
(10 mg/ml)
Good outcome in 5
patients and moderate
in one patient.
Camacho-Alonso 2004 Triamcinolone 0.1%
injection (every 2 weeks for
6 weeks)
Satisfactory
improvement in lip
swelling.
Van de Scheur 2003 Intralesional (2 mL)
triamcinolone acetonide
(10 mg/mL) each month for
6 months
Partially effective
Mignogna 2002 Intralesional triamcinolone
(0.1 ml- 40 mg/ml) 2-4
injections, 2-3 times over 2-
3 weeks
Good response in
management of swelling
Intralesional
corticosteroids
van der Waal 2002 Triamcinolone 0.1% Variable results.
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Table 3.4 (Cont.) Reported therapeutic regimes for the treatment of OFG and
related agents
Drug First author Year Drug Comments
Lourenco 2008 Prednisone (40mg/day) Good improvement in
4/5 patients
Peitsch 2007 Prednisolone,
hydroxychloroquine
(400mg/day) and
sulphasalazine (3 g/day)
Partial resoponse
Thomas 2003 Prednisone (40 mg/day) Lessening lip swelling
but swelling recurred
when stops
prednisone.
Kauzman 2006 Prednisone (50 mg/day)
Intralesional triamcinolone
(40 mg/mL)
Effective
Tonkovic-Capin 2006 Systemic corticosteroids Partial response
Barry 2005 Prednisolone (40 mg/day) Some effect
Mergulhao 2005 Prednisone (60 mg/day) Rapid response
van der Kooi 2005 Systemic corticosteroids Not effective
Taibjee 2004 Systemic corticosteroids Partial response
Camacho-Alonso 2004 Systemic betamethasone
(4 mg/day) and
triamcinolone 0.1%
injection (every 2 weeks for
6 weeks)
Satisfactory
improvement in lip
swelling.
van de Scheur 2003 Prednisone (60 mg/day) Decrease lip swelling
Girlich 2002 Prednisolone (60 mg/day)
5-ASA
Rapid reduction of lip
swelling
Mignogna 2002 Prednisone (25-50 mg/day) Partial or complete
resolution of facial
swelling
Hegarty 2002 Prednisolone/deflazacort
(24 mg/day)
Little improvement or no
effect
van der Waal 2002 Prednisolone/
Dexamethasone
Moderate to good
results
Systemic
corticosteroids
Ziem 2000 Prednisolone (1 mg/kg/day) Labial swelling resolved
with residual mild
enlargement and
persistent facial palsy
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Table 3.4 (Cont.) Reported therapeutic regimes for the treatment of OFG and
related agents
Drug First author Year Drug Comments
Fdez-Freire 2005 Clofazimine 100 -200 mg/
daily for 3 to 6 months
Effective
Barry 2005 Clofazimine (200 mg) Not effective
Camacho-Alonso 2004 Clofazimine 100 mg every
other day
Satisfactory improvement
in lip swelling.
Camacho-Alonso 2004 Clofazimine 100 mg every
other day
Triamcinolone 0.1%
injection (every 2 weeks for
6 weeks)
Satisfactory improvement
in lip swelling.
Sciubba 2003 Clofazimine (50 mg/day)
Intralesional triamcinolone
Systemic corticosteroids
Nystatin, Fluocinonide
Tetracycline
Diphenhydramine
Maalox suspension
Chlorhexidine gluconate
Combination of
clofazimine and topical
preparation lessening the
lip enlargement and
erythema.
Clofazimine
van der Waal 2002 Clofazimine Variable results.
Lourenco 2008 Dapsone (100mg/day) Good improvement in 4/5
patients
Peitsch 2007 Dapsone (100 mg/day)
Oral methylprednisolone
(25 mg/day),
Metronidazole, Ibuprofen
Not effective
Tonkovic-Capin 2006 Dapsone
Doxycycline
Intralesional triamcinolone
acetonide
Partial response
Thomas 2003 Dapsone (50 mg/day) Not effective
van der Kooi 2005 Dapsone Decrease lip swelling
Dapsone
Hegarty 2002 Dapsone (25 mg/day) Not effective
Peitsch 2007 Infliximab (5 mg/kg) Effective
Barry 2005 Infliximab (3-5 mg/kg)+ IV
hydrocortisone (200 mg)
Marked clinical
improvement
Mahadevan 2001 Infliximab (5 mg/kg/day)
Azathioprine (2.5 mg/kg/
day), Prednisone
Effective
Thomas 2003 Thalidomide (100-mg/
day) for 6 months then
every other day for 2
months
Complete disappearance
of lip swelling.
Anti-TNF-α
Hegarty 2002 Thalidomide (50 mg daily) Effective for both labial
swelling and mucosal
ulceration
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Table 3.4 (Cont.) Reported therapeutic regimes for the treatment of OFG and
related agents
Drug First author Year Drug Comments
Methotrexate Tonkovic-Capin 2006 (5-10 mg, once weekly) Marked improvement
Barry 2005 Topical tacrolimus No effect
Casson 2000 Topical tacrolimus
Prednisolone
Good response to
topical tacrolimus
Tacrolimus
Hegarty 2002 Topical tacrolimus 0.1% Improvement in oral
ulceration and little
effect on labial swelling
Barry 2005 Minocycline hydrochloride
(100 mg)
Little effect
Barry 2005 Erythromycine (500 mg
twice/day)
No effect
El-Hakim 2004 Doxycycline No effect
Antibiotics
van der Waal 2002 Metronidazole Not effective
Mergulhao 2005 Sulfasalazine Not respond
Hegarty 2002 Sulphasalazine (500
mg/twice daily)
No effect
van de Scheur 2003 Mesalazine (500 mg)
Sulfasalazine (500 mg)
Used for the treatment
of intestinal Crohn’s
disease
Amino-
salicylates
van der Waal 2002 Sulfasalazine/Mesalazine Moderate improvement
Mergulhao 2005 Hydroxychloroquine Partial improvementHydroxy-
chloroquine van der Waal 2002 Hydroxychloroquine Not effective
Antihistamines van der Kooi 2005 Oral antihistamines Not effective
van der Waal 2002 Cheiloplasty Moderate outcome
Kruse-Losler 2005 Cheiloplasty (Conway
method)
Good results with partial
recurrence in 1 patient
Oliver 2002 Cheiloplasty Good improvement
Surgery
(Cheiloplasty)
Camacho 2001 Cheiloplasty with 40 mg
triamcinolone acetonide
injection with tetracycline
hdrochloride (1 g/day) for 2
months then (500 mg/day)
for 3 months then (250
mg/day) for 6 months
Results were
satisfactory with
9 months follow up
Guttman-Yassky 2003 Replacement of amalgam Complete swelling
disappearance within 6
months
Restoration
replacement
Lazarov 2003 Replacement of gold
crowns and amalgam
Complete resolution of
OFG within 5 months
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Table 3.5 Summary of the reported regimes for the treatment of OFG
Therapy Medication Target Effect Adverse side effects(Reference)
Topical
corticosteroids
Clobetasol ointment (in
orabase)
Betamethasone mouthwash
Fluticasone spray
Benzydamine mouthwash
Triamcinolone in orabase
Intraoral lesions Moderate to good results
in controlling intra-oral
lesions
Topical
immuno-
suppressants
Tacrolimus ointment Intra-oral lesions
and lip swelling
Effective in controlling
intra-oral lesions.
Lip swelling response only
in mild cases.
Intralesional
corticosteroids
Triamcinolone acetonide
10mg/ml
Triamconolone acetonide
40mg/mL
Oro-facial swelling Variable results. From
partial, short-term
improvement to complete,
long-term remission
Hypopigmentation
(Mignogna et al., 2004)
Systemic
corticosteroids
(short courses)
Prednisone (0.5-1 mg/Kg/day)
Deflazacort (24 mg/day)
Betamethasone (4 mg daily)
Orofacial swelling
and severe intra-
oral lesions
Rapidly effective but
recurrence after therapy
termination.
Clofazimine (50-100 mg/day) Clofazimine: Effective but
recurrence after therapy
termination.
Hyper-pigmentation,
morbilliform eruption and
elevation of liver enzymes
(Sciubba and Said Al-
Naief, 2003;Thomas et
al., 2003; Fdez-Freire et
al., 2006)
Systemic
anti-leprotic
therapy
Dapsone (25-50 mg/day)
Orofacial swelling
and severe intra-
oral lesions
Dapsone: Partially
effective
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Table 3.5 (Cont.) Summary of the reported regimes for the treatment of OFG
Therapy Medication Target Effect Adverse side effects(Reference)
Thalidomide (50-100 mg/day) Pruritic rash and
somnolence (Hegarty et
al., 2002)
Infliximab
Anti-TNF-α
Adalimumab
Orofacial swelling
and severe intra-
oral lesions
Effective
Antibiotic
therapy
Minocycline
Erythromycine
Doxycycline
Metronidzole
Orofacial swelling Little or no effect
Amino-
salicylates
Sulphasalazine
Mesalazine
Orofacial swelling Little or no effect
Antimalarial Hydroxychloroquine Orofacial swelling Little or no effect
Azathioprine Azathioprine: Moderately
effective as maintenance
therapy.
Flu-like symptoms
(malaise, fever and
arthralgias) (Tonkovic-
Capin et al. 2006)
Systemic
Immuno-
suppressants
Methotrexate
Orofacial swelling
and severe intra-
oral lesions
Methotrexate: Effective
Surgery Cheiloplasy +/- facial
liposuction (+/- intralesional or
systemic corticosteroids)
Orofacial swelling
Effective but risk of
recurrence
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Table 3.6 Outcome of treatment of some of orofacial granulomatosis cohorts
First author/
year
No of
pts Intervention/ treatment Outcome
White
2006
25 Cinnamon and benzoate free
diet for 8 weeks.
-There was a significant improvement
in oral inflammation in patients on the
diet after 8 weeks
-Significant improvement in both lip
and oral site and activity involvement
Mignogna
2003
19 Intraoral lesions were treated
by topical clobetasol (0.05%).
Lip, cheek, and chin
swellings were treated with
concentrated (40 mg/ml)
delayed-release intralesional
triamcinolone injections.
Facial (zygomatic and
periorbital) swellings were
treated with oral prednisone,
25 50 mg/day (0.3 0.7 mg/
kg/day) for 7–15 days.
Intraoral lesions responded well to
topical clobetasol 0.05% ointment
mixed 1:1 with orabase.
Soft tissue swelling:
intralesional and systemic
corticosteroids resulted in partial or
complete resolution of the swelling
Armstrong
1997
48 Elimination diet for 10
patients.
7 of the 10 who have positive reactions
to the Oral Battery on standard patch
testing reported improvement on
elimination diet.
Williams
1991
29 12 patients received
systemic corticosteroids of
whom three were
corticosteroid-dependent.
5 patients tried elimination
diets.
8 patients required no
therapy
Systemic corticosteroid was the only
effective treatment.
Elimination diets, ciclosporin,
azathioprine sulphasalazine and/or
topical corticosteroids were not
effective.
Wiesenfeld
1985
60 Intralesional corticosteroid
injections (10 pts),
systemic corticosteroids (1
pt),
anti-inflammatory agents (2
pts), co-trimoxazole and
metronidazole (2 pts) and
surgical reduction (2 pts)
None of the patients respond to
systemic corticosteroids, anti-
inflammatory agents or co-trimoxazole
and metronidazole.
Temporary response to intralesional
corticosteroid injections and surgical
reduction
Patton
1985
80 Elimination diet
Systemic corticosteroids
Azathioprine
Salazopyrine
Surgery
Sodium cromoglycate
Response to elimination diet:
Complete response (3 Pts)
Partial response (11 Pts)
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Table 3.7 Age of 49 patients with OFG
Female Male TotalAge
group No % No % No %
1-9 0 0.0 3 6.1 3 6.1
10-19 2 4.1 13 26.5 15 30.6
20-29 3 6.1 4 8.2 7 14.3
30-39 4 8.2 3 6.1 7 14.3
40-49 2 4.1 2 4.1 4 8.2
50-59 7 14.3 1 2.0 8 16.3
60-69 3 6.1 1 2.0 4 8.2
70-79 1 2.0 0 0.0 1 2.0
Total 22 44.9 27 55.1 49 100
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Table 3.8 Referral pattern of OFG patients
Source of referral Frequency %
Oral maxillofacial/oral surgeons 23 47
General dental practitioners 15 30.6
Periodontist 4 8.2
Ear, Nose and Throat Specialist 2 4.1
Orthodontic department 2 4.1
General medical practitioners 1 2.0
Dermatologist 1 2.0
Hospital (Paediatrician) 1 2.0
Total 49 100
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Table 3.9 Past medical history of this cohort of OFG patients
Disorder No %
Penicillin 2 4
Plaster 1 2
Allergy
(excluding asthma
and eczema) Other 11 22
Heart Disease 0 0
Hypertension 2 4
Cardiovascular
DVT 1 2
Asthma 8 16
Bronchitis 1 2
Respiratory
Allergic rhinitis 1 2
Sickle cell anaemia 1 2
Anaemia 2 4
Haematological
Haemophilia 1 2
Diabetes mellitus 2 4Endocrine
Thyroid (disease) 3 6
Gastrointestinal
tract
Irritable bowel syndrome, constipation,
diarrhoea, anal ulceration, perianal
irritation, haemorrhoids, recurrent gastric
complain, gastroesophageal reflux
disease
7 14
Visual 5 10
Hearing 1 2
Learning disability 1 2
Lower motor neurone facial palsy 3 6
Psychiatric problems 3 6
Migraine 2 4
Central nervous
system
Migranous neuralgia 1 2
Eczema 13 26
Vasculitis 1 2
Arthritis 3 6
Other
Osteoarthritis 2 4
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Table 3.10 Presenting clinical features of 49 patients with OFG
Signs and symptoms No %
Lip enlargement 37 75.5
Both lips 9 18.4
Upper lip 9 18.4
Lower lip 19 38.8
Other intra-oral 36 73.5
Cobblestoning 15 30.6
Gingival enlargement 13 26.5
Fissure tongue 7 14.3
Swelling of tongue 1 2.0
Mucosal tags 4 8.2
Other facial 20 40.8
Median lip fissure 7 14.3
Angular cheilitis and fissure of the lip 7 14.3
Facial swelling and/or erythema 6 12.2
Oral ulceration 18 36.7
Aphthous-like ulcers 17 34.7
Linear, deep ulcers 2 4.1
Cervical lymphadenopathy 10 20.4
Neurological 2 4.1
Facial nerve palsy 2 4.1
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Table 3.11 Clinical features of the 49 patients with OFG at disease onset and during
long-term follow-up
Pa
tie
nt Manifestations at
presentation
Subsequent
manifestations
Pa
tie
nt Manifestations at
presentation
Subsequent
manifestations
Group 1 Facial swelling only
(15 Patients)
Group 2 Facial swelling with other manifestations
(11 Patients)
1 Upper/lower lip
swelling
Intra-oral ulceration,
cobblestoning,
cervical lymph node
swelling
16 Upper/lower lip
swelling , perioral
erythema
Intra-oral erythema,
mucosal tags and
cobblestoning,
hypertrophy of palatal
mucosa, cervical
lymph node swelling
2 Upper/lower lip
swelling
Intra-oral ulceration
and cobblestoning
17 Upper/lower lip
swelling,
cobblestoning
and gingival
hyperplasia
Upper/lower lip
swelling
3 Right cheek
swelling
Upper/lower lip
swelling
18 Upper lip swelling
and intra-oral
ulceration
Lower lip swelling,
cobblestoning,
cervical lymph node
swelling
4 Upper lip swelling Lower lip swelling,
cobblestoning and
tags
19 Upper/lower lip
swelling and
fissuring
Perioral erythema,
cobblestoning
5 Upper lip swelling Intra-oral ulceration
and cobblestoning
20 Lower lip swelling +
intra-oral ulceration
Gingival hyperplasia
6 Upper lip swelling None 21 Upper lip swelling
and angular cheilitis
Lower lip swelling
7 Lower lip swelling Intra-oral ulceration 22 Upper/lower lip
swelling and
fissuring, angular
cheilitis, tags and
cobblestoning
Gingival hyperplasia,
perioral erythema
8 Lower lip swelling Upper lip swelling,
intra-oral ulceration
23 Upper lip swelling
and gingival
hyperplasia
Cheek swelling
9 Lower lip swelling Perioral erythema 24 Lower lip swelling +
intra-oral ulceration
None
10 Lower lip swelling Upper lip swelling 25 Lower lip swelling +
intra-oral ulceration
None
11 Lower lip swelling Cervical lymph node
swelling
12 Lower lip swelling None
13 Lower lip swelling None
14 Lower lip swelling None
15 Lower lip swelling None
26 Upper/lower lip and
cheek swelling
None
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Table 3.11 (Cont.) Clinical features of the 49 patients with OFG at disease onset and long-
term follow-up
Pa
tie
nt Manifestations at
presentation
Subsequent
manifestations
Pa
tie
nt Manifestations at
presentation
Subsequent
manifestations
Group 3 Oral ulceration only
(14 Patients)
Group 4 Other intra-oral manifestations
(5 Patients)
27 Intra-oral
ulceration
Upper/lower lip
swelling
41 Tongue swelling Gingival hyperplasia
28 Intra-oral
ulceration
Upper/lower lip and
cheek swelling,
cobblestoning
42 Gingival
hyperplasia
Upper/lower lip
swelling and
cobblestoning
29 Intra-oral
ulceration
Lower lip swelling 43 Gingival
hyperplasia
Upper lip swelling,
cobblestoning
30 Intra-oral
ulceration
Upper/lower lip
swelling, angular
cheilitis
44 Gingival
hyperplasia and
cobblestoning
Lower lip swelling
31 Intra-oral
ulceration
Lower lip swelling,
cobblestoning, tags,
cervical lymph node
swelling
45 Cervical lymph
node swelling +
gingival
hyperplasia
Intra-oral erythema
and mucosal tags
32 Intra-oral
ulceration
Cobblestoning Group 5 Neurological manifestations
(4 Patients)
33 Intra-oral
ulceration
Lower lip and cheek
swelling, tags and
cobblestoning
46 Facial palsy Upper lip and cheeks
swelling, perioral
erythema
34 Intra-oral
ulceration
Lower lip swelling,
cervical lymph node
swelling
47 Facial palsy Upper/lower lip
swelling,
cobblestoning
35 Intra-oral
ulceration
Upper/lower lip
swelling, lip abscess
and mucosal tags
48 Chronic
paroxysmal
haemicrania
Upper/lower lip
swelling
36 Intra-oral
ulceration
Lower lip swelling,
perioral erythema,
cobblestoning, tags,
cervical lymph node
swelling
37 Intra-oral
ulceration
Upper lip swelling
38 Intra-oral
ulceration
Lower lip swelling
39 Intra-oral
ulceration
Lower lip and cheek
swelling,
cobblestoning
40 Intra-oral
ulceration
Upper lip and cheek
swelling, angular
cheilitis, cobblestone-
ing, cervical lymph
node swelling
49 Facial palsy Lower lip swelling,
gingival hyperplasia,
cobblestoning and
tags
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Table 3.12 Abnormal haematological and serological events in relation to type of therapy
(topical* or combined$ [systemic** and topical])
Therapy Elevated events Reduced events
Topical Combined Topical Combined
Haematological and serological
assessments
Total
Red blood cell count 0 10 3 3 16
White Blood Cell 0 5 0 0 5
Absolute lymphocytes 0 0 7 16 23
Haemoglobin
Female 0 0 2 1 3
Male 0 0 8 3 11
Platelets 0 3 2 0 5
Hepatic biochemistry
Alanine aminotransferase 1 9 0 1 11
Alkaline phosphatase 2 0 0 0 2
Albumine 1 2 0 0 3
Renal biochemistry
Sodium 0 0 0 0 0
Potassium 0 0 0 1 1
Urea 5 19 0 0 24
* One or more of the following agents (topical or intralesional corticosteroids, topical tacrolimus or pimecrolimus).
** One or more of the following agents (systemic corticosteroids, azathioprine, dapsone, clofazimine, thalidomide,
mycophenolate mofetil, pentoxifylline, systemic tacrolimus).
$ Any combination of * and **.
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Table 3.13 Abnormal haematological and serological events per patient in relation to type of therapy
(topical* or combined$ [systemic** and topical])
Therapy Elevated events Reduced events
Topical Combined Topical Combined
Haematological and serological
assessments
Total
Red blood cell count 0 3 1 2 5
White Blood Cell 0 5 0 0 5
Absolute lymphocytes 0 0 4 7 11
Haemoglobin
Female 0 0 1 1 2
Male 0 0 5 2 7
Platelets 0 2 1 0 3
Hepatic biochemistry
Alanine aminotransferase 1 3 0 1 5
Alkaline phosphatase 2 0 0 0 2
Albumine 1 2 0 0 3
Renal biochemistry
Sodium 0 0 0 0 0
Potassium 0 0 0 1 1
Urea 4 4 0 0 8
* One or more of the following agents (topical or intralesional corticosteroids, topical tacrolimus or pimecrolimus).
** One or more of the following agents (systemic corticosteroids, azathioprine, dapsone, clofazimine, thalidomide,
mycophenolate mofetil, pentoxifylline, systemic tacrolimus).
$ Any combination of * and **.
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Table 3.14 Different topical and systemic agents used to control OFG lesions
in the present cohort of patients
Agent No of
patients
%
Topical
Fluticasone propionate 0.05% cream- Cutivate 23 47
Clobetasol propionate 0.05% cream - Dermovate 7 14.3
Fluticasone propionate,400 mcg in 15 ml water
as mouthwash 2 4.1
Fluticasone propionate,50 mcg spray 15 30.6
Fluticasone propionate inhaler -Flixotide 2 4.1
Betamethasone mouthwash 10 20.4
Triamcinolone acetonide -Adcortyl 6 12.2
Hydrocortisone 2 4.1
Intralesional triamcinolone acetonide 6 12.2
Tacrolimus 0.03% 5 10.2
Tacrolimus 0.1% 22 44.9
Pimecrolimus 1% 1 2.0
Systemic
Prednisolone 13 26.5
Deflazacort 8 16.3
Azathioprine 7 14.3
Mycophenolate Mofetil 2 4.1
Clofazimine 1 2.0
Dapsone 1 2.0
Thalidomide 7 14.3
pentoxifylline 3 6.1
Systemic tacrolimus 1 2.0
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Table 3.15 Total number of topical and systemic agents employed in the
management of this cohort of patients with OFG
Number of patients
No of agents Topical Systemic Total
(topical and systemic)
0 5 28 4
1 12 9 8
2 17 8 15
3 5 1 4
4 5 1 6
5 3 1 4
6 2 1 4
7 0 0 1
8 0 0 2
11 0 0 1
Total number of
patients 49 49 49
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Figure 3.1 Major patterns of disease onset in this cohort of 49 patients
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Figure 3.2 Therapeutic ladder of lip swelling of oro-facial granulomatosis
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Figure 3.5 Kaplan Meier plot of clinical outcome of soft tissue swelling. The graph
shows that 23 (50%) of the patients had complete resolution of the orofacial swelling
within 3 years of treatment. Also, about a quarter of patients had complete resolution
of swelling within the first year of therapy. However, there were still 6 patients who
did not have complete resolution of swelling during the follow-up period.
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4.1 INTRODUCTION
Mucous membrane pemphigoid (MMP), sometimes termed cicatrical
pemphigoid, is a group of uncommon acquired, autoimmune disorders
characterised by the generation of autoantibodies directed to the
hemidesmosomal protein junction of the epthelial surface, creating a
disruption of cell adhesion and tissue integrity. The resultant
vesiculoulcerative lesions predominately affect mucous membranes and, to a
lesser degree, the skin (Chan et al., 2002).
There is a wide range of other acquired pemphigoid-like immune-mediated
sub-epithelial blistering diseases (IMSEDs), including bullous pemphigoid,
pemphigoid gestationis, lichen planus pemphigoides, dermatitis
herpetiformis, linear IgA disease, anti-p200, anti-p105, and anti-p450
pemphigoid, bullous systemic lupus erythematosus, chronic bullous
dermatosis of childhood, and epidermolysis bullosa acquisita, but MMP is the
most common of these disorders affecting the oral mucosa (Chan et al.,
1993; Verdolini and Cerio, 2003; Darling and Daley, 2005; Eschle-Meniconi
et al., 2005).
Although some authors have suggested that MMP could be subdivided into
ocular and oral variants (Chan et al., 1993; Mobini et al., 1998; Hoang-Xuan
et al., 1999; Dayan et al., 1999), an International Consensus Conference in
1999 concluded that there is only one disorder, which they recommend
identifying as mucous membrane pemphigoid, with different clinical
presentations (Chan et al., 2002). MMP has been termed cicatrical
pemphigoid (Latin word means scar) however, not all patients, indeed very
few, experience scar formation. Also some authors have employed the term
“benign” MMP as oral lesions are usually self-limiting without major
complications, such as scar formation (Dayan et al., 1999), although ocular
lesions may lead to blindness. The most recent consensus view has
recommended using mucous membrane pemphigoid instead of all other
terms (Chan et al., 2002).
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4.1.1 Prevalence
MMP usually affects people in their middle to late life (Laskaris et al., 1982;
Silverman et al., 1986) and rarely affect young individuals (Cheng et al.,
2001; Musa et al., 2002; Lourenco et al., 2006). Desquamative gingivitis may
be a common presenting oral sign in young patients (Lourenco et al., 2006).
The mucocutaneous lesions in young patients are more common and the
disease may be more severe than in older persons. There is no racial or
ethnic predilection, although females are more frequently affected than males
(Laskaris et al., 1982; Silverman et al., 1986; Cotell et al., 2000; Rauz et al.,
2005) with a ratio of 1.5:1 (Laskaris et al., 1982).
MMP is rare (Gallagher and Shklar, 1987), and little is known about its
epidemiology. However, an idea of the prevalence of MMP can be obtained
from reviewing other immune mediated subepidermal diseases (IMSEDs)
studies. A mean annual incidence of IMSEDs was reported as 10.4 per
million people in a French population, with an estimated 590 new cases
annually (Bernard et al., 1995). A 2-year retrospective study of 67 IMSED
patients in Singapore reported bullous pemphigoid (BP) was the most
common disorder (59; 88%), while four (6%) had epidermolysis bullosa
acquisita, two (3%) linear IgA disease, and two (3%) bullous systemic lupus
erythematosus; there were no MMP cases identified (Wong and Chua, 2002).
The prevalence of MMP in the United Kingdom is unknown. However, a
recent population-based study identified 869 people with BP (Langan et al.,
2008) indicating an incidence rate of 4.3 per 100,000 individuals and a yearly
increase of 17%. The annual incidence of BP in Grampian region of Scotland
was estimated to be 14 cases per million per year (Gudi et al., 2005).
4.1.2 Clinical features
MMP can affect any mucosal surface with oral mucosa involved in most
instances. Skin lesions can also develop; however, this is less common than
in bullous pemphigoid (Yeh et al., 2003). The clinical features of MMP and
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their effect on quality of life depend upon the lesion site, the severity, and
duration of the disease.
4.1.2.1 Oral involvement
Oral lesions are present in most cases, either alone or in combination with
other mucocutaneous surfaces (Table 4.1).
Laskaris and co-workers (1982) reported that all of their 55 MMP patients
presented with oral mucosa lesions, but only 3 (5.5%) patients developed
skin lesions. In nearly all the patients (96.4%) oral mucosal lesions preceded
cutaneous involvement and all patients who presented initially with skin
lesions eventually developed oral lesions. The gingivae was the most
common intra-oral site involved (35 patients), followed by buccal mucosa
(32), palate (14), alveolar ridge (9), tongue (8), and lips (4). About half of this
cohort developed extra-oral lesions such as ocular (12 patients), pharyngeal
(9), nasal (4), and genital mucosa (3).
In another case series of 23 patients with MMP, 83% presented with oral
lesions, 70% had ocular involvement, and 22% had cutaneous lesions
(Vincent et al., 1993). Agbo-Godeau and co-workers (2004) reported that 15
of their 17 MMP patients had gingival lesions (in six, this was the only
manifestation), other affected sites included skin, ocular, nasal, and/or
laryngeal mucosa.
The oral manifestations of MMP typically commence as recurrent tense clear
or blood-filled blisters, which generally last longer than those of pemphigus
vulgaris. The blisters usually burst, creating areas of pseudomembrane-
covered, superficial ulceration, and erosions with irregular margins
(Gallagher and Shklar, 1987). These areas of ulceration may coalesce to
produce large eroded patches. Oral scarring is rare (Shklar and McCarthy,
1959). Nikolsky’s sign may be positive in some patients. The disorder
typically affects sites of trauma such as the attached gingivae, and palatal
mucosa although lesions are found less commonly on the tongue and labial
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and buccal mucosa (Chan et al., 2002). As a consequence of the oral
ulceration, patients complain of pain, dysphagia, and/or dysarthria, which
may lessen quality of life (Sami et al., 2002a).
Gingivitis is common among MMP patients; this may be a manifestation of
disease (desquamative gingivitis) or a consequence of the accumulation of
local factors (e.g., plaque) due to the patient’s inability to practice effective
oral hygiene. The gingivae appear deep red and eroded/ulcerated, and
desquamation will usually involve the facial/buccal gingival margin and
attached gingivae. Patients may report bleeding gums following tooth
cleaning (Silverman et al., 1986; Gallagher and Shklar, 1987).
Patients with active MMP and under therapy have higher plaque indices than
those in remission (Tricamo et al., 2006). In addition, Class 1 recession is
more common among patients having the disease more than 5 years
(Tricamo et al., 2006). The risk of developing lesions in any other
mucocutaneous surface in patients presenting initially with oral mucosal
lesions has been estimated to be only 0.12 per person-year (Thorne et al.,
2004).
4.1.2.2 Ocular involvement
Eye involvement represents one of the serious complications of MMP
(Ahmed et al., 2004; Rauz et al., 2005). In a case series of 65 MMP patients,
7 (11%) patients had evidence of symblepharon (Silverman et al., 1986) and
it estimated that 40% of patients with oral lesions also developed ocular
lesions (Dayan et al., 1999). Thorne et al. (2004) reported that the risk of
ocular involvement in MMP patients is 0.05 per person-year.
As with oral involvement, ocular MMP affects older individuals (mean age of
64; range of 20-87) years (Foster, 1986) and more common in women than
men, with a ratio of 1.6:1 (Mondino and Brown, 1981).
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Initially, patients may complain of dry eyes, irritation, discomfort, and
photophobia due to chronic progressive conjunctivitis. Vesicles are rarely
observed on the conjunctiva and lesions usually present as conjunctivitis
(Cotell et al., 2000). Conjunctival erosions, scarring, symblepharon,
ankyloblepharon, entropion, trichiasis, and squamous metaplasia may occur
and lead to decreased or complete loss of vision (Cotell et al., 2000). Initially,
one eye usually involved, with the inflammatory process involving the other
eye within 2 years (Yeh et al., 2003).
There are a number of staging systems for ocular MMP. The Mondino and
Brown (1981) method is based on the conjunctival destruction and the
presence of symblepharon: (i) chronic conjunctivitis and subepithelial fibrosis,
(ii) fornix foreshortening, (iii) any degree of symblepharon, and (iv)
ankyloblepharon and a frozen globe (Mondino and Brown, 1981).
Another is based on the percentage of conjunctival shrinkage and inferior
fornix depth at 4 stages; (i) <25% , (ii) 25% to 50%, (iii) 75%, and (iv) end
stage with complete obliteration of the conjunctival fornices (Tauber et al.,
1992).
Rowsey, et al. (2004) measure the distance between the lower limbus and
the posterior edge of the retracted lower eyelid margin in 3 different gaze
positions: looking up, looking up to the right, and looking up to the left. Foster
and co-workers (1982) used specific clinical signs for staging. This scoring
system comprised 4 staging (i) conjunctival inflammation, mucous discharge,
small patches of rose bengal-staining conjunctival epithelium, and
conjunctival subepithelial fibrosis, (ii) fornix shortening and blunting of the
angle of reflection of the conjunctiva from the eyelid and fornix onto the globe,
(iii) symblepharon, and (iv) sicca syndrome, keratinization, and
ankyloblepharon.
Older patients (>70 years) have milder ocular disease compared to younger
patients, where the disease progresses more rapidly and is less responsive
to treatment. However, mucocutaneous lesions are more prevalent in the
older patients (Rauz et al., 2005).
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Extra-ocular involvement in patients with eye disease is not uncommon. In
one cohort of 36 patients with ocular MMP, oral mucosal lesions were found
in 55.6% patients, nasopharyngeal in 30.6%, genital in 27.8%, and 22% of
this cohort had cutaneous lesions (Rauz et al., 2005).
4.1.2.3 Other mucosal involvement
Although more commonly found in oral and ocular mucosa, MMP also may
affect the nasal, pharyngeal, laryngeal, and genital mucosa (Mobini et al.,
1998).
MMP patients with nasal involvement may complain of epistaxis or chronic
discharge. Ulceration of the septum may lead to scarring and adhesions
resulting in nasal airway obstruction (Whiteside et al., 2003).
Dysphonia, dysphagia, and discomfort may develop if oropharyneal or
laryngeal mucosa is affected. The laryngeal mucosa can be the only site
involved (Fisher et al., 1980), with lesions presenting as erythema, edema, or
blisters in the supraglottis area which may rupture leading to ulceration and
erosions and subsequent mucosal scarring (Ojha et al., 2007).
Patients with oesophageal lesions may complain of dysphagia and
odynophagia due to strictures and web formation. Acid reflux, aspiration, and
a chronic cough also may be present (Syn and Ahmed, 2004). In some
patients the esophagus may be the only site involved (Sallout et al., 2000).
In a large cohort of 110 MMP patients, nasal mucosa was the most affected
upper aeriodigestive mucosa (35 patients), followed by pharynx (19), and
larynx (10) (Alexandre et al., 2006).
Involvement of the bronchial tract is uncommon. Muller and Salzer (1988)
reported a young patient who developed severe stenosis of the left mainstem
bronchus. If the genitalia are involved, painful erosions and ulcers may
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present leading to pruritus, discomfort, and/or dysuria (Schoeffler et al., 2004;
Alkali et al., 2007).
4.1.2.4 Skin involvement
Although rare, cutaneous lesions have been found on the scalp, neck, or the
trunk and resemble those of bullous pemphigoid. There is a wide variation in
skin involvement reported in the literature. It ranges between 0-10.6% in
reported cohorts of MMP patients with oral lesions primarily (Shklar and
McCarthy, 1971; Laskaris et al., 1982; Silverman et al., 1986; Mobini et al.,
1998), however, some of these studies excluded patients with skin lesions
initially (Silverman et al., 1986; Mobini et al., 1998).
Skin lesions can either be recurrent tense bullae, similar to those seen in
bullous pemphigoid, which rupture and heal without significant scarring, or
flaccid blisters surrounded by erythema and usually associated with scaring
(Brunsting-Perry cicatricial pemphigoid) which is usually restricted to the
head and neck area. Blisters generally rupture within 2 days leading to
denuded eroded areas covered by fibrin. Healing is often associated with
either hyperpigmentation or hypopigmentation areas and sometimes with
scar formation (Brunsting and Perry, 1957; Scott and Ahmed, 1998; Miziara
et al., 2002; Yu et al., 2007).
4.1.3 Associated disorders
MMP had been reported to be associated with other autoimmune diseases,
including systemic lupus erythematosus (Redman and Thorne, 1981) and
rheumatoid arthritis (Spigel and Winkelmann, 1978). In one cohort 32% of
patients with MMP found to have other autoimmune disorders (Nayar et al.,
1991).
Patients with anti-epiligrin MMP have been reported to be at risk of
malignancy (Fujimoto et al., 1988; Uchiyama et al., 2000). Sadler et al (2007)
summarized all the reported 15 cases of anti-epiligrin MMP who developed
malignancy. In a cohort of 35 with anti-epiligrin cicatricial pemphigoid, ten
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(29%) patients developed solid tumours. Tumours involved the lung (3
patients), stomach (3), colon (2), or uterus (2) (Egan et al., 2003).
On the other hand, ocular MMP patients with antibodies to human β4 integrin
subunit (Letko et al., 2007) and patients with oral MMP with antibodies to α6
(Malik et al., 2007) have been reported to have a reduced relative risk for
developing cancer.
4.1.4 Pathogenesis
The aetiopathogenesis of MMP is largely unknown. In immune-mediated
subepithelial blistering diseases (IMSEBDs), antigen-provoked-
autoantibodies attack different antigens in the hemidesmosomal structure in
the basement membrane zone (BMZ) leading to the deposition of
immunoglobulins, complement activation, and chemotactic factor production
that eventually result in the loss of attachment between dermis and epidermis
and subepithelial blister formation. Antibodies targeting different basement
membrane components may give rise to clinically indistinguishable disease.
IgG autoantibodies, particularly IgG4, are the main antibodies in MMP;
however, IgA also has been found in some patients (Eversole, 1994).
The antigenic targets of MMP are highly variable and extend to an epitope
level (Hingorani and Lightman, 2006). MMP is associated most frequently
with IgG to BP180 (bullous pemphigoid 180 antigen) and less often with
antibodies against BP230, laminin 5, laminin 6, uncein, type VII collagen, and
integrin subunits β4 or α6 (Chan et al., 2002; Parisi et al., 2003; Yancey,
2005).
In a study of 124 patients designed to identify serum autoantibody profiles
characteristics, Oyama and co-workers (2006) found 75% of patients had IgG
and/or IgA (51%) antibodies against BP180 or its soluble ectodomains. Other
antigens targeted by IgG autoantibodies include BP230 (27%), β4 integrin
(21%), and laminin 5 (2%). The presence of both IgG and IgA anti-BP180
were associated with more severe disease process (Oyama et al., 2006).
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Oral involvement is usually associated with autoantibodies against α6
integrin (Bhol et al., 2001; Rashid et al., 2006), while ocular involvement is
more often associated with autoantibodies against laminin 5 or β4 integrin
(Yancey, 2005; Rashid et al., 2006). In the study by Oyama and co-workers
(2006), most of the patients (85%) with anti β4 integrin had ocular
involvement.
Levels of serum IgG and IgA antibodies may correlate with clinical severity
(Setterfield et al., 1999). A direct correlation has been described between
levels of antibodies to β4-integrin with both disease activity and response to
therapy in patients with MMP attacking multiple mucocutaneous surfaces
(Yeh et al., 2004). However this requires specific antigenic targets to be used
that are not typically used in the clinical practice.
4.1.5 Aetiology
The precise aetiology of MMP is unknown. A number of factors such as
environmental agents and genetic susceptibility have been suggested for the
induction of antibodies that ultimately give rise to MMP. Moreover, some
drugs can evoke lesions that mimic MMP.
4.1.5.1 Genetics
A statistically significant increase in the frequency of DR4 and DQw3 HLA
antigens has observed in a group of MMP patients (Nayar et al., 1991).
Human leukocyte antigen DQB1*0301 found to be significantly associated
with oral pemphigoid in Caucasian patients from United States (Yunis et al.,
1994) and Italy (Carrozzo et al., 2001). However, this was also associated
with other subgroups of MMP, such as patients with ocular involvement
(Chan et al., 1997; Setterfield et al., 2001).
4.1.5.2 Cellular autoimmunity
T-cell lymphocytes, especially those involved in Th2 immunity may have a
role in pemphigoid. The pathogenesis may be mediated by an autoantibody-
induced complement and subsequent cytokine and leukocyte recruitment and
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adhesion and enzyme release resulting in blister formation (Rico et al., 1999;
Verdolini and Cerio, 2003).
Vascular and intercellular cell adhesion molecules (VCAM and ICAM-1) on
endothelial cells of dermal vessels and perivascular fibroblasts are higher in
lesional biopsies of MMP patients than in BP patients or healthy controls
(Giomi et al., 2005). The high levels of endothelial ICAM-1/VCAM and VLA-4
enhance secretion of interleukin (IL-4) by Th2- lymphocytes which could
results in fibroblast activation and induces CAM and subsequent chronic
cycles of inflammation have been suggested to cause the resulting scar
formation (Giomi et al., 2005).
4.1.5.3 Drugs
The drugs likely to induce pemphigoid-like lesions have been reported in a
detailed review by Vassileva (1998). These drugs including furosemide (Koch
et al., 1996; Lee and Downham, 2006), 5-aminosalicylic acid (Ferris et al.,
2005), ampicillin (Hodak et al., 1990), penicillin (Wozniak et al., 2006) and
terbinafine (Aksakal et al., 2003).
4.1.6 Diagnosis
Immune-mediated subepithelial blistering diseases cannot be differentiated
on clinical grounds alone, as they share the same features. Histopathological
studies are often not of value if the epithelial layer lost.. Even when present,
the sub-epithelial clefting could be a feature of several different bullous
disorders. Direct immunofluorescence (DIF) is commonly used to diagnose
this group of disorders, and in differentiating many of these conditions;
however conventional DIF cannot distinguish between subsets of MMP
(Solomon et al., 2007).
4.1.6.1 Histopathology
Unlike the histopathological features of PV, which is characterized by
intraepithelial bulla formation and presence of acantholysis, MMP and other
IMSEDs are histologically characterized by a definite cleavage between
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dermis and epidermis at the basement membrane level. Acantholysis is not a
feature of MMP. The bulla fluid is usually clear with scattered
polymorphonuclear leukocytes, lymphocytes, histiocytes, and, rarely,
eosinophils (Shklar and McCarthy, 1959; Sciubba, 1996; Casiglia et al.,
2001).
4.1.6.2 Immunofluorescence
Direct immunofluorescence (DIF) of MMP perilesional tissue demonstrates a
linear tissue-fixed deposition of IgG/IgA and/or C3 at the BMZ (Chan et al.,
2002). DIF, most often performed on perilesional skin or mucous membrane
tissues, is usually used to confirm the diagnosis of MMP (Chan et al., 2002;
Thorne et al., 2004). In a cohort of 33 patients with oral MMP lesions, DIF
was positive for IgG (97%), IgA (27%), IgM (12%), and C3 (73%) (Laskaris
and Angelopoulos, 1981). IgG was present in 57% of another group of 23
MMP patients, and C3 in 66% (Vincent et al., 1993). DIF results were positive
in 60%-80% in a retrospective study of 280 patients with ocular disease
(Thorne et al., 2004).
However, other disorders such as bullous pemphigoid and epidermolysis
bullosa acquisita, share with MMP the deposition of immunoglobulins at the
BMZ but can be differentiated from MMP by clinical features (Chan et al.,
2002).
4.1.6.3 Indirect immunofluorescence
Indirect immunofluorescence (IIF) does not usually detect circulating IgG
antibodies in the serum of MMP patients with lesions limited to oral mucosa
(Gallagher and Shklar, 1987; Mutasim, 1997; Bagan et al., 2005). The titre of
circulating antibodies in MMP is most commonly absent or significantly lower
than in bullous pemphigoid; this may be due to the low sensitivity of the IIF
techniques usually used to detect the circulating antibodies or may be that
MMP is a limited process (Laskaris and Angelopoulos, 1981). However,
negative IIF results do not exclude MMP (Ahmed et al., 2004).
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IIF was positive for IgG in 12 of 33 patients (36%) with oral MMP lesions but
negative for IgA, IgM, C3, and/or fibrin (Laskaris and Angelopoulos, 1981). In
another study, 24% of subjects had circulating autoantibodies, these being
most likely in patients with ocular involvement (30.6%) (Thorne et al., 2004).
When highly specific antigens are employed in IIF the titers of detectable
antibodies to both α6 and β4 and integrin have been found to correlate with
disease activity (Letko et al., 2000; Sami et al., 2002b).
4.1.6.4 Other diagnostic methods
A number of additional tools are available to confirm the diagnosis of MMP,
but these have not found their way into routine clinical practice.
Immunoperoxidase-based assays have been reported to be more sensitive
than immunofluorescence in diagnosing of MMP (Power et al., 1995; Ahmed
et al., 2004). However, Thorne and co-workers (2004) found the sensitivity of
an immunoperoxidase was similar to that of DIF.
Radioimmunoassay (Ahmed et al., 1989) and immunoblot assay (Bhol et al.,
1996) may be sensitive methods to detect circulating antibodies of MMP and
are used to define target antigens, but they are not considered to be of
practical value in everyday clinical practice. Similarly direct immunoelectron
microscopy (Bernard et al., 1990) and computer-aided fluorescence overlay
antigen mapping and laser scanning confocal microscopy (Solomon et al.,
2007) are research tools rather than clinical technique.
4.1.7 Treatment
The goals for the treatment of MMP are to control new blister formation,
accelerate healing of ulcers and erosions, and induce long periods of
remission. There are few randomized controlled trials (Lozada-Nur et al.,
1994) and only one Cochrane-systematic review (Kirtschig et al., 2003) on
the treatment of MMP and most relevant information comes from case series
and non-randomized trials, reflecting the rarity of the disease (Table 4.2).
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Patients may be divided into high-risk and low-risk. The high-risk group
includes patients with ocular, pharyngeal, laryngeal, esophageal, and/or
genital lesions in whom systemic agents may be necessary to control their
disease. Low-risk patients are considered to be those with oral and with or
without cutaneous lesions in whom topical corticosteroids may be sufficient to
lessen or control the disease (Vincent et al., 1993; Carrozzo et al., 1997;
Chan et al., 2002; Agbo-Godeau et al., 2004).
Therapy has historically included systemic corticosteroids, corticosteroid-
sparing immunosuppressive drugs and high potency topical corticosteroids.
Treatment of widespread mucosal and cutaneous lesions of MMP
necessitates a multidisciplinary management and systemic corticosteroids
alone or in combination with other agents are still the first choice to control
acute exacerbations (Sacher and Hunzelmann, 2005).
A wide range of agents/regimens have been proposed in the treatment of
MMP affecting the oral mucosa. These include:
Topical corticosteroids
Oral lesions of MMP are usually managed by topical corticosteroids
(Silverman et al., 1986), however some patients with only oral lesions may
necessitate treatment with systemic agents (Megahed et al., 2001; Carrozzo
et al., 2008). High potency topical corticosteroids (e.g., clobetasol)
subsequent to a course of systemic corticosteroids are suggested to usually
control MMP lesions (Carrozzo et al., 1997). Candidosis is the most common
complication of potent topical corticosteroids hence some authors
recommends the use of antifungal agents with potent topical corticosteroids
(Silverman et al., 1986; Gonzalez-Moles et al., 2002). Desquamative
gingivitis may respond well to 0.05% clobetasol propionate mixed with
100,000 IU/cc of nystatin in an adhesive paste applied in a tray (Gonzalez-
Moles et al., 2002; Gonzalez-Moles et al., 2003).
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Systemic corticosteroids
Systemic corticosteroids alone or in combination with adjunct
immunosuppressive drugs are considered the mainstay of treatment of
severe MMP and have proven effective for many patients (Ciarrocca and
Greenberg, 1999; Arash and Shirin, 2008). However, in some patients other
therapeutic modalities are needed to control the disease activity and
decrease the adverse side effects (ASEs) which can develop with long-term
corticosteroid use (Megahed et al., 2001; Carrozzo et al., 2008).
Combinations of corticosteroids, dapsone and cyclophosphamide have been
reported to give good results (Espana et al., 2005).
Ciclosporin
Ciclosporin has been used to treat a limited number of MMP patients (Azana
et al., 1993; Williams et al., 1995; Boedeker et al., 2003). The use of topical
cyclosporine with other agents (topical and systemic corticosteroids, systemic
azathioprine, and tacrolimus) failed to control the oral erosions of one patient
with MMP (Salzano et al., 2006). The disease did, however, respond to
mycophenolate mofetil and systemic minocycline.
Tetracycline
Tetracycline may be an effective agent in the management of desquamative
gingivitis (Ronbeck et al., 1990). A combination of minocycline and
nicotinamide was reported effective in the management of MMP (Poskitt and
Wojnarowska, 1995a; Reiche et al., 1998). Improvement in MMP was seen in
a patient who received topical corticosteroids, oral nicotinamide, and
tetracycline (Mallon and Wojnarowska, 1994).
A patient who had a tracheotomy due to laryngeal MMP had dramatic clinical
improvement following a course of tetracycline hydrochloride and
niacinamide (Sakamoto et al., 2002). Similarly a patient whose lesions were
resistant to topical corticosteroids had rapid improvement after treatment with
tetracycline and nicotinamide (Kreyden et al., 2001). Resolution of oral
lesions and no relapse were reported in a patient who received a
mycophenolate mofetil (up to 2 g per day) and systemic minocycline (up to
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200 mg per day), although she did not respond to several earlier treatment
modalities, including topical and systemic corticosteroids, topical ciclosporin,
and several antibiotics (Salzano et al., 2006).
Tacrolimus
Topical tacrolimus has been used to treat oral (Assmann et al, 2004; Suresh
et al., 2006), ocular (Letko et al., 2001; Hall et al., 2003; Michel and Gain,
2006), and genital MMP (Gunther et al., 2004; Lebeau et al., 2004). Its
application in genital lesions usually resulted in complete remission within 3
months (Gunther et al, 2004; Lebeau et al., 2004). It was used successfully in
oral lesions of a patient with long-term mucocutaneous MMP who was
resistant to conventional treatment (Suresh et al., 2006). However, in a
cohort study of patients with uncontrolled ocular disease treated with
conventional immunosuppressive agents, 67% of patients failed to respond
to tacrolimus, while two patients responded just partially. The authors
conclude that tacrolimus is unable to induce remission of ocular MMP lesions
(Letko et al., 2001).
Except for the transient burning sensation at the application site, which is
common with topical application of tacrolimus, it usually well tolerated with no
major side effects (Assmann et al, 2004; Gunther et al, 2004).
Dapsone
A combination of dapsone and topical corticosteroids resulted in 75%
resolution of oral lesions in a cohort of MMP patients (Ciarrocca and
Greenberg, 1999). Dapsone may similarly improve MMP skin lesions (Syn
and Ahmed, 2004).
Dapsone however requires close monitoring even when low doses are used.
In a recent study of 10 patients, Wertheim et al. (2006) reported that 50%
had reticulocytosis including four with clinically significant haemolytic anemia
with a raised mean cell volume and a steady fall in haemoglobin from
baseline levels.
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Methotrexate
Methotrexate has been reported to be effective in the management of MMP
(Miserocchi et al., 2002; McCluskey et al., 2004). In a retrospective,
interventional case series, it was concluded that low-dose oral methotrexate
is highly effective and well tolerated. The authors considered it to be a first-
line systemic agent for the management of ocular lesions (McCluskey et al,
2004).
Anti-TNF-α agents
Infliximab resulted in rapid clinical improvement in a patient with multiple
mucosal involvements of MMP (Heffernan and Bentley, 2006). The tumour
necrosis factor alpha antagonist etanercept has also been reported as an
effective agent in the management of MMP (Sacher et al., 2002; Canizares et
al., 2006). Twice weekly injection of etanercept (25 mg) resulted in
improvement of oral lesions of three patients and in stabilizing the ocular
disease of the one patient with MMP (Canizares et al., 2006). In a recent
case report, etanercept (50 mg weekly) was used successfully to manage
eye lesions in one MMP patient and leading to a decrease in prednisolone
therapy (John et al., 2007). Thalidomide was used in a patient with resistant
MMP lesions (Duong et al, 2002). However, thalidomide is a difficult drug to
use and has the potential for many adverse drug affects such as
teratogenicty and neuropathy. One MMP patient developed venous
thrombosis following treatment with thalidomide (Howell and Johnson, 2004).
Rituximab
Rituximab (862.5 mg intravenously) induced remission in a patient with
multiple mucocutaneous involvement recalcitrant to different
immunosuppressant agents including pulsed intravenous
methylprednisolone, oral prednisolone, cyclophosphamide and dapsone
(Ross et al., 2009).
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Mycophenolate mofetil
In a recent case report, mycophenolate mofetil (MMF) resulted in significant
improvement in the clinical signs of 2 patients with oral MMP (Carrozzo et al.,
2008). Prednisolone had been combined to MMF to accelerate healing and
achieve remission (Alkali et al., 2007). Thorne et al. (2005) suggested that
MMF may be an effective adjuvant agent to corticosteroids in the
management of inflammatory eye conditions including MMP. As noted
previously MMF (up to 2 g per day) and systemic minocycline (up to 200 mg
per day) were used successfully in the management of a patient with severe
oral MMP who had responded only partially to different topical and systemic
agents and developed many adverse side effects (Salzano et al., 2006).
Three patients responded well to treatment with MMF and prednisolone. The
patients had no disease recurrence for 6 to 14 months after treatment was
discontinued and none had any adverse side effects (Megahed et al., 2001).
Adding MMF (1.5 or 2 g per day) to dapsone, achieved good control of
mucosal lesions in 10 of the 14 MMP patients not controlled by dapsone
and/or sulfasalazine and allowed a decreasing of dapsone dosage (Ingen-
Housz-Oro et al., 2005).
Intravenous immunoglobulin
Intravenous immunoglobulin (IVIg) has been reported to be a safe and
effective intervention for the management of MMP recalcitrant to
conventional immunosuppressive agents (Foster and Ahmed, 1999).
In 20 patients with oral MMP, patients who received IVIg had statistically
significant shorter treatment duration, fewer relapses, fewer adverse side
effects, and a better quality of life in comparison with patients received
systemic prednisone with other immunosuppressive agents (e.g.
methotrexate, azathioprine, cyclosporine cyclophosphamide) (Ahmed and
Colon, 2001). IVIg was effective for the treatment of one woman with severe
widespread laryngeal lesions who had been reluctant to use any other
immunosuppressive as she was wishing to become pregnant (Gürcan and
Ahmed, 2009). Remission was achieved in all of 10 patients with progressive
ocular MMP and whose disease had been recalcitrant to a variety of other
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therapies (Foster and Ahmed, 1999). The mean treatment duration was 19.3
months (range 16 to 23 months) and there were no reported ASEs. There
have now been several additional studies suggesting that IVIg can lessen
disease and recurrence of MMP (Sami et al., 2002a; Sami et al., 2002b;
Letko et al., 2004; Sami et al., 2004). IVIg (1 g/kg body weight on 2
consecutive days) given every 4 weeks led to dramatic improvement in the
oral and ocular lesions of MMP in a patient who failed to respond to different
immunosuppressive therapies (Leverkus et al., 2002). Furthermore, IVIg
allowed reduction in systemic corticosteroids and other immunosuppressant
agents in 6 patients with severe oral MMP (Mignogna et al., 2008). IVIg was
administered without any significant ASEs in a cohort with autoimmune
mucoucutaneous blistering diseases, which included 15 MMP patients, who
had developed ASEs to conventional immunosuppressive therapy (Daoud
and Amin, 2006). However, a retrospective analysis of 19 patients with
various autoimmune mucoucutaneous blistering diseases reported that only
four (21%) achieved complete remission, five (26%) did not respond at all
and 10 (53%) had only a partial response (Segura et al., 2007). Daoud and
Amin (2006) has suggested that as IVIg seems to give rise to few ASEs that
require physician visits, laboratory studies and/or hospitalization such therapy
may be statistically significantly less expensive than the conventional
immunosuppressive therapy.
The clinical response to IVIg may become weaker with time, Yu and co-
workers reported a patient who had a significant improvement in
mucoucutaneous lesions after receiving IVIg (1g/kg), however, the clinical
response to subsequent cycles of IVIg lessened (Yu et al., 2007).
Plasmapheresis
Plasmapheresis decreases levels of circulating autoantibodies. Bohn et al.
(1999) reported two patients with severe oral MMP, neither of whom
responded to corticosteroids and other immunosuppressive agents. Their
disease improved with plasmapheresis followed by cyclophosphamide
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therapy. Although both patients developed urticaria and mild hypotension
during treatment, no active disease was observed or additional treatment
required over the next 6 years.
Other treatments
Tracheotomy may be required in patients with laryngeal stenosis. Carbon
dioxide laser has been found to be effective in the management of
supraglottic scarring. Mitomycin was reported to reduce the severity of
stenosis with carbon dioxide laser in the management of supraglottic scarring
(Whiteside et al., 2003) and also when used in the surgical treatment of
cicatricial shrinkage of conjunctival fornices (Secchi and Tognon, 1996).
Repeated dilatation using endoscope may be indicated to manage
oesophageal strictures (Whiteside et al., 2003).
4.1.8 Clinical outcome
The long-term outcome of MMP is unknown, as there would seem to be no
appropriate studies. Certainly it is evident that the long-term outcome of MMP
is highly variable. Some patients have only mild disease limited to oral
mucosa that never impacts greatly upon morbidity. However other individuals
can have significant morbidity due to conjuctival scarring (which may result in
loss of vision) or laryngeal scaring that can compromise the airway (Cotell et
al., 2000). The risk of death associated with MMP is unknown, although there
may be a risk of early death with BP (Langan, et al., 2008), in one report, 48
per cent of patients died within 2 years of diagnosis of BP (Gudi et al., 2005).
There remain few (if any) recent detailed reports on efficacy and safety of
long-term therapy of substantial number of MMP patients. The overall aim of
this chapter was to describe the long-term outcomes of therapy in a large
cohort of MMP patients attending single clinical centre.
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4.2 AIMS
The aims of this chapter were to determine:
1. The clinical characteristics of a substantial cohort of patients with
mucous membrane pemphigoid resident in England, UK.
2. The clinical outcomes of long-term therapy of mucous membrane
pemphigoid.
3. The frequency and nature of adverse side effects of therapy of mucous
membrane pemphigoid.
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4.3 PATIENTS AND METHODS
4.2.1 Patients group
The study group comprised 62 patients managed by the Oral Medicine Unit
of UCL Eastman Dental Institute and UCLH Eastman Dental Hospital, with
the diagnosis of mucous membrane pemphigoid (MMP). The patients had
been under the care of the clinicians of the unit between 1981 and 2007.
4.2.2 Methods
The case record of each patient was examined using multiple data extraction
forms for details of demographics, past medical history, extra-oral and intra-
oral clinical features and clinical progress data. Details of diagnostic and
monitoring investigations were also systematically extracted. These included:
histopathology, full blood cell count, differential white cell count, hepatic and
renal biochemistry and details of the different topical and systemic therapies
employed in the management of each patient (Appendices 1-5).
Inclusion criteria
Inclusion criteria: (1) evidence of erosion/blistering/scarring of the oral
mucosa with/without extra-oral involvement, (2) histopathological evidence of
sub-epithelial blistering, (3) evidence of direct immunofluorescence on
mucosal/skin biopsies of linear deposits of any one or combinations of the
following in the basement membrane zone (BMZ); IgG, IgA and/or C3, (4)
evidence of indirect immunofluorescent of circulating autoantibodies to BMZ
(Chan et al., 2002). In all patients at least criterion 1 and either 3 or 4 were
present to assign a diagnosis of MMP.
Outcome of therapy
The outcome of therapy was evaluated for symptoms and signs separately.
Symptoms evaluation was reported as presence, improved or absence of
intra-oral pain/soreness and based on comparison between patients’ self-
reported pain/soreness status before therapy and at last review in 2007.
Chapter 4 Mucous membrane pemphigoid
180
The outcome of therapy (clinical signs) was analysed by 2 different methods.
The first one according to site of the lesion, either gingival or mucosal, using
a 2-point scoring system: (0) absence of mucosal and/or gingival lesions and
(1) presence of mucosal or gingival lesions. Also, the treatment outcome was
analysed by the comparison between disease status (signs and sites) before
therapy and last review in 2007. Evaluation of response to therapy was
based on clinicians’ judgments during clinical examination and/or upon
clinical photographs when present in the clinical notes.
Statistical analysis
The differences between females and males in relation to duration of oral
symptoms before attending to Oral Medicine clinics and duration of the
treatment were analyzed using Student’s t-test. McNemar’s test was used to
compare symptoms and signs before and after treatment in Oral Medicine
Clinics. Descriptive and analytical statistics were undertaken using the SPSS
program (SPSS for Windows: (Statistical Package for the Social Sciences)
software, version 12.0.
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4.4 RESULTS
4.4.1 Patient demographics
Age and gender
The mean age of the patients at the time of diagnosis or referral of MMP to
the oral medicine unit was 63.9 years (SD 14.7, median 64.1), this being 70.2
for males (SD 12.4), and 60.6 for females (SD 14.7). There was an age
range of 11.3 to 94.1 years. The onset of the clinical features of disease was
thus usually in the sixth, seventh or eighth decade of life. There were a
higher number of females (41; 66.1 %) than males (21; 33.9%), with a female
to male ratio of 2:1 (Figure 4.1).
Ethnic group
The majority of patients were white British (52; 83.9%) (self-reported,
according to 2001 UK Census) (Office for National Statistics, 2003). In
present cohort there were 6 (9.7%) white other than British, 3 (4.8%) Asian,
and 1 (1.6%) mixed-White and Black African.
Marital status
Marital status was stated under four categories; married which included
married patients and patients in a civil partnership; single, divorced and
widowed patients. 29 (46.8%) were married or living with a partner, 13
(21.0%) were widowed, 8 (12.9%) single, 6 (9.7%) were divorced and the
marital status was not reported in the case notes of 6 patients.
Tobacco use and alcohol consumption
Sixteen (25.8%) of the patients were previous tobacco users and 8 (12.9%)
were current users of tobacco. The mean number of self- reported cigarettes
per day by the present tobacco users was 12.6. Forty two (67.7%) of the
group currently drank alcohol. The mean total weekly consumption by the
present alcohol users was 10.2 units.
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Sources of referral to oral medicine
Fifteen (24.2%) of the patients had been referred to the oral medicine unit by
general dental practitioners. 13 (21.0%) were referred by specialists in Oral
and Maxillofacial Surgery (OMFS). Twelve (19.4%) patients were referred by
a periodontist and the remaining patients were referred by their general
medical practitioner, medical or a dental specialist (Table 4.3). The patients
had been referred to oral medicine clinics for the diagnosis and/or
management of variety of oral lesions such as desquamative gingivitis or
mucosal blisters and/or ulcers.
4.4.2 Past medical and drug histories
4.3.2.1 Past medical history
The patients had a history of a wide variety of common medical problems
(Table 4.4), the most common of which were: allergies, cardiovascular,
respiratory, endocrine and gastrointestinal diseases. A wide variety of allergic
diseases were reported by the patients: 7 (11.3%) patients were allergic to
penicillin, 2 to aspirin, one to plaster (sticky-plaster, e.g. band-aid) and 13
were allergic to a variety of other allergens. Six (9.7%) patients had a history
of asthma. Twenty (32.3%) patients were hypertensive while 4 had diabetes
mellitus. 12 (19.4%) patients had thyroid disease.
4.3.2.2 Past drug history
The patients were receiving a wide range of medication at the time of their
clinical consultation in the Oral Medicine Unit. Some of these agents were
being used to control oral and/or mucocutaneous lesions likely to be due to
MMP (Table 4.5). And as expected from the medical history, the most
common drugs were anti-hypertensives, anti-asthmatic agents and topical
corticosteroids (Table 4.6).
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4.4.3 Presenting clinical signs and symptoms and duration of
symptoms
4.4.3.1 Duration of oral symptoms at first visit
The duration of oral symptoms before attending the oral medicine clinics
varied from 2 months to 15 years, with a mean of 23.6 months (median 12
months). The mean duration of pre-consultation symptoms for males (21.7
months) was broadly similar to that of females (24.6 months) (P= 0.77).
4.4.3.2 Presenting clinical signs and symptoms
Intra-oral
At their clinical consultation in the Oral Medicine Unit, most (46; 74.2%) of the
62 patients had symptomatic oral lesions, although 10 patients were
asymptomatic at this time. Data concerning symptoms were not available for
6 patients. A total of 119 lesions in 95 oral mucosal sites were recorded in
this cohort of patients, with a mean of 2 oral lesions per patient.
Two patients presented initially with oral mucosal scaring. Desquamative
gingivitis was the most common intra-oral sign of MMP and reported in 48
(77.4%). Thirty seven (59.7%) patients present initially with desquamative
gingivitis only. Five (8.1%) patients presented with mucosal lesions
(ulceration/erosion/blister) only, while 18 (29.0%) patients had both mucosal
lesions and desquamative gingivitis at their first clinical consultation in Oral
Medicine clinics.
Oral ulceration was the second most common sign after desquamative
gingivitis: 22 patients (35.9 %) presented with mucosal ulceration, 10 had
ulcers on the alveolar ridge, 7 with buccal ulcerations and 7 on the soft
palate. The remaining ulcers were on the hard palate, floor of the mouth or
tongue. Fifteen patients presented with mucosal erosions and 13 with
mucosal blisters in different oral mucosal sites.
With regards to the site of involvement, gingivae were mostly affected.
Gingival erosion/blisters were observed in 55 patients (88.7%) and were the
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only affected site in 37 patients (59.7%). The second most commonly
affected site was the soft palate (12; 19.4%) followed by the buccal mucosa
(11; 17.7%), tongue and hard palate (5; 8.1%) labial mucosa and floor of the
mouth (3; 4.8%). Scarring of the oral mucosa was present in two patients.
More details about clinical presentation features are presented in table 4.7.
Extra-oral
Twenty patients (32.3%) had a history of likely MMP at extra-oral sites (Table
4.8). Most of these patients (13) had just one extra-oral site involvement,
three had 2, two had 3 and one had 4 and another had 5 extra-oral sites
involved in the MMP course. The eyes were the most common extra-oral
mucosal surface affected in the MMP course. 15 patients had had eye
lesions ranging from corneal abrasion to conjunctival scaring and loss of
vision. The skin was affected in 6 patients and two patients had cutaneous
scalp lesions. The pharynx was affected in 3 patients, larynx in 2; nasal
mucosa in 4, and vagina in 1.
4.4.4 Histopathological and immunofluorescence studies
Histopathological examination of peri-lesional tissue was undertaken on 50
(80.6%) of the 62 patients. The histopathological reports of the remaining 12
patients were not present in their clinical notes.
In accordance with the clinical presentation, biopsies had been obtained from
the gingivae (24; 48%), buccal mucosa (21; 42%), tongue (1; 2%) hard palate
(1; 2%) and pharynx (1; 2%). The sites of 2 biopsies were unknown. 28
mucosal biopsies had a demonstrable split between the dermis and
epidermis, although 7 had no epithelium. Inflammatory cells were found in 34
sections and the most common infiltrating cells were lymphocytes (11
specimens), plasma cells (7), eosinophils (4) and neutrophils (3).
Direct immunofluorescence was undertaken on 40 biopsy specimens, of
which 36 had linear deposits of IgG (34) C3 (26) although 4 specimens had
an absence of such immune deposits. 21 of 47 investigated patients had
Chapter 4 Mucous membrane pemphigoid
185
circulating antibodies to basement membrane components, usually in the
range of 1:10-100.
4.4.5 Therapies provided
A wide variety of different topical and systemic agents had been provided in
an attempt to control the clinical signs of MMP in this group of 62 patients.
Patients with oral lesions alone were almost always managed initially with
topical corticosteroids and/or tacrolimus. However, if the signs failed to
reduce and/or the patient had sustained painful symptoms with topical agents
alone, and/or there was extra-oral mucoucutaneous involvement, systemic
agents were prescribed. In this cohort, 3 patients did not require treatment.
58 patients received topical therapies, while systemic agents had been
provided for 33 of the 58 patients (56.9%). The mean total number of agents
(topical and systemic) prescribed to the patients was 4.6 (3.2 and 1.5 for
topical and systemic agents respectively) (Tables 4.9, 4.10 and 4.11).
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4.4.6 Clinical outcome
The mean duration of treatment in this cohort of MMP patients was 4.6 years
(median 2.7). Most of patients in this group responded well to treatment.
4.3.6.1 Symptoms
Absent 9No Symptoms 10
Present 1
Absent/Improved 40
Present 4Pain/Discomfort 46
No data 2
Absent 6No data 6 Present 0
Figure 4.2 Status of patients with regards to intra-oral symptoms at initial
visit (left side) and at last visit (right side).
Of the 62 patients, data concerning symptoms (i.e. soreness, pain) were
available for 56 patients at initial presentation. Of this group, 10 were
asymptomatic at initial presentation to oral medicine clinics and 9 of this
group were still pain-free when last examined in oral medicine clinics (median
duration of follow up was 3 years), while one patient had a worsening of
symptoms at the end of the observation period.
Most of patients (46; 74.2%) had symptoms (pain, discomfort, soreness or
burning) at the initial consultation in oral medicine unit and 40 of these had
had some self-reported lessening or cessation of these symptoms at the end
of the treatment.
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4.4.6.2 Clinical signs
i Analysis of clinical outcome according to site
At the end of the observation period (2007), 27 of the 37 (73%) patients with
solely gingival involvement at the initial consultation still had gingival lesions
(erosion/blisters). The remaining 10 patients (27.0%) had no evident clinical
lesions at the gingivae at last review but 1 had developed oral mucosal
involvement.
Of the five patients presenting with solely oral mucosal lesions at first visit, 3
(60%) had had a persistence of mucosal ulcerations/erosions or blisters,
while 2 (40%) were free of lesions at last review.
Of the 18 patients who presented initially with combined mucosal and
gingival involvement, complete absence of clinical lesions was observed in 4
(22.2%) of the end of the observation period. Ten patients (55.6%) showed
persistence of gingival lesions but disappearance of mucosal
ulceration/blisters. Mucosal lesions were not controlled by therapy in 2
(11.1%) patients who however showed disappearance of gingival
erosion/blisters. Gingival and mucosal lesions persisted in 2 other patients
(11.1%) at last review. (See Table 4.12).
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ii Analysis of clinical outcome according to signs and sites
Desquamative gingivitis:
Absent 13Absent 14
Present 1
Absent 14Present 48
Present 34
Figure 4.3 Status of patients with regards to desquamative gingivitis at initial
visit (left side) and at last visit (right side).
Of the 62 patients, 14 were free of desquamative gingivitis at initial
presentation, and 13 of these remained free at the end of the study period.
Most of patients (48; 77.4%) had desquamative gingivitis at the initial
consultation in the oral medicine unit and of these 34 still have desquamative
gingivitis at the end of the treatment.
The total number of patients with desquamative gingivitis reduced
significantly from 48 to 34 (P= 0.001, McNemar’s test).
Gingival blisters
53 of the 62 patients were free of gingival blisters at initial presentation.
However, 4 developed new blisters at the end of the study.
Nine patients had gingival blisters at the time of their initial consultation in
Oral Medicine clinics. All were free of such blistering at the end of the study
period.
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Buccal mucosal ulceration
Absent 53Absent 55
Present 2
Absent 5Present 7
Present 2
Figure 4.4 Status of patients with regards to buccal mucosa ulceration at
initial visit (left side) and at last visit (right side).
Of the 62 patients, 55 were free of buccal mucosa ulceration at their initial
presentation to Oral Medicine clinics; however, 2 developed ulcers at the end
of the study.
Seven patients had ulceration of the buccal mucosa at their initial
presentation to Oral Medicine clinics and of these only 2 still had ulcers of
this site at the end of the treatment. This change was not statistically
significant (P= 0.453).
Buccal mucosal blisters
Absent 57Absent 58
Present 1
Absent 4Present 4
Present 0
Figure 4.5 Status of patients with regards to buccal mucosa blister at initial
visit (left side) and at last visit (right side).
Blisters of the buccal mucosa were observed in 4 patients at their initial
consultation in Oral Medicine clinics. All 4 had had resolution of these lesions
by the end of the study period. However, one patient who had initially
presented without blisters of the buccal mucosa had developed blisters at
this site at their last clinical observation.
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Hard palate
Two of 61 patients who had not had ulceration of the hard palate at their
initial consultation in oral medicine had developed ulceration and 2 had
developed blisters at the end of the study period.
All 3 patients who had had ulceration of the hard palate at the time of their
initial consultation had had resolution of this at the end of the study period.
One patient with previous erosions at the hard palate had had resolution by
the end of the study period.
Floor of the mouth
Three patients had ulceration of floor of the mouth at time of their initial
diagnosis. All had resolution of this by the end of the observation period.
4.4.7 Adverse drug reactions
As reported in section 4.4.5, a wide variety of different agents were employed
in the management of present cohort of MMP patients.
Thirty one (50%) patients had adverse side effects (ASEs) that included
malaise, gastrointestinal upset, nausea, vomiting, diarrhoea, skin rash, oral
candidosis, unpleasant taste (dysgusia), and haematological changes
lymphopenia and anaemia.
In the majority of instances, patients had only 1 ASEs (20/31; 64.5%). Seven
patients had 2 ASEs (7/31; 22.6%), 3 (9.7%) had 3 ASEs and 1 had 4 ASEs.
Nineteen (61.3%) and 10 (32.3%) patients had ASEs likely to be due to
systemic or topical agents respectively. Two patients (6.5%) developed ASEs
due to both topical and systemic therapy.
Most adverse effects in this cohort of MMP patients were associated with
azathioprine. Seven of the 15 patients (46.7%) who received this agent
developed adverse effects including nausea and vomiting (4 patients), skin
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rash (1), sore throat (1), and headache (1). ASEs due to azathioprine were
observed in patients with both normal and abnormal levels of TPMT.
Eleven (34.4%) of the 23 patients who received dapsone developed an ADR
including malaise (2 patient), photosensitive skin eruption (1), headache (1),
and heamatological changes (8).
One patient who was prescribed systemic corticosteroids developed a “moon
face” while ten patients on topical corticosteroids had ASEs including
candidosis, median rhomboid glossitis and unpleasant taste. Some patients
on topical tacrolimus had a burning sensation and/or peppery taste and
gastrointestinal upset but these were not related to blood tacrolimus levels.
Further details of the adverse drug reactions reported in this cohort of
patients are reported in Table 4.13.
4.4.8 Duration of the treatment
In this cohort of MMP patients, treatment duration differed greatly, ranging
from a few months to more than 19 years (until data collected). The mean
duration of therapy was 4.6 years (SD 4.9, Median 2.7). There was no
significant difference between men and women in the duration of
management of oral lesions of MMP (mean treatment duration of 3.8 for men
and 5.0 for women) (P= 0.352) (Table 4.14).
All but 14 patients remain under the clinical care of the oral medicine unit.
Three patients failed to attend their follow up appointments while another four
had travelling problems into the clinics or they moved into another city. Three
patients were discharged as they were asymptomatic, 4 died and the
remainder are still under follow-up.
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4.5 DISCUSSION
Although mucous membrane pemphigoid (MMP) has the potential to
adversely affect the quality of life of patients, there are few data on the long-
term behaviour or effective therapy for the condition. In addition there are no
recent reports of the clinical manifestations of a substantial group of patients
in the UK.
Results of the study confirmed that MMP is a disease of middle to late age
females (mean age of onset, 64 years) (Mobini et al., 1998; Alkan et al.,
2003; Chiou et al., 2007). MMP rarely affects children. Of note the present
cohort included an 11 years old child. Musa et al. (2002) and Lourenco et al.
(2006) published case reports on nine-year old and four-year old children,
respectively. Mucocutaneous lesions are more common in younger
individuals and the disease may be more severe than in adults (Lourenco et
al., 2006).
The mean duration of symptoms before patients attended the oral medicine
clinics was 23.6 months, suggesting that mild symptoms, misdiagnosis, or
delay in referral occurred in a number of instances. Moreover, as most of this
cohort presented initially with only gingival lesions, it could be assumed that
some general dental practitioners assume that this clinical presentation
represents plaque-related gingivitis and thus explain the delay of referral of
some patients.
Oral involvement in MMP is common (Silverman et al., 1986); however, the
number of patients in studies from oral medicine clinics is generally lower
than those in studies from ophthalmological clinics. This may represent a
referral bias, as MMP patients are usually seen by ophthalmologist or
dermatologist.
The oral clinical features of MMP resemble those of bullous pemphigoid and
other immune-mediated sub-epithelial blistering diseases such as linear IgA
disease and epidermolysis bullosa acquisita (Solomon et al., 2007). In the
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present study, MMP gave rise to recurrent multiple areas of ulceration with a
clear predominance of gingival involvement (as desqumative gingivitis); and
thus are in agreement with the results of other reports (Mobini et al., 1998;
Chiou et al., 2007).
Of note, however, scarring of the oral mucosa was rarely observed. In the
present group, only two had such a feature. It is interesting to note that while
scaring is often cited in textbooks as being a feature of MMP, it has actually
been rarely documented in previous studies (Shklar and McCarthy, 1959;
Chiou et al., 2007). However the previous studies did not provide long-term
data of patients, hence it is possible that with time some of the patients would
have developed this feature. However as the present study included
observation over many years the low frequency of oral mucosal scarring of
MMP does seem to be real.
Approximately one-third of the patients had a history or clinical and
histopathological evidence of MMP at extra-oral sites, the conjunctivae being
the most commonly affected extra-oral site. This is in agreement with
previous study by Higgins and co-workers that reported ocular lesions
occurring in about 37% of patients with oral MMP (Higgins et al., 2006).
However, this is greater than that reported by Chiou et al (2007) who
observed two of 29 patients having extra-oral involvement. Although not
detailed in the present study, it was the authors’ view the severity of oral
disease did not correlate with the likelihood of patient having extra-oral
manifestations. It would thus seem possible that there are actually subgroups
of MMP each with particular anatomical targets.
Thus, the clinical picture of MMP in this cohort of patients who present to an
Oral Medicine unit in the UK was dominated by oral ulceration, desquamative
gingivitis and less frequently by associated ocular involvement. However, this
observation should be interpreted with caution as it might represent a referral
bias as the patients oral disease were much more likely to be referred to Oral
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Medicine. However, data of patients from ophthalmological units show that
oral lesions are common in the MMP patients (Elder et al., 1996).
More than half of the available biopsies (28/50; 56%) in the present cohort
showed the characteristic sub-epithelial cleft of MMP. Epithelium has been
lost in many specimens possibly during the biopsy surgery or at tissue
preparation.
The precise aetiology of MMP is largely unknown but it is characterized by
antibody attack of the hemidesmosomal junction of epithelial surfaces,
creating a disruption of cell adhesion and tissue integrity (Scully and Lo
Muzio, 2008). Direct immunofluorescence demonstrating a linear tissue-fixed
deposition of IgG/IgA and/or C3 at the basement membrane zone was
evident in about 90% of the tested specimens, which is in agreement with
previous results of the oral mucosa (Laskaris and Angelopoulos, 1981) and
conjunctivae (Thorne et al., 2004) studies.
Twenty-one of the 47 patients tested for indirect immunofluorescence had
demonstrable circulating antibodies to basement membrane components,
usually in the range of 1:10 to 1:100. No clear correlation between auto-
antibody titre and the extent of clinical features was observed (data not
shown). The sera of the present patients were assessed using monkey
oesophagus and hence the low frequency of titre of detectable circulating
antibodies is perhaps unexpected. As detailed in the introduction to this
chapter it is possible that the use of more complex diagnostic tools may allow
more frequent detection of circulating antibodies and thus provide more
effective methods of diagnosing and monitoring MMP (Ahmed et al., 1989;
Bhol et al., 1996; Bernard et al., 1990; Solomon et al., 2007).
Regarding therapy, there are few randomized controlled trials (Foster 1986a;
Foster 1986b) and only one systematic review (Kirtschig et al., 2003) on the
treatment of MMP. Most information concerning the treatment of MMP has
arisen from case series and non-randomized clinical trials (Kirtschig et al.,
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2003), perhaps reflecting the rarity of this disease when compared to other
oral mucosal (e.g. oral lichen planus) and dermatological (e.g. psoriasis)
disorders.
A wide variety of topical and systemic agents were used in an attempt to
control the oral MMP of the present group of patients. Patients with oral
lesions alone were almost always initially managed with topical
corticosteroids. If the signs did not abate or the patient experienced painful
symptoms, and/or there was extra-oral mucocutaneous involvement,
systemic agents tended to be prescribed. This approach is in accordance
with the recommendations by the First International Consensus of Mucous
Membrane Pemphigoid (Chan et al., 2002) which divided patients into low
and high- risk groups based on the sites involved. In a recent paper, Saw and
co-workers (2008) suggested a stepladder immunosuppression approach for
treatment of severe MMP disease, starting with cyclophosphamide and a
short course of oral corticosteroids followed by drugs with fewer adverse side
effects (such as azathioprine or mycophenolate) after the disease was under
control. For milder symptoms, they recommended commencing with dapsone
or sulfapyridine, stepping up to azathioprine or mycophenolate, and
progressing to cyclophosphamide if the disease persists. This regimen
resulted in partial or complete controlling of inflammation in 95% of their
patients. This recommended regimen was not applied in the present group of
patients.
It is suggested that MMP is a chronic disorder with an unpredictable course
with periods of remission and relapse (Bruch-Gerharz et al., 2007). Certainly
specialist personally indicate that patients may have a waxing and waning of
disease for extended periods, even during therapy, but there are no definitive
long-term studies assessing the behaviour of this disease. In the present
cohort, complete resolution of oral mucosal lesions was evident in just one-
third of patients. This may attributed to the high number of patients
presenting with desquamative gingivitis, which is known to respond usually
partially to topical corticosteroid (Rogers et al., 1982).
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The majority of patients with gingival involvement at the initial consultation
still had clinical lesions at the last examination. However, persistence of
these lesions does not necessarily correlate with symptoms. Accordingly,
more than 90% of patients reported absence of significant intra-oral pain at
their last review appointment.
Of the five patients presenting with solely oral mucosal lesions at first visit,
sixty per cent showed persistence of mucosal ulcerations/erosions or blisters.
In the eight patients who presented initially with combined mucosal and
gingival involvement, complete absence of clinical lesions was observed in
around 20%. Although most patients in this group who still had lesions at last
examination also had gingival lesions.
The clinical outcome of the present study does not reflect data from other
studies showing effectiveness of topical corticosteroids (Lozada and
Silverman, 1980; Lozada-Nur et al., 1994; Gonzalez-Moles et al., 2003). This
difference can be explained by the fact that the outcome measure used in the
present study did not recorded partial improvement but only presence vs
absence of gingival lesions. As a consequence patients with partial clinical
improvement of gingival MMP were not identified in our analysis.
It is thus evident that despite therapy MMP of the oral mucosa and gingivae
rarely resolves, hence any therapy being provided must at least reduce
painful symptoms and be free of adverse side effects.
In the current cohort, three patients did not require treatment. Fifty-eight
patients received topical therapies, while systemic agents were prescribed for
33 (56.9%) of them when the initial treatment failed to alleviate their
condition. Thirty-one (50%) patients had adverse side effects (ASEs), such
as malaise, gastrointestinal upset, nausea, vomiting, diarrhoea, skin rash,
candidosis, unpleasant taste, and haematological changes, including
lymphopenia and anaemia. The ASEs occurred with both topical and
systemic agents, although unsurprisingly the haematological abnormalities
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arose in patients who had been receiving azathioprine. It is important to note
that the International Consensus of mucous membrane pemphigoid (Chan et
al., 2002) seems to strongly advocate the use of systemic
immunosuppressives for the treatment of severe MMP. Suggested initial
therapy with cyclophosphamide is likely to give rise to haematological and
other significant adverse effects, yet in the present group azathioprine (a
second line therapy suggested by the consensus) caused notable adverse
effects. It would seem important that if a patient with MMP receives agents
such as azathioprine there is good communication between the oral medicine
specialist and the general medical practitioner to ensure that there is regular
and effective haematological monitoring to ensure that any adverse effects
are detected at the earliest opportunity. This high proportion of patients who
experienced ASE may be attributed to the wide variety of topical and/or
systemic agents received. It could also be due to the chronicity of the
disease, which necessitates long periods of treatment that may increase the
risk of some ASEs, such as osteoporosis and diabetes for patients receiving
systemic corticosteroids.
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4.6 CONCLUSION
The results of this study indicate that MMP affecting the oral tissue typically
manifests as recurrent oral mucosal ulceration and/or desquamative
gingivitis. The disease is chronic with symptoms and clinical signs waxing
and waning hence necessitating various treatment strategies and long-term
follow up to prevent complications.
The main limitation of the present study is its retrospective design and
associated methodological inadequacies, including differences in reporting
clinical features and outcomes, lack of a control group, and variations in
diagnostic and monitoring procedures. The establishment of a national
register for these rare disorders would help researchers and practitioners to
better understand the clinical symptoms and aetiopathology of these
diseases, resulting in earlier diagnoses and initiation of appropriate
treatment.
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Figure 4.1 Age of mucous membrane pemphigoid patients
Chapter 4 Mucous membrane pemphigoid
200
Table 4.1 Some of the larger studies in the literature that reported patients with oral MMP
GenderAuthors
(year)
Patients
No.
Age
(range) Female Male F:M ratio
Mouth Gingivae Eye Skin DIF* IIF**
Lever
(1953)
30 60
(30-84)
19 11 1.7:1 27 - 24 - - -
McCarthy
and Shklar
(1958)
15 ?
(23-75)
9 6 1.5:1 15 - - - - 20% of
patients
Shklar and
McCarthy
(1971)
85 ?
(23-75)
73 12 6:1 85 - 52 9 - -
Laskaris and
Angelopoulos
(1981)
33 ?
(43-83)
18 15 1.2:1 33 - 10 1 IgG (97%)
IgA (27%)
IgM (12%),
C3 (73%),
fibrin (39%)
36% of
patients
Laskaris et al
(1982)
55 66
(43-80)
33 22 1.5:1 55 35
(63%)
12
(21.8%)
3 - -
Silverman
(1986)
65 59
(19-82)
47 18 2.6:1 65 94% 7 (11%) 0 Positive in
81%
-
Gallagher and
Shklar
(1987)
120 ?
(20-90)
105 15 7:1 100% 100 % 95.3 % 10 - -
Mobini et al
(1998)
29 55
(35-76)
24 5 4.8:1 29 27 0 0 Positive in
100%
0
Chiou et al
(2007)
29 NR 20 9 2.2:1 93 26 ? ? >70% ?
*DIF direct immunofluorescence, **IIF indirect immunofluorescence. NR: Not reported.
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Table 4.2 Studies reported the effectiveness of different therapeutic agents in the management of mucous membrane pemphigoid
Agent* Study Site** Dosage No of
Pt’s
Efficacy/Adverse side effects/
Comments
Triamcinolone in
orabase
Arash and
Shirin., 2008
Oral 3 times/day for
2-4 weeks
5 Effective
No adverse side effects (ASEs)
Carrozzo et al.,
1997
Oral Clobetasol (2-3
times/day)
8 Effective
Oral candidosis
Clobetasol
propionate
Gonzalez-Moles
et al., 2002
Oral Mouthwash with 10 cc
of the solution
containing 0.05%
clobetasol propionate
and 100 000 IU/cc
nystatin 3 times/day
3/30 Effective
Hirsutism?
Clobetasol with
systemic
prednisone
Carrozzo et al.,
1997
Oral Clobetasol (2-3 times/
day) prednisone (25 to
100 mg/day)
3 Effective
Insomnia, fluid retention, gastralgia and oral
candidosis
Topical/systemic
corticosteroids,
dapsone,
cyclophosphamide
plasmapheresis
Espana et al.,
2005
Multiple
mucosal
surfaces
including
oral
mucosa
- 5 Effective
Prednisone Miserocchi
et al., 2002
Mainly
ocular
1 mg/kg body
weight/day
17/61 Effective
Leukopenia, gastritis, hypertension,
myocardial infarction, transient ischemic
attack, thrombosis, bleeding, ecchymosis,
osteoporosis, bone fractures, myalgia,
myopathy, psychosis, diabetes mellitus,
Cushing face, weight change, hyper-
triglyceridemia and urinary tract infection.
* Patients may be on other agents, but we report the main one which the authors suggested to be the most effective.
** The site is mainly which reported here however, other site may be involved but to a lesser extend.
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Table 4.2 (Cont.) Studies reported the effectiveness of different therapeutic agents in the management of mucous membrane
pemphigoid
Agent Study Site Dosage No of
Pt’s
Efficacy/Adverse side effects/
Comments
Topical tacrolimus Assmann et al,
2004
Oral 0.1% ointment
twice/day
2 Effective
Transient burning sensation
Hall et al., 2003 Ocular 0.03% tacrolimus 1 Effective
No ASEs
Michel and
Gain, 2006
Ocular/ scalp 0.03%, 0.1% ointment
1-2 times/day
1 Effective
Gunther et al.,
2004
Genital 0.1% ointment 1 Effective
No ASEs
Lebeau et al.,
2004
Genital 0.1% ointment
twice/day
1 Effective
No ASEs
Poskitt and
Wojnarowska,
1995a
Multiple
mucosal
surfaces
including
oral mucosa
Oxytetracycline hydro-
chloride 500 mg twice/day
Nicotinamide (initial dose
500 mg/day)
1 EffectiveTetracycline and
nicotinamide
Kreyden et al.,
2001
Mucocu-
taneous
- 1 Effective
Tetracycline/
nicotinamide and
topical
corticosteroids
Mallon and
Wojnarowska,
1994
Mainly skin - 1 Effective
Tetracycline and
niacinamide
Sakamoto et al.,
2002
Larynx Tetracycline (1500 mg/day)
Niacinamide (1500 mg/day)
1 Effective
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Table 4.2 (Cont.) Studies reported the effectiveness of different therapeutic agents in the management of mucous membrane
pemphigoid
Agent Study Site Dosage No of
Pt’s
Efficacy/Adverse side effects/
Comments
Minocycline Poskitt and
Wojnarowska,
1995b
- - 7 Effective
Hyperpigmentation,
gastrointestinal discomfort
Minocycline and
nicotinamide
Reiche et al.,
1998
NR Minocycline (100 mg/day)
Nicotinamide (initial dose
500 mg/day)
8 Effective
Headache and nausea
(nicotinamide),
hyperpigmentation (minocycline)
Systemic
tacrolimus
Letko et al.,
2001
Ocular (8 mg/day) 6 Not effective.
Elevated BUN (Blood Urea
Nitrogen), worsening of diabetes
mellitus, anaemia, tremor
thrombocytopenia and nausea
Dapsone Miserocchi et
al., 2002
Mainly ocular 50-150 mg/day 51/61 Haemolytic anaemia,
leucopoenia, fatigue, malaise,
fever, myalgia, myopathy,
dizziness, tinnitus, skin rash, GI,
respiratory and urinary ASEs
Dapsone and
fluocinonide
(0.05%)
Ciarrocca and
Greenberg,
1999
Mainly oral 125-150 mg/day
(initial dose: 25 mg/day)
11/20 Fatigue and shortness of breath
in association with haemolytic
anaemia & methemoglobinemia
Dapsone and
triamcinolone in
orabase
Arash and
Shirin., 2008
Mainly oral 25-100 mg/day 17 Reduced haemoglobin
Dapsone and
topical
corticosteroids
Wertheim et al.,
2006
Ocular 50 mg twice/day 12 Reticulocytosis, clinically
significant haemolytic anaemia
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Table 4.2 (Cont.) Studies reported the effectiveness of different therapeutic agents in the management of mucous membrane
Pemphigoid
Agent Study Site Dosage No of
Pt’s
Efficacy/Adverse side effects/
Comments
Miserocchi
et al., 2002
Mainly
ocular
0.2 mg/kg body
weight/week
24/61 Effective
Leucopoenia, gastrointestinal, pulmonary
and neurological ASEs.
Methotrexate
McCluskey
et al., 2004
Ocular 5 to 25 mg/week 17 Effective
Fatigue, lethargy, mouth ulceration,
nausea, gingivitis, abdominal pain,
derangement of liver function test, cough,
alopecia, infection, and hot flushes.
Azathioprine Miserocchi
et al., 2002
Mainly
ocular
2–3 mg/kg body
weight/day
23/61 Effective
Leucopoenia, thrombocytopenia, fatigue,
malaise, fever, myalgia, myopathy, skin
rash and shingle, GI, pulmonary, urinary,
cardiovascular, and neurological ASEs
Cyclophosphamide Miserocchi
et al., 2002
Mainly
ocular
2 mg/kg body weight/day 15/61 Effective
Leucopoenia, thrombocytopenia,
meningitis, hemorrhagic cystitis
gastrointestinal and other urinary ASEs
Sacher et al.,
2002
Subcutaneous etanercept
(25 mg twice/week) with
prednisone (initially 60
mg/day)
1 Effective
No ASEs
Canizares
et al., 2006
Oral/
ocular
subcutaneous injections
of 25 mg/ week
3 Effective
No ASEs
Etanercept
John et al.,
2007
Eye Etanercept 50 mg/week
subcutaneously
Prednisolone tapered by
1 mg/month
1 No ASEs
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Table 4.2 (Cont.) Studies reported the effectiveness of different therapeutic agents in the management of mucous membrane
pemphigoid
Agent Study Site Dosage No of
Pt’s
Efficacy/Adverse side effects/
Comments
Infliximab Heffernan and
Bentley, 2006
Multiple
mucosal
surfaces
600 mg with additional
infusions at weeks 2 and 6
and then every 8 weeks
1 Effective
No ASEs
Rituximab Ross et al.,
2009
Multiple
muco-
cutanous
862.5 mg intravenously in
2 doses
1 Effective
Thalidomide and
topical
corticosteroids
Duong et al,
2002
Nose/
Oropharynx/
larynx & skin
100 mg/day 1 Effective
Mycophenolate
mofetil and
prednisolone
Alkali et al.,
2007
Oral 2 g/day 1 Effective
Megahed et al.,
2001
Oral/
genitalia/
skin
MMF (2 g/day) and
prednisolone (0.5-1 mg/kg
day)
3 Effective
No ASEs
Mycophenolate
mofetil and
systemic
minocycline
Salzano et al.,
2006
Oral MMF (up to 2 g/day) and
minocycline (up to 200
mg/day)
Effective
Carrozzo et al.,
2008
Oral MMF (2 g/day) and
systemic minocycline (200
mg/day)
2 Effective
No ASEs
Mycophenolate
mofetil and
dapsone
Ingen-Housz-
Oro et al., 2005
- MMF (1.5-2 g/day) 14 Effective
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Table 4.2 (Cont.) Studies reported the effectiveness of different therapeutic agents in the management of mucous membrane
Pemphigoid
Agent* Study Site** Dosage No of
Pt’s
Efficacy/Adverse side
effects/ Comments
Foster and
Ahmed, 1999
Mainly
eyes
2-3 g/kg body weight/ cycle,
divided over 3 days repeated
every 2-6 weeks
10 Effective
No ASEs
Leverkus
et al., 2002
Oral and
ocular
(1 g/kg body weight on 2
consecutive days) every 4 weeks
1 Effective
Transient arthralgia and
nausea
Sami et al.
2002a
1-2 g/kg/cycle 15 Effective
Headache, palpitation,
nausea and vomiting
Yu et al.,
2007
Oral/eye
and skin
1g/kg daily for 2 consecutive days 1 Effective but clinical
response become weaker
with time
Gürcan and
Ahmed.,
2009
Oral/
laryngeal
1-2 g/kg per cycle (a cycle
consists of the total dose divided
into 3 equal doses, each given on
3 consecutive days)
1 Effective
No ASEs
Galdos et al.,
2008
Eyes A total dose of 3 g/kg of body
weight per cycle, infused over 3
days on divided doses, repeated
every 2-10 weeks up to cycle 13
1 Effective
No ASEs
Intravenous
immunoglobulin
Mignogna
et al., 2008
Oral/eyes A total dose of 3 g/kg of body
weight per cycle, infused over 3
days on divided doses, repeated
every 2-10 weeks up to cycle 13
6 Effective
Headaches, nausea, chills,
flushing, myalgia, and fever.
Plasmapheresis/
cyclophosphamide/
prednisone
Bohn et al.,
1999
Mainly
oral
Cyclophosphamide 150 mg/day
Prednisone 50 mg/day
2 Effective
Urticaria and mild
hypotension
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Table 4.3 Referral pattern of 62 patients with mucous membrane pemphigoid
Source of referral Frequency %
General dental practitioners 15 24.2
Periodontist 12 19.4
Oral maxillofacial/oral surgeons 13 21.0
General medical practitioners 4 6.5
Ear, Nose and Throat Specialist 4 6.5
Ophthalmologist 4 6.5
Restorative dentist 2 3.2
Hospital 1 1.6
Dermatologist 1 1.6
Orthodontist 1 1.6
School of hygiene 1 1.6
Self referral 1 1.6
Unknown 3 4.8
Total 60 100
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Table 4.4 Past medical history of 62 patients with mucous membrane pemphigoid
Disorder No. %
Penicillin allergy 7 11.3
Plaster (band-aid) allergy 1 1.6
Aspirin allergy 2 3.2
Allergy
Other Allergies 13 21.0
Heart murmur 1 1.6
Hypertension 20 32.3
Angina 4 6.5
Rheumatic fever 1 1.6
Cardiovascular
Palpitation 1 1.6
Asthma 6 9.7
Allergic rhinitis 1 2.5
Sinusitis 1 1.3
Respiratory
Tuberculosis 2 3.2
Anaemia 1 1.6Haematological
Perncious anaemia 1 1.6
Diabetes mellitus 4 6.5Endocrine
Thyroid abnormalities 12 19.4
Peptic ulcer 1 1.6
Duodenal ulcer 1 1.6
Gastroesophageal reflux disease 3 4.8
Hiatus hernia 4 6.5
Inguinal hernias 1 1.6
Gastric sarcoidosis 1 1.6
Irritable bowel syndrome 2 3.2
Pancreatitis 1 1.6
Bowel obstruction 1 1.6
Gastrointestinal
tract
Indigestion 1 1.6
Visual 8 12.9
Learning disability 1 1.6
Cerebral vascular accident (CVA) 3 4.8
Meningioma 1 1.6
Central nervous
system
Recurrent headache 2 3.2
Eczema 2 3.2
Arthralgia 1 1.6
Arthritis 3 4.8
Osteoarthritis 1 1.6
Rheumatoid arthritis 2 3.2
Raynaud’s phenomenon 1 1.6
Urinary and renal problems 4 6.5
Back pain 2 3.2
Carpal tunnel syndrome 2 3.2
Sjogren's syndrome 1 1.6
Pre-cancerous lesions of cervix 1 1.6
Contact dermatitis 1 1.6
Gout 1 1.6
Hyperlipidemia 1 1.6
Laryngeal stenosis 1 1.6
Lichen Sclerosus et atrophicus 3 4.8
Ovarian cancer 1 1.6
Tinnitus 1 1.6
Vaginal soreness 1 1.6
Genital lichen planus 1 1.6
Xerosis (Dry skin) 2 3.2
Malignancy 3 4.8
Osteomyelitis 1 1.6
Others
Lupus erythematosus 1 1.6
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Table 4.5 Different therapeutic agents prescribed to patients to manage MMP
lesions before attending the Oral Medicine clinics
Drug group Drug name
No of
patients
Topical
Triamcinolone acetonide in 0.1% carmellose paste
(Adcortyl in Orabas)
11
Hydrocortisone sodium succinate (Corlan pellets) 8
Betamethasone sodium phosphate (Betnesol) 9
Betamethasone esters (Betnovate ) 1
Beclomethasone (Bectoid) 5
Fluticasone propionate (Flixonase spray) 1
Tri-adcortyl (Triamcinolone, nystatin, neomycin,
gramicidin)
1
Prednisol mouthwash 1
Other topical corticosteroids 1
Corticosteroids
Systemic
Prednisolone 8
Anti-viral
Aciclovir
Antibiotics
Metronidazole 7
Penicillin 1
Tetracycline 1
Doxycycline 1
Others (not specified) 2
Anti-fungal
Nystatin 2
Anti-infective
agents
Others (not specified) 1
Ciclosporin (mouthwash) 1Calcinurin
inhibitors Topical tacrolimus (protopic) 1
Azathioprine 4
Cyclophosphamide 1
Chlorhexidine gluconate 8
Benzydamine hydrochloride (Difflam) 9
Dapsone 5
Co-codamol Analgesics 1
Xylocaine 1
Aloclair 1
Eludril® 2
Gengigel (Hyaluronan) 2
Sulphapyridine 2
Sulphamethoxypyridazine 2
Others
Multivitamins 1
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Table 4.6 Past drug history of 62 patients with mucous membrane pemphigoid
Drug group Drug name
Calcium-channel blockers
Amlodipine
Nifedipine
Beta-adrenoceptor blocking drugs
Atenolol
Timpotol maleate
Sotalol hydrochloride
Propranolol
Diuretics
Bendroflumethiazide
Frusmaide
Angiotensin-converting enzyme inhibitors
Enalapril
Ramipril
Perindopril tert-butylamine
Nitrates
Glyceryl trinitrate
Isosorbide mononitrate
Potassium-channel activators
Nicorandil
Cardiovascular
Others
Atorvastatin (lipid-regulating drugs). Aspirin, Dipyridamole (antiplatelet)
Amiodarone (antiarrhythmic). Amiloride (potassium-sparing diuretic)
Digoxin. Doxadura (alpha-blocker). Warfarin sodium (anticoagulants)
Respiratory Albutamol (salbutamol + etofylline)
Beclometasone dipropionate (corticosteroids)
Beclomethasone dipropionate (corticosteroids)
Salbutamol (selective beta 2 agonists)
Salmeterol (Serevent) (beta 2 agonists)
Endocrine Calcichew, Calceos chewable (Vitamin D)
Hormone replacement therapy
Insulin (antidiabetic)
Repaglinide (antidiabetic)
Thyroxin (thyroid hormones)
Carbimazole (anti-thyroid drugs)
Anti-infective agents Doxycycline (antibacterial drugs)
Mupirocin (antibacterial drugs)
Acyclovir (antiviral drugs)
Topical corticosteroids Betamethasone
Betamethasone esters ( Betnovate)
Hydrocortisone sodium succinate (Corlan)
Clobetasol propionate cream
Fluticasone propionate
Triamcinolone acetonide
Urinary Detrusitol (urinary incontinence)
Tolterodine tartrate (urinary incontinence)
Tamsulosin MR (urinary retention)
Proton pump inhibitors Omeprazole, Lansoprazole
Others Acetaminophen/paracetamol (non-steroidal anti-inflammatory drug)
Azathioprine (immunosuppressant). Balmosa cream.
Benzodiazepine. Cetirizine hydrochloride (antihistamines).
Chlorhexidine (gluconate mouthwashes). Contraceptive pills
Coproxamol (dextropropoxythene and paracetamol). Dapsone.
Fenasteride (Anti-androgens). Hypromellose (tear replacement and eye
lubricants). Imipramine hydrochloride (tricyclic anti-depressants)
Iron. Ioratadine. Multivitamins. Naproxen (non-steroidal anti-
inflammatory drug). Rantidine (H2-receptor antagonists).
Sulfinpyrazone (anti-gout). Truspot eye drops. Tamoxifen (breast
cancer). 2-Amino-2-deoxyglucose (Glucosamine) antiarthritis
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Table 4.7 Presenting clinical signs of oral mucous membrane pemphigoid
in 62 patients at initial and final clinical appointment
Signs First visit Last visit
Buccal mucosa
ulceration 7 4
erosion 2 1
bullae 4 1
Lip
ulceration 0 0
erosion 0 0
bullae 0 0
Labial mucosa
ulceration 1 0
erosion 0 0
blister 2 0
Lingual
ulceration 1 3
erosion 4 0
bullae 1 0
Desquamative gingivitis 48 35
Alveolar ridge/ gingival
ulceration 10 5
erosion 5 1
blister 9 4
Soft palate
ulceration 7 0
erosion 4 1
bullae 0 0
Hard palate
ulceration 3 2
erosion 1 0
bullae 0 2
Floor of mouth
ulceration 3 0
erosion 0 0
bullae 0 0
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Table 4.8 Extra-oral involvement in this cohort of 62 patients with oral mucous
membrane pemphigoid
Site Frequency %
Skin 6 9.7
Eye 15 24.2
Pharynx 3 4.8
Larynx 2 3.2
Nasal mucosa 4 6.5
Genitalea 1 1.6
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Table 4.9 Topical agents employed to limit the signs of mucous membrane
pemphigoid of the mouth
Topical agent
No of
patients %
Fluticasone propionate 0.05% cream- Cutivate 29 46.8
Clobetasol propionate 0.05% cream - Dermovate 18 29.0
Fluticasone propionate,400 mcg in 15 ml water as mouthwash 16 25.8
Fluticasone propionate,50 mcg spray 25 40.3
Fluticasone propionate inhaler 13 21.0
Betamethasone mouthwash 40 64.5
Beclomethasone dipropionate inhaler 3 4.8
Triamcinolone acetonide in Orabase 16 25.8
Hydrocortisone pellets 2 3.2
Prednisol mouthwash 7 11.3
Fluocinolone acetonide 0.025% cream 1 1.6
Tacrolimus 0.1% ointment 17 27.4
Tacrolimus 0.03% ointment 1 1.6
Pimecrolimus 1% ointment 1 1.6
Doxycycline mouthwash 4 6.5
Ciclosporin mouthwash 3 4.8
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Table 4.10 Different systemic agents employed to limit the signs of mucous
membrane pemphigoid of the mouth
Systemic agent No of patients %
Prednisolone 11 17.7
Deflazacort 9 14.5
Azathioprine 15 24.2
Mycophenolate mofetil 11 17.7
Dapsone 23 37.1
Tacrolimus 1 1.6
Sulfamethoxypyridazine 6 9.7
Cyclophosphamide 1 1.6
Methotrexate 2 3.2
Thalidomide 1 1.6
Doxycycline 2 3.2
Nicotinamide 1 1.6
Ciclosporin 1 1.6
Minocycline 4 6.5
Intravenous immunoglobulin (IVIG) 1 1.6
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Table 4.11 Total number of topical and systemic agents employed in the management
of this cohort of 62 patients with MMP of the mouth
No of agents Topical Systemic Total number of agents
(topical & systemic)
0 3 28 3
1 9 10 6
2 12 10 6
3 15 6 13
4 9 5 10
5 6 1 6
6 2 1 6
7 1 0 2
8 2 1 2
9 2 0 2
10 0 0 0
11 1 0 2
12 0 0 2
13 0 0 0
14 0 0 1
15 0 0 1
Total number of
patients
62 62 62
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Table 4.12 Status of gingival and mucosal surfaces before and after therapy
Before therapy After therapy
27 patients (73%): persistence of lesions
9 patients (24.3%): no lesions
37 patients had gingival
lesions only
1 patient (2.7%): No gingival lesions but
developed mucosal involvement
3 patients (60%): persistence of lesions5 patients had mucosal
lesions only 2 patients (40%): no lesions
10 patients (55.6%): gingival lesions only
4 patients (22.2%): no lesions
2 patients (11.1%): mucosal lesions only
18 patients had combined lesions
(mucosal and gingivae)
2 patients (11.1%): combined lesions
(mucosal and gingivae)
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Table 4.13 Clinically apparent and patient-reported drugs reactions
Drugs involved Adverse Drug Reaction No
Systemic agents
Prednisolone Moon face 1
Vomiting 1
Diarrhoea 1
Mycophenolate mofetil
Abdominal discomfort 1
Nausea 4
Vomiting 1
Rash 1
Patient feel unwell 1
Fever 1
Sore throat 1
Headache 1
Azathioprine
Paraesthesia 1
Stomach cramp 1
Headache 1
Rash 1
Paraesthesia 1
Fatigue 1
General malaise 1
Chest infection 1
Exfoliative cheilitis 1
Dapsone
Photosensitive skin eruption 1
Headache 1Sulfamethoxypyridazine
Skin rash 1
Systemic tacrolimus and/ or deflazacort Mild indigestion 1
Thalidomide Paraesthesia 1
Minocycline Arthralgia 1
Median rhomboid glossitis 1
Topical agents
Betamethasone (Betnesol)
Pseudomembranous candidosis 2
Fluticasone propionate,50 mcg-(Flixonase) Pseudomembranous candidosis 1
Unpleasant taste 1Clobetasol propionate (Dermovat)
Oral thrush 2
Fluticasone propionate (Cutivate) Mouth soreness 1
Fluticasone propionate (Flixonase nasules) Pseudomembranous candidosis 1
Burning sensation 1Topical tacrolimus
GI upset 1
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Table 4.14 Duration of treatment of MMP patients
Number of patientsDuration (Years)
Female Male Total
< 3 19 16 35
3- < 6 8 2 10
6- < 9 5 0 5
≥ 9 9 3 12
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5.1 INTRODUCTION
Pemphigus is a group of rare, chronic, intra-epithelial, immunologically-mediated
disorders characterized by humoral immune attack of epithelial cell-adhesion
and that manifests clinically as vesiculobullous disease of the skin and/or
mucous membranes. There are many types of pemphigus; the two most
frequently observed are deep pemphigus vulgaris (variant, vegitans) and
superficial pemphigus foliaceous (variant, erythematosus). Other less common
forms include IgA pemphigus, drug-induced pemphigus, pemphigus
herpetiformis, and paraneoplastic pemphigus (Robinson et al., 1999; Yeh et al.,
2005).
5.1.1 Disease forms
5.1.1.1 Pemphigus vulgaris
Pemphigus vulgaris (PV), the most common and severe form, was considered a
fatal condition before the availability of immunosuppressive therapy. This
disorder affects both genders and can arise at any age, but is most commonly
observed in middle aged and elderly individuals. In a recent population-based
retrospective study in the UK, the median age at presentation was 71 (range: 21
to 102) years (Langan et al., 2008). Although rare in children, it has been
observed in individuals as young as 3 years (Robinson et al., 1997). As a
consequence of transplacental transfer of IgG class antibodies pemphigus
vulgaris can transiently occur in neonates of affected mothers (Shieh et al.,
2004; Fenniche et al., 2006). PV affects all ethnic groups; however it frequently
affects Ashkenazi Jewish. It has been estimated that PV is found four to 10
times more frequently among the Ashkenazi Jewish population than other
Caucasian groups (Pisanti et al., 1974; Gazit and Loewenthal, 2005; Mimouni et
al., 2008).
Pemphigus vulgaris does not typically have a familial pattern of involvement,
although there have been case reports on a familial tendency (Starzycki et al.,
1998; Gokdemir et al., 2006). In a large cohort of pemphigus patients from Iran
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(Chams-Davatchi et al., 2005), 1.5% of patients had a familial pattern. PV is
strongly associated with HLA haplotypes DRB1*0402 and DQB1*0503 (Mobini
et al., 1997; Carcassi et al., 1996; Gonzalez-Escribano et al., 1998; Lombardi et
al., 1999), thus suggesting an immunogenitic basis of the disease.
Clinical features
PV may predominantly affects the skin with minimal mucosal lesions or affect
mainly mucous membranes with little dermal involvement or it may affect both
simultaneously (Chams-Davatchi et al., 2005). Imunologically, the
mucocutaneous variant with wide spread skin involvement presents with both
anti-desmoglein 3 and anti-desmoglein 1 autoantibodies while patients with
mainly mucous membrane involvement usually have only circulating anti-
desmoglein 3 antibodies (Yeh et al., 2005).
The majority of PV patients present initially with oral involvement (Uzun et al.,
2006; Benchikhi et al., 2008). In a large cohort of 1209 patients, 62% presented
with initial lesions of the mouth, and ultimately the oral mucosa was involved in
81.5% of affected patients (Chams-Davatchi et al., 2005).
In another study 82.1% of 123 patients with PV had oral lesions before skin
involvement (Uzun et al., 2006). This increased with time to affect 116 (94.3%)
patients. Both skin and oral mucosa involvement were reported at same time by
three (2.4%) patients. Nine patients had lesions limited to the mouth (Uzun et
al., 2006).
The mean time lag between oral mucosa involvement and skin has been
reported as six months (Uzun et al., 2006). In another study, the time lag was
reported as 7.6 and 8.8 months in female and male patients, respectively (Sirois
et al., 2000).
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Oral lesions in pemphigus are characterized by flaccid blisters that rapidly
rupture in response to mechanical trauma, resulting in painful, wide areas of
erosions or irregular ulcers. The blisters usually affect the soft and hard palate,
buccal mucosa, gingivae, and lips. However in general any surface in the oral
mucosa (or gingivae) can be involved and blisters and ulcers can commence in
one area and spread to others. Because of the continuous mechanical trauma
to oral mucosa, there is often a separation between epithelium and underlining
connective tissue (positive Nikolsky sign). With therapy the oral lesions heal
slowly, usually without scarring (Yeh et al., 2003).
Gingival involvement is common in PV. In one series of pemphigus patients the
gingivae were the most commonly affected site (Iamaroon et al., 2006). Gingival
involvement leads to desquamative gingivitis characterized by diffuse erythema,
a glazed appearance, and areas of atrophy or erosions which usually resulting
in pain or discomfort. However, it should be noted that desquamative gingivitis
can be a manifestation of other disorders.
Extra-oral mucosal surfaces such as the conjunctiva, pharynx, larynx,
esophagus, rectum, and genitourinary mucosa can also be affected. In a cohort
of 148 patients from Turkey, nasal mucosa involvement was reported in 4.0% of
patients, larynx in 3.2%, esophagus in 0.8%, and conjunctiva in 1.6% (Uzun et
al., 2006).
Histopathological and immunological features of PV
In PV, autoantibodies of the IgG class attack desmosomes which leads to
acantholysis- loss of cohesion between keratinocytes in the stratum spinosum.
Characteristic Tzanck cells may be observed in the developing blisters while the
basal cell layer remains attached to the basement membrane. In pemphigus
foliaceus (PF), the autoantibodies attack keratinocytes in more superficial
layers, resulting in subcorneal separation with acantholysis.
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Immunopathologically, PV is characterized by the presence of cell-attached and
circulating IgG autoantibodies against extracellular components of desmosomal
desmoglein. There may also be a deposition of C3 (Yeh et al., 2003).
Tissue bound antibodies can be observed by direct immunofluorescence studies
of peri-lesional tissue, demonstrating that the effect of the antibodies is not
severe enough to disrupt the cell-cell attachment and produce clinical blisters.
Applied pressure can enhance the development of blisters in Nikolsky's sign
(Hameed and Khan, 1999), although this is not always unique to pemphigus.
5.1.1.2 Pemphigus vegetans
Pemphigus vegetans is a rarely diagnosed subset of pemphigus vulgaris. It
gives rise to ulceration and erosion that mimic vulgaris; however, in the healing
process hypertrophic, hyperpigmented vegetative plaques develop particularly
in the groin, axillae, neck, scalp, and mouth. The tendency for bulla formation
(e.g., of the skin) is less than that of pemphigus vulgaris. Oral involvement is
common in pemphigus vegetans (Ahmed and Blose, 1984; Markopoulos et al.,
2006; Cozzani et al., 2007). Pemphigus vegetans has two forms: Hallopeau,
characterized by pustular formation and a benign course with spontanous
remission , and the more common and aggressive Neumann form, where the
oral lesions mimic those of pemphigus vulgaris and heal with hypertrophic,
vegetating plaques (Ahmed and Blose, 1984; Downie et al., 1998; Cozzani et
al., 2007). Among 1,209 patients with pemphigus, pemphigus vegetans was
observed in 33 patients, 30 of who had the Neumann type and 3 the Hallopeau
type (Chams-Davatchi et al., 2005).
Histopathological examination of lesions of pemphigus vegetans reveals
papillomatous, proliferating, suprabasal acantholytic lesions in the epidermis, an
eosinophilic infiltrate in the dermis together with intra-epidermal microabscesses
formation. Direct immunofluorescence reveals intercellular IgG and C3 deposits
usually found in the lower layers of the epidermis while IgG class autoantibodies
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can be present in the serum (Markopoulos et al., 2006; Danopoulou et al., 2006;
Cozzani et al., 2007).
5.1.1.3 Pemphigus foliaceous
Pemphigus foliaceous (PF) is primarily a cutaneous disorder that rarely affects
the mucous membranes. Autoantibodies targeting desmoglein 1 cause
acantholysis in the subcorneal layer of epithielium, and the erosions are usually
more superficial, less severe, and less painful than that of pemphigus vulgaris.
Foliaceous and its variants may have a better prognosis than PV (Warren et al.,
2000; Uzun et al., 2006; Ishii et al., 2008a).
PF is more likely found in certain developing countries and arises at an earlier
age than pemphigus vulgaris (Bastuji-Garin et al., 1996). It is strongly
associated with DRB1*0102, 0404, 1402 or 1406 (Petzl-Erler and Santamaria,
1989; Moraes et al., 1991; Moraes et al., 1997). Histopathological features of PF
are indistinguishable from those of PV; however, the autoantibodies attack
keratinocytes in more superficial layers than in PV, resulting in subcorneal
separation with acantholysis.
There are two forms of PF: a non-endemic-pemphigus erythematosus (Senear-
Usher syndrome) and an endemic form, known as fogo selvagem. Both
conditions share the same clinical, histopathological, and immunopathological
features. Clinically, patients have facial erythematous, scaly, crusted lesions.
Other areas such as the scalp, back, and chest may be involved.
Fogo selvagem appears more prevalent in some countries (Tunisia and Peru)
(Bastuji-Garin et al., 1996; Loayza et al., 2006) perhaps reflecting an
autoimmune response to local environmental factors (Aoki et al., 2004) however
unlike other types of pemphigus this disease is characterized by a familial
tendency.
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Additionally fogo selvagem can affect patients at a younger age than those with
non-endemic pemphigus foliaceous (Chiossi and Roselino, 2001). In Tunisia
fogo selvagem characteristically affects young women without a familial pattern
and presents as the herpetiform variant (Morini et al., 1993).
Immunopathologically, PF is characterized by the presence of cell-attached and
circulating IgG autoantibodies against desmosomal desmoglein. In variant, fogo
selvagem, the antibodies are mainly of the IgG4 class. Moreover, anti-
desmoglein 1 antibodies were found to be high among resident in areas of
endemic fogo selvagem (Warren et al., 2000).
5.1.1.4 Paraneoplastic pemphigus
Paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome
(Nguyen et al., 2001) is an autoimmune disorder associated with an underlying
neoplasm that primarily affects elderly persons and may be more common in
females. Paraneoplastic pemphigus (PNP) is typically associated with malignant
process, more commonly, non-solid haematological proliferative process (e.g.
non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, Castleman's disease,
Waldenstrom's macroglobulinemia, Hodgkin’s lymphoma, and monoclonal
gammopathy). However 16% of reported patients have had PNP associated
with non-haematological malignancies (e.g., carcinoma, sarcoma, and
malignant melanoma) (Kaplan et al., 2004). In PNP there are autoantibodies
targeting desmoplakin I, desmoplakin II, bullous pemphigoid antigen, periplakin
and envoplakin (Horn and Anhalt, 1992; Kaplan et al., 2004).
Although perhaps the least common, PNP is the most serious form of
pemphigus. It presents clinically as do other types of pemphigus. Painful oral
mucosal erosions and ulcerations are found in almost all affected individuals
and can be the initial clinical manifestation. Erosions also may affect the lips,
esophagus, larynx, conjunctivae, and genitalia (Kimyai-Asadi and Jih, 2001;
Nguyen et al., 2001). Histopathologically, PNP gives rise to epidermal
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acantholysis, suprabasal cleft formation, dyskeratotic keratinocytes, and
epidermal exocytosis (Horn and Anhalt, 1992). Perivascular infiltration mainly
with lymphocytes is common, but without vasculitis (Zhu and Zhang, 2007).
Patients with cutaneous lesions present clinically with blisters/erosions on the
upper trunk, head, neck, and proximal extremities. The lesions mimic other
types of pemphigus, lichen planus, graft-versus-host disease, erythema
multiforme, and Stevens–Johnson syndrome. PNP may also present as
lichenoid eruptions, keratotic lesions on the palms and soles, psoriasiform, and
vegetative or pustular lesions (Zhu and Zhang, 2007).
The aetiopathogenesis of PNP is largely unknown; however, several
mechanisms have been postulated. The tumour cells are thought to initiate the
development of anti-epithelial humoral response that lead to the production of
autoantibodies to desmosomal and hemidesmosomal antigens (Billet et al.,
2006; Zhu and Zhang, 2007).
5.1.1.5 IgA pemphigus
IgA pemphigus is a rare subset of pemphigus mediated by IgA (as opposed to
IgG) class antibodies. Although more likely to occur in middle to late life,
children can be affected. There are two forms of IgA pemphigus, subcorneal
pustular dermatosis (SPD; also known as IgA pemphigus foliaceus) and less
commonly intra-epidermal neutrophilic IgA dermatosis (IEN; also known as IgA
pemphigus vulgaris) (Robinson et al., 1999; Heng et al., 2006). Patients usually
present with cutaneous pruritus, superficial pustules, erythema, and crusts
(Hashimoto et al., 2002).
Histopathologically, SPD gives rise to subcorneal pustules mimicking
pemphigus foliaceus with neutrophilic infiltration, while IEN shows pustular
formation in deeper layers (as with pemphigus vulgaris) and the presence of a
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neutrophilic infiltration. Acantholysis is usually present in both variants
(Hashimoto et al., 2002).
Direct immunofluorescence of SPD lesions usually demonstrates IgA bound to
superficial layers of epidermis, while IEN lesions are characterized by IgA bound
to keratinocytes throughout the epidermis (Hashimoto et al., 2002). The
antigenic target of SPD type is desmocollin 1, whereas in IEN the targets are
desmogleins 1 and 3 or desmocollin 1 (Hashimoto et al., 2002; Heng et al.,
2006), hence underlying the different clinical presentation of the 2 disorders.
5.1.1.6 Drug-induced pemphigus
A number of drugs can give rise to pemphigus-like diseases including (i)
sulfhydryl radical containing agents (e.g., penicillamine and captopril), (ii)
masked thiols that contain S molecule and can be converted to a thiol (e.g.,
penicillin), and (iii) non-thiol or other drugs (e.g., cephalosporins) (Heymann et
al., 2007).
The clinical features of drug-induced pemphigus usually mimic pemphigus
foliaceus. Eliminating the causative agent usually results in complete healing of
the lesions. However, identifying the precise causative drug can be difficult (and
hence delayed) if patients are receiving multiple drugs (Cotell et al., 2000).
5.1.2 Diagnosis
There are a number of disorders that can give rise to oral mucosal and gingival
features similar to those of PV (e.g. mucous membrane pemphigoid, erythema
multiforme) and therefore, diagnosis should be based on correlation of clinical,
histopathological, and immunofluorescence studies. Definitive diagnosis of PV
can be delayed when disease affects younger people or is restricted to oral
mucosa (Ariyawardana et al., 2005).
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Disease that solely affects the oral mucosa seems to be particularly delayed in
diagnosis, and the number of clinical consultations can be higher for oral as
opposed to cutaneous disease (4.3 versus 2.1 clinicians respectively) (Sirois et
al., 2000), possibly reflecting the clinical interests of the attending clinicians. The
delay in diagnosis can also reflecting the type of pemphigus, in a cohort of 148
patients, the mean time between disease onset and diagnosis of PV was
20 months, 27 months for PF, 10 months for PE, and much longer for PNP
(3 years) (Uzun et al., 2006).
5.1.3 Treatment
Pemphigus has the potential to be life threatening if not treated, and
occasionally patients still die as a consequence of adverse drug reactions rather
than the disease itself (Mignogna et al., 2000). A wide range of agents have
been used to control pemphigus, these being assessed in placebo-controlled
trials (Werth et al., 2008), randomized controlled trials (Ioannides et al., 2000;
Fernandes and Perez, 2001; Rose et al., 2005; Mentink et al., 2006; Beissert et
al., 2006; Chams-Davatchi et al., 2007), case series and case reports (Enk and
Knop, 1999; Mignogna et al., 2000; Sirois et al., 2000; Williams et al., 2000 ;
Ljubojevic et al., 2002; Mimouni et al., 2003a; Sheehan and Lesher, 2004;
Kawashita et al., 2005; Salmanpour et al., 2006). Treatment is directed towards
decreasing the number of circulating antibodies to achieve disease remission
and healing of lesions.
In the past, systemic corticosteroids were often the only effective agents but
there is now a substantial literature on the role of other agents including
pilocarpine gel (Iraji and Yoosefi, 2006), azathioprine (Chams-Davatchi et al.,
2007), dapsone (Heaphy et al., 2005), mycophenolate mofetil (Chams-Davatchi
et al., 2002), ciclosporin (Gergely et al., 2003), cyclophosphamide (Bhat et al.,
2005), intravenous immunoglobulins (IVIG) (Engineer et al., 2000), chlorambucil
(Shah et al., 2000) and rituximab (Cecchi and Gasperini, 2005). Some agents,
such as high doses of corticosteroids, plasmapheresis, and IVIG can induce
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clinical response rapidly, while more slowly acting agents include azathioprine,
methotrexate, and mycophenolate mofetil (Bystryn, 2002). Although there are
many therapies available, few have been assessed in well-designed
randomized clinical trials. To date no single agent or protocol is widely accepted
in the management of PV.
Researchers dealing with the treatment of pemphigus face many challenges.
Rarity of the disease and resulting limited number of patients is a major factor in
development of high quality controlled studies; a multicentre approach may be
the solution for this problem. An additional complication is the lack of widely
accepted measurements for clinical outcomes and definitions used in the
treatment of pemphigus such as remission, active disease, and relapse. A
recent consensus statement from the International Pemphigus Committee
(Murrell et al., 2008) addressed most of these issues, aiming to develop uniform
outcome measures and to initiate more multicentre controlled trials to define
effective therapies for pemphigus.
This section reviews the different treatment modalities available to treat different
types of pemphigus including PV. Generally, there have been equivocal results
of the efficacy of different agents, apart from systemic corticosteroids.
Treatment could be divided into control, consolidation, and maintenance stages,
based upon the activity of the disease (Bystryn, 2002). In the control stage,
high dose and sometimes multiple agents are used to suppress new lesion
development and induce healing. In the majority of instances, if appropriate
drugs and dosage are employed, PV usually responds rapidly to therapy. In the
second stage, the patient should continue the effective agents and dose until
most lesions have healed. In the maintenance stage, the therapeutic agents are
gradually tapered to the minimum dose effective in preventing the development
of new lesions. In all three stages, the longer the stage and/or continued
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disease activity may be an indication of either misdiagnosis or inadequate
treatment (Bystryn, 2002).
Topical corticosteroids
Topical corticosteroids are usually prescribed in addition to systemic agents to
manage and accelerate healing of persistent oral mucosal ulceration (Ben
Lagha et al., 2005; Camacho-Alonso et al., 2005). In one cohort, most of
pemphigus patients were treated with topical corticosteroid and other topical
creams (Ljubojevic et al., 2002). All patients responded favourably with
resolution of oral lesions in another cohort of 14 patient who received
triamcinolone acetonide (0.5% suspension preparations, 3 times/day) and
systemic prednisone (60 mg/day for 4 weeks). One patient necessitates the
addition of intralesional parametasone (Once every 2 weeks for 6 weeks)
(Camacho-Alonso et al., 2005).
Complete resolution of oral lesions within 2 weeks was reported in an infant
after treatment with topical application of triamcinolone in an orabase gel (Shieh
et al., 2004). Occlusive therapies with triamcinolone acetonide (Endo et al.,
2005) and dexamethasone (Robinson et al., 2004) were reported as effective
methods in managing oral lesions, especially desquamative gingivitis. However,
topical therapy is generally inadequate and systemic corticosteroids with or
without immunosuppressants is required to decrease the circulating antibodies
and control the immunological process (Mignogna et al., 2000). Candidosis is
the most common complication of long-term use of topical corticosteroids
(Thongprasom and Dhanuthai, 2008) especially with the more potent agents.
Systemic corticosteroids
Systemic corticosteroids are currently the mainstay of initial treatment of PV.
Moreover, adding an adjuvant agent significantly reduces the mortality rate
compared to corticosteroids alone (Carson et al., 1996).
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There is however no consensus on the appropriate initial corticosteroids
dosage. An initial dose of 1 to 1.5 mg/day is often suggested to be required to
produce beneficial effects and control lesions (Mimouni et al., 2003b). However,
higher doses may be needed to obtain remission and rapid healing of lesions.
Due to the chronic recurrent course of PV and the adverse effects of
corticosteroids, or if there is a poor initial clinical response, corticosteroids have
been used in combination with other immunomedulatory or immunosuppressant
agents (Mignogna et al., 2000; Bystryn, 2002), such as azathioprine (Robinson
et al., 1997), cyclophosphamide (Cummins et al., 2003), dapsone (Benchikhi et
al., 2008) or gold (Lange et al., 2006).
In a survey of 24 pemphigus experts, half of them prescribed 1mg/kg/day of
prednisone as an initial dose, while 31% and 19% prescribe 1 to 1.5 and 1.5 to
3 mg/kg/day, respectively (Mimouni et al., 2003b). In a cohort of 221 patients,
151 (68.4%) received a combination of prednisolone and azathioprine; 45
(20.3%) were prescribed prednisolone alone; and dapsone was added to
prednisolone and azathioprine for 25 (11.3%) patients (Salmanpour et al.,
2006).
In another cohort of 262 patients (mean follow-up 24.8 months), all patients
received systemic corticosteroids: 212 (80.9%) received 1 mg/kg/day and 34
(12.9%) received 1.5 mg/kg daily (Benchikhi et al., 2008). A bolus of
methylprednisolone (1 g/day for 3 days) followed by oral corticosteroids, was
given to 37 patients (14.1%). Adjuvant agents were used in 48 (18.5%) patients.
The most common was azathioprine which was prescribed to 33 patients.
Cyclophosphamide or dapsone was each taken by 15 patients. Topical
corticosteroids were prescribed to 89 patients while all patients were instructed
to use topical antiseptics. Fifty-seven (21.7%) patients were lost to follow-up.
133 patients (50.7%) had complete remission, 49 (18.7%) had partial remission,
and 23 (8.7%) had a flare-up of their disease. Seventeen (6.4%) patients died
with the most common cause of death was septicemia (Benchikhi et al., 2008).
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Fernandes and Perez, (2001) used two regimens in the treatment of 71 patients:
high (>120 mg/day) and low (<100 mg/day) doses of prednisone. There was no
significant difference between the 2 dosages in initial control of lesions.
Response to treatment was reported in 24 and 27 patients who received the low
and high prednisone doses respectively. The authors concluded that an initial
dose of 1 to 2 mg/kg/day with maximum of 120 mg/day of systemic
corticosteroids was adequate to control pemphigus lesions without increasing
mortality or morbidity.
Systemic prednisone remains the first-line treatment in the management of
pregnant women with pemphigus (Lehman et al., 2008). Prednisone may
reduce the risk of passive transmission of the autoantibodies to the fetus and as
a result minimizing the risk of neonatal PV.
A high initial dose of deflazacort (120 mg) was used in the management of 14
patients with PV (Mignogna et al., 2000). Eight patients had complete healing
within 2 to 4 weeks. The other 6 had partial or no response; however, when
these patients received azathioprine in addition to deflazacort all went into
remission within 2 to 4 weeks. In comparison with prednisone, deflazacort has a
lesser adverse effect on bone metabolism (Mignogna et al., 2000), however 10
of the 14 patients treated with deflazacort had adverse side effects such as
insomnia, mood alterations, acute psychosis, hyperglycemia, cataract, or
cushingoid (Mignogna et al., 2000).
In a randomized trial involving 33 patients, the addition of ciclosporin (5 mg/kg)
to oral methylprednisolone (prednisone equivalent, 1 mg/kg) offered no
advantage over treatment with methylprednisolone alone using different
outcome measures such as time for healing of majority of lesions, flare up on
tapering, percentage of patients in complete or partial remissions, and total dose
of systemic corticosteroids required to control disease activity (Ioannides et al.,
2000).
Chapter 5 Pemphigus Vulgaris
233
A combination of dexamethasone-cyclophosphamide pulse therapy has been
reported to be effective for PV. This regimen resulted in long-term remission and
accelerated lesions healing in addition to a shorter hospital stay (Kanwar et al.,
2002; Mahajan et al., 2005). In a multicentre randomized trial, the combination
of dexamethasone and cyclophosphamide appeared to be well tolerated and
was associated with fewer recurrences than a methylprednisolone and
azathioprine regimen (Rose et al., 2005).
However, in a randomized controlled trial with 20 patients, there was no
significant difference between patients who did or did not receive oral
dexamethasone pulse therapy (300 mg pulses/3 days/month) in addition to
prednisolone (80 mg/d) and azathioprine (3 mg/kg/day). The authors concluded
that the oral dexamethasone pulse therapy is not beneficial when used in
addition to systemic corticosteroids and azathioprine (Mentink et al., 2006).
In a study of 30 PV patients, pulse therapy (140 mg of dexamethasone
dissolved in 200 mL of 5% dextrose with 500 mg of cyclophosphamide) resulted
in asymptomatic ventricular arrhythmias in two patients and sinus bradycardia in
10 patients (Jain et al., 2005).
Clinical improvement was reported within a week in patients with severe
oropharyngeal pemphigus using pulse therapy with intravenous
methylprednisolone (30 mg/kg body weight to a maximum of 1 g for 3 to 5 days)
(Mignogna et al., 2002). It has been suggested that the effect of
methylprednisolone is due to both the up-regulated synthesis and post-
translational modification of the keratinocyte adhesion molecules (Nguyen et al.,
2004).
The use of different therapeutic agents in the treatment of PV has the potential
for adverse side effects (ASEs) particularly with systemic corticosteroids. In one
case series with 159 patients, 37 (23%) patients developed hyperglycemia, skin
Chapter 5 Pemphigus Vulgaris
234
infections reported in 26 (16%), arterial hypertension in 23 (14%),
cardiorespiratory diseases in 22 (14%) and sepsis in nine (6%) patients
(Ljubojevic et al., 2002).
Corticosteroids adjuvant agents
Because of the known ASEs of long-term systemic corticosteroid use, an
adjuvant non-corticosteroid immunosuppressive regime is often provided to
allow a lowering of corticosteroid dose (Ljubojevic et al., 2002).
However there are many problems with the use of adjuvant agents in particular
there is no definitive agent or dosage that seems to be of particular benefit.
Additionally all of the suggested immunosuppressants have the potential to give
rise to adverse side effects, some of which can be life-threatening. Furthermore,
there are no guidelines regarding how long the adjuvant agents should be used
when managing most immune-mediated disorders including PV. In the
previously cited survey, about half of physicians maintain corticosteroids
adjuvant agents for 6 to 12 months, 36% prescribed them for 1 to 2 years and
the rest for an indefinite period (Mimouni et al., 2003b).
Azathioprine
Among one group of specialists, azathioprine was the most commonly used
corticosteroid-sparing agent followed by mycophenolate mofetil,
cyclophosphamide, and ciclosporine (Mimouni et al., 2003b). Azathioprine is an
inhibitor of purine metabolism and hence may lessen the proliferation of
lymphocytes.
In a recent randomized controlled trial with 120 patients comparing four different
treatment regimens (prednisolone alone, or with either azathioprine,
mycophenolate mofetil, or intravenous cyclophosphamide pulse therapy),
systemic corticosteroid efficacy was improved with the adding of the adjuvant
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agents, azathioprine being the most effective agent in reducing the dose of
corticosteroids (Chams-Davatchi et al., 2007).
However, in a multicentre, randomized, non-blinded study, both azathioprine
and mycophenolate mofetil were reported to have the same efficacy and safety
as adjuvant agents to oral methylprednisolone (Beissert et al., 2006).
Azathioprine should be prescribed with caution in view of the risk of bone
marrow suppression, hepatotoxicity as well as risk of malignancies. It is
however suggested that azathioprine can be provided to pregnant women or
those planning to be pregnant as corticosteroid-sparing agent (Lehman et al.,
2008).
Mycophenolate mofetil
Mycophenolate mofetil (MMF) is the 2-morpholinoethyl ester of mycophenolic
acid which selectively inhibits proliferation of both T and B lymphocytes (Allison
and Eugui, 2000) resulting in suppression of both cell-mediated and humoral
immunity. MMF is a relatively recently introduced immunosuppressive agent and
hence its exact benefit in the management of pemphigus is perhaps is not as
evident as agents such as azathioprine.
In a case series of 12 relapsed pemphigus patients, MMF was prescribed as an
alternative to azathioprine as an adjuvant to systemic corticosteroids. Adding
MMF (2 g/day) to prednisolone (2 mg/kg/day) resulted in lessening the disease
of 11 patients. The remaining patient did not respond (Enk and Knop, 1999).
There have since been a number of reports suggesting the efficacy of MMF as
an effective adjuvant agent in patients with recalcitrant PV (Chams-Davatchi et
al., 2002) without (in general) major adverse drug reactions (Kawashita et al.,
2005; Sarma and Ghosh, 2007). In a case series of 31 patients with PV, MMF
was effective in lessening the clinical lesions of 67.7% patients. However, it was
less effective in the management of patients with severe wide-spread disease
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than those with limited disease (Esmaili et al., 2008). In another cohort of 42
patients treated with MMF and prednisone (median time 22 months), 27 patients
had complete healing of lesions while 5 had partial remission and 10 did not
respond. The median time to achieve complete remission was 9 months (range,
1-13 months). Eight patients had gastrointestinal ASEs, one musculoskeletal
and another had neutropenia. Two patients discontinued MMF, one because of
reversible neutropenia and the other due to nausea (Mimouni et al., 2003a).
Powell and co-workers (2003) used slightly high doses of MMF (2.5 g/day;
range from 750 mg to 3.5 g/day as appose to the typical dose of 2-3 g/day) to
control refractory pemphigus in 17 patients who also had systemic disorders
such as diabetes and ischemic heart disease. MMF had a beneficial effect for
12 of the 17 and permitted the reduction of systemic corticosteroids dose
without disease flare-up.
MMF has also been reported to be found effective for some, but not all, patients
with paraneoplastic pemphigus (Sirois et al., 2000; Williams et al., 2000;
Sheehan and Lesher, 2004).
The evidence that MMF is safe and effective means of managing PV is thus
rather mixed, and based upon small number of patients. Like azathioprine MMF
has the potential to give rise to adverse systemic effects and long-term use may
increase the risk of malignancy. This agent is more expensive than azathioprine
and required similar long-term haematological and chemical/ biochemical
monitoring.
Dapsone
By virtue of its immunosuppressive action the anti-leprotic dapsone has been
employed in the treatment of PV. Dapsone has been reported to be beneficial
when combined with oral or intramuscular corticosteroids (Mahajan et al., 2005)
or cyclophosphamide (Tirado-Sanchez and Leon-Dorantes, 2006) in the
management of PV.
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In a retrospective evaluation, eight of nine PV patients had their disease
controlled with dapsone as an adjuvant agent allowing patients to taper
corticosteroid therapy without worsening of the disease (Heaphy et al., 2005).
In a detailed literature review of 792 patients, after excluding systemic
corticosteroids, dapsone considered as a first-line oral therapeutic agent in the
management of PV (Yeh et al., 2005). In a recent randomized, double-blind,
placebo-controlled trial using dapsone in the maintenance phase of treatment of
pemphigus patients in whom corticosteroids tapering was unsuccessful, 73% of
the patients receiving dapsone were able to reduce their prednisone dosage to
≤ 7.5 mg/day while only 30 % of those receiving placebo were able to do so
(Werth et al., 2008).
There are no detailed reports of the precise benefits of dapsone therapy upon
PV limited to the oral tissue. Additionally dapsone can give rise to adverse
effects including “dapsone syndrome” following initiation of therapy and
haemolytic anaemia. As with aforementioned immunosuppressive agents
careful long-term clinical and haematological monitoring is warranted for all
patients receiving this agent.
Ciclosporin
Ciclosporin is a calcineurin inhibitor that ultimately inhibits T cell proliferation
(Beauchesne et al., 2007). There is some evidence that ciclosporin may be an
effective agent for the treatment of some, but not, all patients with PV.
A patient with B cell lymphoma who developed paraneoplastic pemphigus
partially responded to corticosteroids, cyclophosphamide, plasmapheresis, and
IVIG, was successfully treated using ciclosporin A (7 mg/kg) and all
mucocutaneous lesions healed within 6 weeks (Gergely et al., 2003).
Lieb et al. (2006) reported on a patient with PV nail lesions who did not respond
completely to cyclophosphamide (150 mg/day), gold (intramuscular
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100 mg/week), and methylprednisolone (1 g/day for 5 days) and who developed
hemorrhagic cystitis secondary to the use of cyclophosphamide, responded well
to ciclosporin 50 mg twice daily and gold (intramuscular 50 mg twice weekly)
after the flare up was controlled by methotrexate (25 mg/week).
Ciclosporin (2.5 mg/kg daily) achieved rapid resolution of PV oral ulceration in
an HIV-positive patient and circulating IgG antibodies disappeared. A later flare
up of the disease was controlled within 9 days of ciclosporin as a monotherapy
(Hodgson et al., 2003). However, ciclosporin was stopped after 6 weeks in an
HIV patient with oral PV after he exhibited fatigue, headache, and
gastrointestinal upset and was diagnosed with acute renal toxicity due to
ciclosporin interaction with hyperactive antiretrovirus therapy (HAART).
Interestingly, oral lesions completely healed (Mignogna et al., 2005).
A meta-analysis concluded there is a risk in treating patients with autoimmune
disorders with ciclosporin and recommended strict monitoring of renal function
(creatinine) and ciclosporin levels during therapy for these patients and for those
receiving ciclosporin for more than a year (Vercauteren et al., 1998).
Topical ciclosporin (100 mg in 5 mL suspension 2-3 times/ day) has been
reported to maintain remission of oral lesions of PV (Gooptu and Stoughton,
1998; Hodgson et al., 2003).
In a case report of a woman with mucocutaneous lesions whose painful oral
ulcerations did not responded to a wide verity of topical and systemic agents
such as prednisolone, azathioprine, methotrexate, dapsone, chloroquine,
cyclophosphamide, intramuscular sodium aurothionate and potent topical
corticosteroids agents (or she stopped using some of the agents due to ASEs)
responded well to topical ciclosporin (Gooptu and Stoughton, 1998).
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Cyclophosphamide
Cyclophosphamide is an alkylating agent that may be useful as an
immunosuppressant in severe immunologically-mediated disease.
Cyclophosphamide has been suggested as effective and safe in combination
with prednisolone (Bhat et al., 2005) and dexamethasone (Sehgal et al., 2005).
Pulse therapy with 100 mg dexamethasone in 5% glucose daily for 3
consecutive days in addition to cyclophosphamide (500 mg on first day followed
by 50 mg/day) achieved complete remission of pemphigus lesions (Sehgal et
al., 2005).
In an open-label clinical trial, 26 pemphigus patients who partially responded to
corticosteroids received intravenous cyclophosphamide (15 mg/kg/month) in
addition to prednisolone (1 mg/kg/day). All patients had a significant
improvement in their signs and symptoms. Cutaneous healing preceded that of
mucosa by a mean time of 1.5 months. The most common adverse drug
reaction was weight gain due to the corticosteroids (Bhat et al., 2005).
Due to the adverse side effects associated with cyclophosphamide and
methylprednisolone, some authors reserved their use to resistant patients not
responding to high doses of systemic corticosteroids (Mignogna et al., 2000).
In a randomized clinical trial with 22 patients, a dexamethasone-
cyclophosphamide regimen was found better tolerated and had more remission
periods than methylprednisolone-azathioprine therapy (Rose et al., 2005).
Within 2 years after treatment initiation, three of the 11 patients who received
dexamethasone-cyclophosphamide treatment had a complete remission while 2
had partial remission. Three patients treated by methylprednisolone-
azathioprine combination had complete remission while 6 had partial remission.
However, there were more relapses in methylprednisolone-azathioprine group
than in dexamethasone-cyclophosphamide group (Rose et al., 2005). Ablative
intravenous cyclophosphamide (50 mg/kg per day for 4 days) without stem cell
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rescue was shown to be relatively safe in treating a patient with oral and skin PV
that had been recalcitrant to other agents (Hayag et al., 2000).
Similar to other immunosuppressants cyclophosphamide therapy warrants close
clinical and haematological monitoring, probably in view of the risk of bone
marrow suppression and haemorrhagic cystitis (Mukhtar and Woodhouse,
2010).
Other therapeutic regimes
Chlorambucil
Chlorambucil is an alkylating agent that been used to treat patients with chronic
lymphocytic leukemia. It also has been employed in the treatment of some
immune-mediated disorders such as nephrotic syndrome and bullous
pemphigoid (Milligan and Hutchinson, 1991; Chave et al., 2004; Hodson et al.,
2008). There is a very limited report on chlorambucil efficacy in the
management of PV. A retrospective study reported that 6 of 9 patients
prescribed chlorambucil had a lessening of their mucocutaneous disease (Shah
et al., 2000). However, the patients also received concurrent prednisone and
thus the clinical effect may have reflected the corticosteroids. Three of the 9
patients developed haematological abnormalities including pancytopenia,
lymphopenia, and thrombocytopenia (Shah et al., 2000).
Intravenous immunoglobulin
The efficacy of intravenous immunoglobulin (IVIG) in the management of PV
was reviewed by Engineer et al., (2000) who reported that it is safe and effective
in the treating recalcitrant PV, but, long-term outcome data are not available yet.
Guidelines have been suggested for the use of IVIG in the treatment of
pemphigus (Akerman et al., 2005).
At least 3 cycles of IVIG with a minimum dose of 2 g/kg is reported to induce
clinical remission of PV recalcitrant to other regimens (Engineer et al., 2000);
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however, clinical improvement may not arise until the sixth cycle (Baum et al.,
2006). Complete remission may be as high as 50% (Baum et al., 2006).
Intravenous immunoglobulin therapy is expensive and should only be provided
by appropriate specialists. There is little place for such therapy for disease
limited to the oral mucosa and there seems to be no studies of the benefit of
IVIG upon such clinical presentations.
Rituximab
Rituximab is a monoclonal antibody that binds to CD20- positive cells (pre-B
and mature B lymphocytes) resulting in their lysis. It does not affect the CD20-
negative plasma cells that may produce autoantibodies PV (Belgi et al. 2006;
Niedermeier et al., 2006) hence clinical benefit may be delayed.
A recent review indicates that rituximab may be of application for the treatment
of PV (El Tal et al., 2006). Most of the reported patients (88%) had resolution of
disease following rituximab therapy, although one patient died as a
consequence of opportunistic infection (El Tal et al., 2006). All 11 patients of
another study (Ahmed et al., 2006) responded well to rituximab between the
third and sixth infusion. Nine (82%) of the patients had rapid healing and a
remission period of 22 to 37 months. The other two patients (18%) had
recurrence 6 months after the tenth infusion of rituximab. Both had complete
remission after receiving additional rituximab infusions alone (once a week for 3
consecutive weeks); however, one had another flare-up and received another
rituximab infusion (once a week for 3 consecutive weeks) which resulted in
complete remission (Ahmed et al., 2006).
Rituximab therapy is expensive and requires carful clinical monitoring in view of
the risk of adverse side effects (e.g. systemic infection, infusion reactions).
There are few reports of rituximab therapy for PV limited to the oral tissue (Arin
et al., 2005; Niedermeier et al., 2006).
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Plasmapheresis
Plasmapheresis has been suggested to be a means of providing rapid control of
severe PV in patients who have not had clinical benefit to conventional
treatment with systemic corticosteroids and other agents. Long-term remission
may be occasionally achieved (Ljubojevic et al., 2002). There are however only
small number of reports of the efficacy of plasmapheresis in the management of
PV and no studies of the benefit of this treatment modality for disease limited to
the oral tissue.
Others
The treatment of PNP clearly requires identification and management of
causative malignancy. However there may be a need for concomitant
corticosteroids/immunosuppressant therapy of the accompanying PNP
(Menenakos et al., 2007).
In conclusion, there is some evidence of the role of all aforementioned
therapeutic agents however, well designed randomized controlled studies with
good number of patients is needed to support the use of each agent in the
treatment of mucocutaneous pemphigus vulgaris lesions.
5.1.4 Outcome of pemphigus
Despite significant advances in therapy, particularly the range of potentially
effective immunosuppressants, the long-term behaviour of PV is unclear as
long-term data are often lacking. Recent studies suggesting that just over half of
all patients have complete remission, with the remainder having variable
recurrence of disease (Benchikhi et al., 2008). Mortality due to disease, or
associated therapy or unknown causes may range from 1.5 to 8.3 (Uzun et al.,
2006; Chams-Davatchi et al., 2005; Michailidou et al., 2007).
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5.2 AIMS
The aims of this chapter were to determine:
1. The clinical characteristics of a substantial cohort of patients with pemphigus
vulgaris resident in England, UK.
2. The clinical outcomes of long-term therapy of pemphigus vulgaris.
3. The frequency and nature of adverse side effects of therapy of pemphigus
vulgaris.
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5.3 PATIENTS AND METHODS
5.3.1 Patients group
The study group consisted of 40 patients referred to the Oral Medicine Unit of
UCL Eastman Dental Institute and UCLH Eastman Dental Hospital between
1975 and 2007, with clinical and usually histopathological features consistent
with the diagnosis of pemphigus vulgaris (PV).
5.3.2 Methods
The case record of each patient was examined using multiple data extraction
forms for details of demographics, past medical history, extra-oral and intra-oral
clinical features and clinical progress data. Details of diagnostic and monitoring
investigations were also systematically extracted. These included:
histopathology, full blood cell count, differential white cell count, hepatic and
renal biochemistry. Details of the different topical and systemic therapies
employed in the management of each patient were also recorded (Appendices
1-5).
Inclusion criteria
(1) evidence of erosion/ulceration/blistering of the oral mucosa with/without
extra-oral involvement, (2) histopathological evidence of intra-epithelial cleavage
and acantholysis, (3) evidence of direct immunofluorescence on mucosal/skin
biopsies of intercellular tissue-fixed antibodies (4) evidence of indirect
immunofluorescent of circulating autoantibodies to desmosomes.
In all patients at least criterion 1 and either 3 or 4 were present to assign a
diagnosis of PV.
Outcome of therapy
The outcome of therapy was evaluated for symptoms and signs separately.
Symptoms evaluation was reported as improved, presence or absence of intra-
oral pain/soreness and based on comparison between patients’ self-reported
pain/soreness status before therapy and at last review in 2007.
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The outcome of therapy (clinical signs) was analysed on the basis of the
comparison between disease status before therapy and last review in 2007
utilising 2 different methods. (i) The first one according to site of the lesion,
either gingival or mucosal, using a 2-point scoring system: (0) absence of
mucosal and/or gingival lesions and (1) presence of mucosal or gingival lesions.
(ii) The second method was a comparison between disease status (signs in
different anatomical sites) before therapy and at last review.
Evaluation of response to therapy was based on clinicians’ judgments during
clinical examination and/or upon clinical photographs when present in the
clinical notes.
Statistical analysis
The differences between females and males in relation to duration of oral
symptoms before attending to Oral Medicine Clinics and duration of the
treatment were analyzed using Student’s t-test. McNemar’s test was used to
compare symptoms and signs before and after treatment in Oral Medicine
Clinics. Descriptive and analytical statistics were undertaken using the SPSS
program (SPSS for Windows: (Statistical Package for the Social Sciences)
software, version 12.0.
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5.4 RESULTS
5.4.1 Patient demographics
Age and gender
The mean age of the patients at the time of diagnosis was 51.1 years (SD 16.4);
46.3 for males (SD 12.5) and 53.5 for females (SD 17.8). The age range was
18.8 to 95.8 years. The onset of the clinical features of disease was usually in
the fifth and sixth decade of life. There were more females (27; 67.5 %) than
males (13; 32.5%) (Figure 5.1).
Ethnic Background
The majority of patients were white British (14; 35%) (self-reported, according to
2001 UK Census) (Office for National Statistics, 2003). The second most
common ethnic group was Indian (11; 27.5%) (Table 5.3).
Tobacco use and alcohol consumption
Three (7.5%) patients were previous tobacco users and 3 were current users
with a mean number of self-reported cigarettes per day of 6.4. Twenty one
(52.5%) patient currently drank alcohol with a mean total weekly consumption of
3.2 units.
Sources of Referral to Oral Medicine Unit
Eleven (27.5%) of the patients had been referred to the oral medicine unit by
general dental practitioners; 11 by a specialist in the Oral and Maxillofacial
Surgery and the remainder by their general medical practitioner or a medical or
dental specialist (Table 5.4). The patients had been referred to oral medicine
clinics for the diagnosis and/or management of variety of oral lesions such as
desquamative gingivitis or mucosal blisters and/or ulcers.
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5.4.2 Past medical and drug histories
5.4.2.1 Past medical history
The patients had a history of a variety of common medical problems (Table 5.5),
the most common of which were allergic, cardiovascular, respiratory, endocrine,
and gastrointestinal disorders.
Five (12.5%) patients had diabetes mellitus and 4 (10%) had a history of
hypertension; 2 (5%) patients had a history of asthma and two (5%) patients
had thyroid disease. Among the gastrointestinal conditions reported were
gastroesophageal reflux disease 2 (5%) and abdominal hernia (3; 7.5%) while
others had a variety of signs and symptoms. Additional medical history details
are provided in Table 5.5.
5.4.2.2 Drug history
The patients were receiving a wide range of medications at the time of their
clinical consultation. As expected from past medical history reviewed above, the
most common drugs were anti-hypertensives, and anti-asthmatic agents. A wide
range of topical and/or systemic agents had been prescribed to present cohort
of patients to control their oral and/or mucocutaneous lesions likely due to PV
and. (Tables 5.6 and 5.7).
Triamcinolone acetonide (Adcortyl in Orabase) was prescribed to 7 (17.5%)
patients; betamethasone sodium phosphate and hydrocortisone sodium
succinate were prescribed to 6 and 5 patients, respectively. Patients also were
prescribed other preparations of topical corticosteroids, antimicrobial and/or
analgesic agents. Systemic corticosteroids (prednisolone) prescribed to 17
patients by different medical and dental specialist before attending Oral
Medicine clinics. Additional details on different agents used to control the
patients’ disease before attending Oral Medicine clinics are summarised in
Table 5.7.
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5.4.3 Presenting clinical signs and symptoms and duration of oral
symptoms
5.4.3.1 Duration of oral symptoms at first visit
The duration of oral symptoms before attending the oral medicine clinics
varied from 1 month to 26 years, with a mean of 30.9 months. Males had
a shorter duration of pre-consultation symptoms (23.1 months) compared
to females (34.2 months), however, this was not statistically significant
(P= 0.595).
5.3.3.2 Presenting clinical signs and symptoms
Intra-oral
At their clinical consultation at the oral medicine unit, most patients (38; 95%)
had symptomatic oral lesions, although 1 patient was asymptomatic at this time
and another had pain related to TMJ. A total of 151 lesions were recorded in
present cohort of patients, with a mean of 3.8 oral signs. Oral ulceration was the
most common sign: buccal ulcerations (21 patients), gingivae (18), tongue (15),
soft palate (12), floor of the mouth (6), hard palate (5), and labial mucosa (5)
(Table 5.8).
Extra-oral
Eighteen (45%) patients had a history of PV at extra-oral sites. Most of these
patients (15) had just one extra-oral site involvement, two had 2, and one had 3
extra-oral sites involved in the PV course. Skin was the most common extra-oral
site affected (17) followed by eyes (2), genitals (2), and nasal mucosa (1).
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5.4.4 Diagnostic clinical investigations
5.4.4.1 Histopathological features
Histopathological examination of peri-lesional tissue was undertaken on 26
(65%) of the 40 patients. The histopathological reports of the remaining 14
patients were not present in their clinical notes as they had been diagnosed by
other medical specialists and referred for the treatment of oral lesions.
In accordance with the clinical presentation, biopsies tended to be taken from
the buccal mucosa (12). Although specimens were also obtained from tongue
(3), labial mucosa (2), lip (1), gingivae (1), hard palate (1), soft palate (1) and
unknown site (5). Inflammatory cells were found in 22 sections. In 24 (92%) of
patients who had histopathological report, histopathological examination
confirmed or was suggestive of PV diagnosis. Intraepidermal cleavage and
acontholysis (Tzanck cells) found in most (22/26) of the tested lesional
specimens.
5.4.4.2 Immunofluorescence features
Direct immunofluorescence was undertaken on 17 biopsy specimens, of which
intercellular deposits of IgG found in (16) and C3 in (9) although one specimen
had an absence of such immune deposits. Thirty four of the 36 patients tested
for indirect immunofluorescence had circulating antibodies to intercellular
components of monkey/human epithelium substrate with a very wide range of
titres (1:10 to 1:5120).
5.4.5 Therapy
A number of different topical and systemic agents had been prescribed to
control the clinical signs of PV. Initial treatment consisted of prednisolone and
topical corticosteroids. Patients who required long-term therapy also received
adjunctive agents such as azathioprine, dapsone or methotrexate. Topical
agents included different preparations of fluticasone propionate, clobetasol
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propionate, and betamethasone and other topical agents (Table 5.9). Due to the
long periods of using potent topical corticosteroids, some patients receive
multiple courses antifungal agent, either to treat or prevent candidosis.
Thirty nine patients (97.5%) received topical therapies and 37 (92.5%) systemic
agents. The mean number of topical agents prescribed was 2.9, while the mean
number of systemic agents was 3.3 (5.8 and 5.9). Initial systemic therapy
usually consisted of a moderate dose of prednisolone (60 mg/day; range 20-80
mg/day) with/without adjunctive agent such as azathioprine (1-3 mg/kg per day).
Additional details about systemic therapies and number of agents in Tables 5.10
and 5.11.
5.4.6 Outcomes of therapy
The mean duration of treatment in this cohort of PV patients was of 4.8 years
(median 3.5 years). Most of patients responded well to treatment.
5.4.6.1 Symptoms
Asymptomatic 2Asymptomatic 2
Pain/discomfort 0
Absent/improved 28Pain/discomfort 38 Pain/discomfort 10
Figure 5.2 Patients’ symptoms at initial visit (left side) and at last visit (right
side).
Of this group of PV patients, 2 were asymptomatic at initial presentation and
remain pain-free when last examined in oral medicine (median duration of follow
up was 3.5 years).
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Most patients (38; 95%) had symptoms (pain, discomfort, soreness or burning)
at initial consultation and 28 of this group (73.7%) had self-reported lessening or
cessation of the symptoms at the end of the treatment.
5.4.6.2 Clinical signs
i Analysis of clinical outcome according to site
Of the 19 patients who had solely oral mucosal lesions without gingival
involvement at the initial consultation, ten (52.6%) patients had complete
healing of oral ulcerations at the last review. Six (31.6%) patients showed
persistence of mucosal ulcerations/erosions or blisters while two patients
developed combined mucosal and gingival lesions and another developed
gingival lesions alone.
Of the 15 patients who presented initially with combined mucosal and gingival
lesions, complete absence of clinical lesions was observed in seven (46.7%)
patients. Combined gingival and mucosal lesions persisted in five patients
(33.3%), while 3 patients present at last review with just oral mucosal lesions.
Of the three patients presenting with solely gingival lesions at their first oral
medicine consultation, two showed healing of gingival lesions but one
developed mucosal ulceration. The third patient also developed mucosal with
the gingival lesions. There were no apparent lesions in three patients who
attend for consultation at oral medicine clinics. In general, half (21/40; 52.5%) of
patients had complete absence of clinical lesions at last review (Table 5.12).
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ii Analysis of clinical outcome according to signs and sites
Desquamative gingivitis:
Absent 26Absent 27
Present 1
Absent 7Present 13
Present 6
Figure 5.3 Status of patients with regards to desquamative gingivitis at initial
visit (left side) and at last visit (right side).
Twenty-seven patients (67.5%) were free of desquamative gingivitis at initial
presentation and only one had developed gingival features of pemphigus by the
end of the study period.
The number of patients with desquamative gingivitis fell from 13 to 7 within the
observation period, but this was not statistically significant (P= 0.07).
Buccal mucosa ulceration
Absent 15Absent 20
Present 5
Absent 18Present 20
Present 2
Figure 5.4 Status of patients with regards to buccal mucosa ulceration at initial
visit (left side) and at last visit (right side).
Twenty patients were free of buccal mucosa ulceration at their initial
presentation; however, 5 of them developed ulcers at this site by the end of the
study.
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Twenty patients had buccal mucosa ulceration at their initial presentation but
only 2 still had ulcers at this site at the end of the treatment. This change was
statistically significant (P= 0.01).
Buccal mucosal erosions
Erosions in buccal mucosa were observed in 6 patients at their initial
consultation, which resolved in 4 of them by the end of the study period. None of
the 34 patients who presented initially without erosions developed any lesions at
the buccal mucosa.
Soft palate
Absent 27Absent 29
Present 2
Absent 10Present 11
Present 1
Figure 5.5 Status of patients with regards to soft palate ulcerations at initial visit
(left side) and at last visit (right side).
Most patients (29) were free of soft palate ulceration at their initial presentation;
however, 2 developed ulcers at the end of the study.
Eleven (27.5%) patients had ulceration of the soft palate at their initial clinical
presentation but only 1 still had ulcers of this site at the end of the observation
period. This change was statistically significant (P= 0.039).
Seven patients with previous erosions at the soft palate had had resolution by
the end of the study period which one patient who had no erosions had
developed lesions at soft palate at the end of the observation period.
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Hard palate
One of the 5 patients who had ulceration of the hard palate at their initial
consultation still had ulceration at the end of observation period while two
patients with previous erosions at the hard palate had resolution of disease at
this site.
Floor of the mouth
Six patients had ulceration of the floor of the mouth at their initial presentation to
oral medicine and all were free of ulcers at this site at the end of treatment. Only
one patient who was free of floor of the mouth ulceration developed ulcers at
this site by the end of the study. Also, another patient developed new erosions
at floor of the mouth at the end of the study while, 4 patients had their erosions
resolved at the end of the study.
5.4.7 Adverse drug reactions
The mean number of agents prescribed to patients was 6.1 (2.9, 3.3 were the
mean numbers of topical and systemic agents respectively). Thirty nine (97.5%)
patients received topical agents and 37 (92.5%) received systemic agents. 20
patients had adverse side effects (ASEs) such as malaise, gastrointestinal
upset, nausea, vomiting, diarrhoea, cushingoid appearance, skin rash,
candidosis and unpleasant taste, and haematological changes such as
lymphopenia and haemolysis.
Eight patients had one ASE, 9 had two, 2 had three and 1 had 4 ASEs. 19 of the
37 patients on systemic agents developed 29 ASEs events; while 7 of the 39
patients who received topical agents developed 7 ASEs events.
Most adverse effects in this cohort of PV patients were associated with
azathioprine. It was prescribed to 24 patients; adverse effects developed in 9 of
these patients including nausea (4 patients) and vomiting (2), diarrhoea (1), skin
rash (1) , headache (1) lymphopenia (2) and abnormalities in liver enzymes (1).
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Prednisolone was prescribed to 28 patients; adverse effects developed in 7
patients including dyspepsia (1), osteoporosis (1), hypothalamic-pituitary-
adrenal (HPA) axis suppression (1), diabetes (2), cataract (1), moon face and
cushingoid appearance (3). Deflazacort was prescribed to 18 patients; adverse
affects developed in 3 patients including, irritability and morning waking,
diabetes, and osteoporosis.
Five patients on topical corticosteroids had ASEs including candidosis, and
blurred vision. Some patients on topical tacrolimus had burning sensation or
peppery taste. More details about adverse drug reactions in table 5.13.
5.4.8 Duration of treatment
In this cohort of PV patients, treatment duration differed greatly, ranging from a
few months to more than 25 years (until data collected). The mean length of
therapy was of 4.8 years (SD 5.2). Men had a longer treatment duration (mean,
5.9 years) than women (mean, 4.3 years), however, this was not significant (P=
0.374) (Table 5.14).
Thirty patients remain under the care of the oral medicine unit. Three have been
discharged as they were asymptomatic, while three referred to other units for
follow-up. One patient failed to attend and the other (3 patients) died. The
cause of death of these 3 patients is unknown but unlikely to reflect PV or its
treatment.
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5.5 DISCUSSION
Although pemphigus vulgaris (PV) has the potential to adversely affect the
patient’s quality of life (Paradisi et al., 2009), there are few data on the long-term
behaviour or effective therapy for this condition.
Pemphigus vulgaris is a rare disease that gives rise to oral and other
mucocutaneous blistering and ulceration (Murrell et al., 2008). Oral involvement
gives rise to recurrent, sometimes extensive ulceration and pain, which can
result in dysphagia, dysarthria and poor dietary intake, all of which can
adversely affect quality of life. In the present study PV was typically diagnosed
in middle to late life (mean age of onset, 51.1 years) and predominantly affected
females, a finding reported by others (Robinson et al., 1997; Ljubojevic et al.,
2002; Chams-Davatchi et al., 2005; Iamaroon et al., 2006; Shamim et al., 2008).
The female-to-male ratio (2.1:1) was higher than that reported in some studies
(Ljubojevic et al., 2002; Chams-Davatchi et al., 2005; Kavusi et al., 2008), but in
agreement with other reports (Tallab et al., 2001; Sirois et al., 2000; Iamaroon
et al., 2006). PV rarely affects children (Laskaris and Stoufi 1990; Robinson et
al. 1997; Harangi et al., 2001; Chams-Davatchi et al. 2005a) and there was only
one teenage patient (18 years of age) in the present cohort.
In the present cohort, White-British and Asian-Indian were the most common
ethnic backgrounds (35% and 27.5%, respectively), the remaining 37.5%
represented by other ethnic groups. This distribution reflects that of general
London population in 2001 census (Office for National Statistics, 2003) and
does not indicate any ethnically-oriented predisposition. PV had been reported
in patients from many parts of the world such as US (Woldegiorgis and Swerlick,
2001), Brazil (Chiossi and Roselino, 2001), UK (Langan et al., 2008), Greece
(Michailidou et al., 2007), Morocco (Benchikhi et al., 2008), Israel (Mimouni et
al., 2008), Saudi Arabia (Tallab et al., 2001), Iran (Salmanpour et al., 2006),
India (Kumar, 2008), and Japan (Ishii et al., 2008a) and other countries (Alsaleh
et al., 1999; Goon and Tan, 2001; Iamaroon et al., 2006; Budimir et al., 2008);
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however, a predominance of Ashkenazi Jewish patients has been suggested in
some studies (Pisanti et al., 1974; Gazit and Loewenthal 2005).
The mean duration of symptoms before patients attended the oral medicine
clinics was 30.9 months, suggesting that mild symptoms, misdiagnosis, oral
lesions treated by other medical specialists (e.g., dermatologists), or delay in
referral, are likely to have occurred in a significant number of patients. This
delay in diagnosis of PV and other vesiculobullaous disorders is not uncommon
(Uzun et al., 2006; Ariyawardana et al., 2005) as mouth ulcers are common and
may be diagnosed as one of the more common oral diseases, such as
recurrent aphthous stomatitis (Daneshpazhooh et al., 2009) or oral lichen
planus. Although males had a shorter duration of pre-consultation symptoms
(23.1 months) compared to females (34.2 months), this was not statistically
significant and probably not of clinical relevance.
The clinical features of PV often resemble those of mucous membrane
pemphigoid and other vesiculobullaous disorders. In the present study, PV gave
rise to recurrent bout of ulcers that typically affected multiple oral mucosal sites.
In the majority of patients, the disease was characterised by mild onset and
lesions were usually localized. The buccal mucosa and gingivae were the most
affected intraoral sites, as previously reported (Robinson et al., 1997; Shamim
et al., 2008; Iamaroon et al., 2006). Desquamative gingivitis was observed in 13
patients. This condition may also present in other immunological-mediated
disorders, commonly mucous membrane pemphigoid and lichen planus (Leao et
al., 2008), which may lead to delay in an accurate diagnosis.
Approximately half of the patients in present cohort had a history of clinical and
histopathological evidence of PV at extra-oral sites, with the skin being the most
common. Oral lesions usually preceded other mucocutaneous lesions and were
the sole manifestation in most cases. However, this observation should be
interpreted with caution, as there may be a referral bias since as this was study
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carried in an oral medicine unit. However, other studies support the observation
that oral disease may be the first and/or only manifestation of PV (Robinson et
al., 1997; Shamim et al., 2006).
The diagnosis of PV should base on clinical, histopathological, and
immunological results. Most of the available biopsies (22/26; 84.6%) of the
present cohort showed the characteristic supra-basal intraepithelial cleft of PV.
Direct immunofluorescence revealed intercellular deposits of IgG and C3
throughout the epidermis in approximately 94% of the tested specimens, which
is in agreement with previous studies (Sano et al., 2008). Thirty-four of the 36
patients who underwent indirect immunofluorescence examination had
circulating antibodies to intercellular components of monkey/human epithelium
substrate with titre ranging from 1:10 to 1:5120. Although the levels of
circulation anti-epithelial antibodies have been reported to be associated with
the patient’s clinical condition in one study (Sams and Jordon, 1971), other
reports have not found this correlation (Judd and Lever, 1979; Judd and Mescon,
1979) or has observed that this association was inconsistent throughout the
course of PV (Acosta et al., 1985). In the present cohort, the titre of circulating
antibodies tended to decrease in response to treatment and sometimes
reflected the clinical course of the disease.
There are few randomised controlled trials (RCTs) (Mentink et al., 2006;
Ratnam et al., 1990; Rose et al., 2005; Tabrizi et al., 2007; Werth et al., 2008)
and only one systematic review (Martin et al., 2009) of the treatment of
pemphigus. Most information concerning the efficacy of therapies has come
from case series and non-randomized trials. A recent Cochrane review (Martin
et al., 2009) identified 11 RCTs for the treatment of pemphigus. However, the
authors concluded that there is insufficient evidence to provide clear guidelines
for the treatment of this disorder.
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An initial dosage of systemic corticosteroids of 60 to 80 mg/day (typically of
prednisone) is often recommended (Robinson et al., 1997). Most
recommendations for the treatment of PV have been based on cohort studies
and attending clinician experience (Harman et al., 2003). The daily dose being
gradually reduced or increased by increments of 10 to 20 mg daily until optimum
dose is established. However as noted above there is evidence-based protocol
for the treatment of PV.
The cutaneous blisters, erosions, and ulcers can be portal of entry for infection
and ultimately septicemia which can result in death. It is thus essential to initiate
therapy in the early stages of the disease to induce remission and to reduce the
dosage of corticosteroids as quickly as possible to avoid associated adverse
side effects (Bystryn, 2002). A wide range of corticosteroids-sparing
immunosuppressant agents are available to control PV, but most of them have
not been evaluated by well-designed RCTs (Bystryn, 2002).
In the present study, a variety of topical and systemic medications were used to
control the oral lesions. Patients usually received an initial dose of prednisolone
(20 to 80 mg) or deflazacort (18 to 42 mg) with or without azathioprine (25 to 50
mg three times daily) the corticosteroids being maintained at the initial dose for
2 to 3 weeks, to suppress new ulcer formation and induce lesion healing.
Prednisolone (or deflazacort) was usually prescribed as a single dose taken in
the early morning to minimise adverse side effects (ASEs). The treatment
usually continued until most lesions had healed and symptoms resolved. Some
authors (Lever and Schaumburg-Lever, 1984) have recommended higher doses
of prednisolone than those used in the present group of patients while others
(Chams-Davatchi and Daneshpazhooh, 2005) used moderate to high doses (1-
2 mg/kg). In a randomised trial, there were no long-term significant differences
between high- (120 mg/day) and low-dose (60 mg/day) prednisolone regarding
frequency of flare ups or complications (Ratnam et al., 1990). In the present
cohort, as with other patients receiving systemic corticosteroids, administration
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of systemic prednisolone was usually gradually reduced to the minimum
effective dose, concomitant with the use of topical agents. In severe cases
which necessitated long periods of systemic corticosteroid therapy, an
adjunctive agent such as azathioprine (25-50 mg 3 times/day) was usually
prescribed when prednisolone therapy was initiated, since these agents
generally require several weeks to become effective (Bystryn, 2002). Also other
adjunctive agents such as dapsone or methotrexate were used in present
cohort. Nearly all the patients received topical agents, commonly topical
corticosteroids, including high potency agents such as clobetasol propionate, to
accelerate oral mucosal healing.
Some patients may be prescribed a gastric mucosal protectant (e.g. proton
pump inhibitors) to help avoid gastric ulcers aiming to decrease the potential
gastrointestinal adverse side effects of corticosteroids. Other patients
undergoing long-term systemic corticosteroid treatment may be, referred for
bone scans and, based on the results, may receive vitamin D supplements to
decrease adverse effects, such as osteoporosis. Some of the present group of
patients received antifungal therapy to treat candidal infections which developed
as an ASE of the topical corticosteroids. All patients were monitored for weight
and blood pressure.
The clinical outcome of treated PV patients that of the mouth is not well
documented this may be as a result of lacking a widely, reproducible and
objective outcome measuring system for recording oral mucosal diseases.
In the present cohort, complete resolution of oral mucosal lesions was evident in
about half of the patients, and there was a trend of decreased severity in those
patients who did not response completely to therapy (Data not shown).
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About half of the 19 patients with only oral mucosal lesions and no gingival
involvement at the initial consultation had complete healing at the last
examination. Six patients showed persistent mucosal ulcerations/erosions or
blisters, while two patients developed combined mucosal and gingival lesions
and another developed gingival lesions alone.
Of the 15 patients who presented initially with combined mucosal and gingival
lesions, complete resolution of the clinical lesions was observed in seven
(46.7%); gingival and mucosal lesions persisted in five patients (33.3%); and
three presented with just oral mucosal lesions at the last examination.
Two of the three patients presenting with solely gingival lesions at their first visit
showed healing of gingival lesions, but one developed mucosal ulceration. The
third patient developed mucosal lesions.
The high number of patients who did not have complete remission may reflect
the study being at oral medicine unite, a specialised (tertiary) care centre and it
may be that patients with probably severe disease are referred to this unit as
evident by the majority of patients being referred by specialists.
In the current cohort, 39 patients received topical therapies, while systemic
agents were prescribed for 37 patients. Twenty patients reported ADRs,
including malaise, gastrointestinal upset, nausea, vomiting, diarrhoea,
cushioned appearance, skin rash, candidosis and unpleasant taste sensation,
and haematological changes such as lymphopenia and haemolysis. This high
proportion may be attributed to the wide variety of topical and/or systemic
agents they received. It could also be due to the chronic nature of these
diseases, which necessitates long periods of treatment that may increase the
risk of some ADRs, particularly osteoporosis and diabetes in patients receiving
systemic corticosteroids. In present study, morbidity and mortality in pemphigus
vulgaris patients was higher than MMP (Chapter 4).
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5.6 CONCLUSION
The present data confirm previous studies that PV is a chronic disease most
frequently occurs in women and affected patients usually in their middle
decades of life. Most of the patients present initially with oral mucosal lesions
where general dental practitioner may have a role in early diagnosis. Therapy is
complex although adverse side effects are more likely with azathioprine. The
main limitation of the present study is its retrospective design and associated
methodological inadequacies, including differences in reporting clinical features
and outcomes, lack of a control group, and variations in diagnostic and
monitoring procedures. The establishment of a national register for these rare
conditions would help researchers and practitioners better understand the
clinical symptoms and aetiopathology of these diseases, resulting in earlier
diagnosis and initiation of appropriate treatment.
Chapter 5 Pemphigus Vulgaris
263
Age profile of sample
0
1
2
3
4
5
6
7
8
10
_1
9
20
_2
9
30
_3
9
40
_4
9
50
_5
9
60
_6
9
70
_7
9
80
_8
9
90
_9
9
Age-group
N
um
be
r
of
pe
op
le
Female
Male
Figure 5.1 Age of this cohort of pemphigus vulgaris patients
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Table 5.1 Some of the larger studies in the literature that reported patients with oral pemphigus
Oral mucosal
involvementFirst
author/Year Country
No of
Pts Female Male
F:M
ratio Age (range) Prevalence Incidence
Initial Total
Mortality
rate
Kumar/2008 India 13 9 4 2.3 ? (25-82) - 4.4 per
million
- - -
Budimir/2008 Croatia 15 10 5 2:1 ? (20-95) - - 40% 87% -
Ishii/2008a Japan 55 37 18 2.1 55.3 (15-83) - 5 new
cases/year
21 28 -
Benchikhi/2008 Morocco 262 171 91 1.9 47 (18–90) - - 69/111
(62%)
- 6.4%
Mimouni/2008 Israel 155 ? ? 1.5:1 - - - 88 - -
Michailidou/
2007
Greece 129 88 41 2.25:1 ? (30-83) - 0.8 per
100,000
99.3% - 2.3
Heymann/2007 Iseael 363 192 171 1.1:1 49.8 (?) - 5.3 per
100,000
- - -
Iamaroon/2006 Thailand 18 12 6 2:1 37.7 (18-55) - - 100% - -
Salmanpour/
2006
Iran 221 126 95 1.33:1 38 (12-93) - 0.67 per
100,000
59.3% - -
Chams-
Davatchi/2005
Iran 1209 717 492 1.5 42 (4-82) - 110 750
(62%)
978 6.2%
Mahajan/2005 India 54 29 25 1.16:1 ?(10-95) - - 6.81% 63.6% 0
Uzun/2006 Turkey 148 85 63 1.3 43 (11–85) 1.46 per
100,000
0.24 per
100,000
104 116 4.8
Ljubojevic/ 2002 Croatia 203 126 77 1.6:1 53 (19-89) - - 31% - -
Chapter 5 Pemphigus Vulgaris
265
Table 5.2 Different pemphigus types in some published studies and the results of immunofluorescent studies
No of patients withFirst
author/Year
Total
No of pt PV PF P veg. P ery. PNP Drug-
induced
P herp. PIgA
DIF IIF
Budimir/2008 15 15 0 0 0 0 0 0 0 - -
Kumar/2008 13 10 2 0 1 0 0 0 0 8 -
Ishii/2008a/b 55 28 15 2 3 4 0 3 0 55 51
(93%)
Benchikhi/2008 262 111 15 20 116 0 0 0 0 - -
Mimouni/2008 155 145 9 0 0 1 0 0 0 - -
Michailidou/2007 129 129 0 0 0 0 0 0 0 - -
Salmanpour/2006 221 194 20 7 0 0 0 0 0 - -
Chams-
Davatchi/2005
1209 1111 89 33 0 0 2 0 4 93% 78%
Mahajan/2005 54 44 8 1 1 0 0 0 0 - -
Uzun/2006 148 123 13 1 6 1 0 0 0 - -
Ljubojevic/2002 203 154 30 5 13 0 0 0 1 89% 77%
PV= pemphigus vulgaris, PF= pemphigus foliaceous, P veg.= pemphigus vegetans, P ery.= pemphigus erythmatosus;
P herp.=pemphigus herpetiformis, PNP= paraneoplastic pemphigus, P IgA= IgA pemphigus
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Table 5.3 Ethnicity of pemphigus vulgaris patients
Ethnic group Frequency %
White British 14 35
Asian-Indian 11 27.5
Other White 7 17.5
Asian-Pakistani 1 2.5
Asian-other Asian 1 2.5
Chinese 1 2.5
Black-Caribbean 1 2.5
Black-African 1 2.5
Other ethnic group 3 7.5
Total 40 100
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Table 5.4 Referral pattern of pemphigus vulgaris patients
Source of referral No. %
General dental practitioners 11 27.5
Oral maxillofacial/oral surgeons 11 27.5
General medical practitioners 5 12.5
Dermatologist 6 15.0
Hospital 1 2.5
Periodontist 1 2.5
Ear, Nose and Throat specialist 2 5.0
Missing data 3 7.5
Total 40 100
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Table 5.5 Past medical history of patients with pemphigus vulgaris
Disorder No. %
Penicillin allergy 4 10.0Allergic
Other allergies 4 10.0
Hypertension 4 10.0
Ischemic heart disease 1 2.5
Cardiovascular
Cardiac arrhythmia 1 2.5
Asthma 2 5.0
Hay fever 1 2.5
Respiratory
Recurrent pneumonia 1 2.5
Haematological Sickle cell disease 1 2.5
Diabetes mellitus 5 12.5Endocrine
Thyroid disorders 2 5.0
Gastroesophageal reflux disease 2 5.0
Hernia 3 7.5
Crohn's disease 1 2.5
Irritable bowel syndrome 2 5.0
Constipation 3 7.5
Gastritis 1 2.5
Diverticulitis 2 5.0
Gastrointestinal
Jaundice (transient) 1 2.5
Visual 6 15.0
Hearing 1 2.5
Epilepsy 1 2.5
Viral meningitis 1 2.5
Central nervous
system
Psychiatric illness 2 5.0
Migratory arthralgia 1 2.5
Arthritis 1 2.5
Osteoarthritis 4 10.0
Psoriatic arthritis 1 2.5
Rheumatoid arthritis 1 2.5
Raynaud’s disease 1 2.5
Osteoporosis 1 2.5
Ill-defined dermatitis 1 2.5
Finger dislocation 1 2.5
Vertigo 1 2.5
Malaria as child 1 2.5
Ill-defined back pain 1 2.5
Ankylosing Spondylitis 1 2.5
Cutaneous lichen planus 1 2.5
Others
Human Immunodeficiency Virus Infection 1 2.5
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Table 5.6 Past drug history of patients with pemphigus vulgaris
Drug group Drug name No ofpatients
Calcium-channel blockers
Amlodipine 1
Nifedipine 1
Beta-adrenoceptor blocking drugs
Bisoprolol Fumarate 1
Co-tenidone 1
Timolol Maleate 1
Diuretics
Bendroflumethiazide 1
Frusmide 1
Angiotensin-converting enzyme inhibitors
Losartan potassium 1
Ramipril 1
Perindoprid 1
Others
Doxazosin (alpha-adrenoceptor blocking) 1
Warfarin sodium (anticoagulants) 1
Cardiovascular
Digoxin (cardiac glycosides) 1
Beclomethasone dipropionate (corticosteroids) 1Respiratory
Salbutamol (selective beta 2 agonists) 2
Thyroid hormones
Thyroxin 1
Antidiabetic
Insulin 1
Metformin 1
Tolbutamid 1
Vitamin D
Calceos chewable 1
Adcal-D3 1
Calcichew 4
Endocrine
Others
Contraceptive pills 1
Rantidine (H2-receptor antagonists) 2
Sulfasalazine (aminosalicylates) 1
Lansoprazole (proton pump inhibitors) 1
Gastrointestinal
Omeprazole (proton pump inhibitors) 2
Amoxicillin 1Antibacterial
Clarithromycin 1
Topical
Betamethasone 5
Clobetasol propionate 1
Fluticansone propionate (flixonase spray) 2
Rimexolone eye drops 1
corticosteroids
Systemic
Prednisolone 17
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Table 5.6 (Cont.) Past drug history of patients with pemphigus vulgaris
Drug group Drug name No ofpatients
Mycophenolate mofetil (antiproliferative) 5
Azathioprine (antiproliferative) 4
Mrthotrexate (antimetabolites) 3
Topical tacrolimus (calcineurin inhibitors) 2
Sirolimus 2
Immunosuppressants
and immunomodulator
agents
Ciclosporin (calcineurin inhibitors) 1
Vitamin B-12 2
Folic Acid 2
Cyanocobalamin 1
Ferrous Sulphate 1
Hydroxocobalamin 1
Potassium chloride 1
Nutrition and blood
Iron supplements 1
Timoptol maleate (beta-blockers) 1Agents used for the
treatment of glaucoma Travatan (prostaglandin analogues) 1
Alendronic acid 4Bone metabolism
Risedronate sodium 1
Acetaminophen (paracetamol) 2
Chlorhexidine gluconate mouthwashe 2
Others
Metoclopramide hydrochloride (drugs used in
nausea and vertigo)
1
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Table 5.7 Different agents prescribed to patients to control their PV lesions before
attending oral medicine clinics
Drug group Drug name No ofpatients
Topical
Triamcinolone acetonide (Adcortyl in Orabas 7
Beclomethasone (Bectoid) 1
Betamethasone sodium phosphate (Betnesol) 6
Budesonide 1
Clobetasol propionate (Dermovate) 1
Fluticasone propionate (Flixonase spray) 2
Hydrocortisone sodium succinate (Corlan pellets) 5
Other topical corticosteroids 3
Systemic and intravenous
Prednisolone 17
Corticosteroids
Intravenous corticosteroids 1
Anti-viral
Aciclovir 1
Antibiotics
Amoxicillin 1
Co-amoxiclave 1
Doxycycline 1
Flucloxacillin 1
Metronidazole 3
Tetracycline 1
Others (not specified) 7
Anti-fungal
Miconazole 2
Nystatin 4
Anti-infective
agents
Others (not specified) 1
Ciclosporin (mouthwash) 2
Ciclosporin (systemic) 1
Calcinurin
inhibitors
Topical tacrolimus (protopic) 1
Others Azathioprine 4
Methotrexate 4
Mycophenolate mofetil 4
Dapsone 2
Thalidomide 1
Sirolimus 1
Intravenous immunoglobulin 1
Gold 1
Aspirin 1
Bonjela® 1
Carbenoxolone 1
Chlorhexidine gluconate 4
Benzydamine hydrochloride (Difflam) 4
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Table 5.8 Clinical signs of patients with oral pemphigus vulgaris at initial and
final clinical appointment
Signs First visit Last visit
Buccal mucosa
ulceration 20 7
erosion 6 2
bullae 3 0
Lip
ulceration 4 1
erosion 2 0
bullae 0 0
Labial mucosa
ulceration 5 2
erosion 3 1
blister 1 0
Lingual
ulceration 15 9
erosion 8 2
bullae 0 0
Desquamative gingivitis 13 7
Alveolar ridge/ gingival
ulceration 5 1
erosion 1 1
blister 0 0
Soft palate
ulceration 11 3
erosion 7 1
bullae 2 1
Hard palate
ulceration 5 1
erosion 2 0
bullae 1 0
Floor of mouth
ulceration 6 1
erosion 4 1
bullae 0 0
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Table 5.9 Topical agents employed to limit the signs of pemphigus vulgaris of
the mouth
Topical agent No %
Betamethasone mouthwash 30 75.0
Fluticasone propionate,50 mcg spray 18 45.0
Fluticasone propionate,400 mcg in 15 ml water as mouthwash 15 37.5
Triamcinolone acetonide in Orabase 10 25.0
Fluticasone propionate 0.05% cream- Cutivate 9 22.5
Clobetasol propionate 0.05% cream - Dermovate 8 20.0
Fluticasone propionate inhaler 8 20.0
Prednisol mouthwash 4 10.0
Beclomethasone dipropionate inhaler 1 2.5
Hydrocortisone pellets 1 2.5
Fluocinolone acetonide 0.025% cream 2 5.0
Tacrolimus 0.1% ointment 7 17.5
Tetracycline mouthwash 1 2.5
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Table 5.10 Different systemic agents employed in the management of 40 patients with
pemphigus vulgaris
Systemic agent No %
Prednisolone 28 70.0
Deflazacort 18 45.0
Intravenous methylprednisolone 4 10.0
Azathioprine 24 60.0
Mycophenolate mofetil 18 45.0
Dapsone 5 12.5
Tacrolimus 3 7.5
Sulfamethoxypyridazine 1 2.5
Cyclophosphamide 4 10.0
Methotrexate 4 10.0
Thalidomide 1 2.5
Intravenous immunoglobulin (IVIG) 5 12.5
Colchicine 2 5.0
Ciclosporin 3 7.5
Sirolimus 3 7.5
Rutiximab 2 5.0
Infliximab 1 2.5
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Table 5.11 Total number of topical and systemic agents employed in the
management of 40 patients with pemphigus vulgaris
No of agents Topical Systemic Total
0 1 3 0
1 11 4 2
2 8 11 4
3 8 6 4
4 6 7 3
5 3 3 9
6 1 2 3
7 0 3 3
8 1 0 4
9 0 0 3
10 1 1 1
11 0 0 0
12 0 0 1
13 0 0 0
14 0 0 1
15 0 0 1
16 0 0 1
Total number of
patients 40 40 40
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Table 5.12 Status of gingival and mucosal surfaces before and after therapy
Before therapy After therapy
6 patients (31.6%): persistence of lesions
10 patients (52.6%): no lesions
1 patient (5.2%): no mucosal lesions but
developed gingival lesions
19 patients had mucosal lesions only
2 patients (10.5%)had combined lesions
(mucosal and gingivae)
3 patients (20.0%): buccal mucosa lesions only
7 patients (46.7%): no lesions
15 patients had combined lesions
(mucosal and gingivae)
5 patients (33.3%): combined lesions
(mucosal and gingivae)
1 patient (33.3%): patient had
combined lesions (mucosal and gingivae)
1 patient (33.3%): no lesions
3 patients had gingival lesions only
1 patient (33.3%): no gingival lesions but
developed mucosal involvement
3 patients did not have any lesions 3 patients did not have any lesions
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Table 5.13 Clinically detected and patient-reported drugs reactions
Drugs involved Adverse Drug Reaction No ofPts
Systemic agents
Dyspepsia 1
Osteoporosis 1
Adrenal suppression 1
Diabetes 2
Cushingoid appearance 3
Prednisolone
Cataract 1
Deflazacort Irritability and morning waking 1
Diabetes 1
Osteoporosis 1
Mycophenolate mofetil Nausea 1
Diarrhoea 1
Abdominal discomfort 2
Skin rash 1
Azathioprine Nausea 4
Vomiting 2
Diarrhoea 1
Headache 1
Rash 1
Dapsone Lethargy/unwell 1
Sulfamethoxypyridadin Skin rash 1
Methotrexate Nausea 1
Rituximab Sever malaise and fatigue 1
Ciclosporin Gingival hyperplasia 1
Candidal infection 5
Topical agents
Topical corticosteroids
Blurred vision 1
Topical tacrolimus Burning sensation 1
Peppery taste 1
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Table 5.14 Duration of treatment of pemphigus patients
Duration (Years) Number of patients
< 3 19
3 - < 6 10
6 - < 9 5
> 9 6
Total 40
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General discussion
Painful oral mucosal disease can adversely affect the ability to speak, eat and
swallow, and ultimately can lessen quality of life (Hegarty et al., 2002; Rozycki
et al., 2002). Additionally disorders that also affect the profile of the lips or face
(e.g. orofacial granulomatosis) have the potential to cause patient
embarrassment and upset, particularly if they arise in children or young adults.
In the last two decades there have been significant advances in relation to oral
medicine. The clinical skills of specialists in oral medicine have potentially
widened as a consequence of the introduction of medical training (at least in the
UK), the establishment of international societies (e.g. the European Association
for Oral Medicine), and workshops (e.g. the World Workshop in Oral Medicine),
the establishment of new specialised journals (e.g. Oral Disease and Oral
Oncology) and the availability of therapies may collectively have enhanced the
ability to improve the patients care. Against this background there remain few
detailed studies of the effectiveness and safety of contemporary oral medicine
practice for the management of common oral mucosal disorders or at least
disorders that are commonly seen in oral medicine clinics in the developed
world.
The present series of studies has sought to retrospectively determine if the
clinical care of large groups of patients with well defined oral mucosal diseases
is effective and safe. The study included groups of patients with oral lichen
planus, mucous membrane pemphigoid, pemphigus vulgaris and orofacial
granulomatosis as these are amongst the major immunologically-mediated
disorders that affect the mouth. Potentially malignant and malignant diseases
were not included as their management (generally) does not involve solely non-
surgical therapies and indeed certainly with respect to epithelial dysplasia there
is a paucity of data on the most effective means of managing these disorders
(Lodi and Porter, 2008).
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Immune-mediated disorders (IMDs) are usually characterized by persistent or
recurrent oral mucosal ulceration/erosions. Oral lesions may precede, follow or
occur simultaneously with other mucocutaneous involvement. In most of the
disorders discussed in the present study, patients had oral mucosal involvement
before other mucocutaneous sites; however, this may represent referral bias as
patients with other mucocutaneous involvement were most probably referred to
other specialist units such as dermatology, ophthalmology or gynaecology.
In addition to oral mucosal lesions, many IMDs can give rise to lesions of other
areas such as the conjunctival and genital mucosa and skin. A careful
examination of the patient’s medical history with specific questioning about
potential affected sites is important, as many patients may have undiagnosed
involvement in other sites. Many studies reporting on dental and oral cohorts do
not include proper extra-oral examination and this means they are most likely
underreported (Bidarra et al., 2008). In the present cohort, many patients
referred by oral medicine specialists to other medical specialists were found
eventually to have extra-oral involvement suggesting that reports in the
oral/dental literature may underreport non-oral involvement of IMDs.
Prevalence
The prevalence of IMDs that affect the oral mucosa is largely unknown.
However the true prevalence has been suggested to be higher than that
suggested previously in published papers as some patients may be
asymptomatic (e.g. reticular oral lichen planus). There are few well structured
published papers detailing the prevalence of these disorders, however (as noted
above) they may be complicated by the referral bias as they are conducted on
selected groups of patients. There is little population-based research to
determine the true prevalence of these disorders, and usually there are
methodological problems to such studies. At present it would seem that
orofacial granulomatosis (OFG), mucous membrane pemphigoid and
pemphigus vulgaris are not as common as oral lichen planus or recurrent
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aphthous stomatitis, but it is evident that specialists in oral medicine are treating
more patients with these diseases (e.g. OFG). This may reflect a true increase
in the prevalence of these disorders, an increasing recognition of them by
primary care provider or a reflection of improved referral systems between
different specialised units. The establishment of a national and international
register for these rare disorders would help researchers and practitioners to
better understand the clinical features and prevalence of these diseases,
resulting in earlier diagnoses and initiation of appropriate treatment (although
there are some in some countries (e.g. Italian Group for Epidemiologic
Research in Dermatology)).
The present study explored aspects of the clinical presentation and behaviour of
4 disorders:
Oral lichen planus (OLP)
Lichen planus is the most common mucocutaneous disorder that can affect the
oral mucosa and OLP is one of the most common chronic immunologically-
mediated oral mucosal diseases (Mignogna et al., 2005). It represents one of
the most challenging disorders that oral medicine physicians have to manage on
a regular basis (Mignogna et al., 1998; Mignogna et al., 2005; Gonzalez-Moles
et al., 2003). The results of the present study indicate that symptomatic OLP
remains difficult to manage. Tacrolimus is not superior to topical corticosteroids,
and malignant transformation is rare with topical corticosteroids and/or
tacrolimus.
Orofacial granulomatosis (OFG)
The present study has confirmed that onset of OFG is characterised by facial
swelling in only half of the patients whilst in the other half early disease gives
rise to intra-oral or neurological manifestations only. Mucosal cobblestoning,
gingival enlargement and other intra-oral mucosal changes are more common
than oral ulceration. The long-term behaviour of OFG is characterised by
Chapter 6 General discussion
283
development of further clinical manifestations with most patients developing
orofacial swelling and/or intra-oral ulceration. The response of OFG to therapy is
typically remitting but some improvement of tissue swelling and oral ulceration
can be achieved in most of patients. Complete remission of facial swelling is
possible in about half of patients within 36 months of therapy but may be
achieved quicker when intra-lesional corticosteroids are used. Intra-oral
ulceration is usually less responsive. Significant adverse side effects are rarely
observed and spontaneous remission may occur in only a few patients.
Mucous membrane pemphigoid (MMP)
The results of this study indicate that MMP affecting the oral tissues typically
manifests as recurrent oral mucosal ulceration and/or desquamative gingivitis.
The disease is chronic with symptoms and clinical signs waxing and waning
hence necessitating various different treatment strategies and long-term follow
up to prevent complications.
Pemphigus vulgaris (PV)
The present data confirm previous studies that PV is a chronic disease of
middle age most frequently affecting women. Most of the patients present
initially with oral mucosal lesions. Management is challenging and necessitates
topical and systemic therapy which may be associated with adverse side
effects.
It is evident that treatment of such disease is likely to be long-term and does not
lead to complete resolution of any of the investigated disorders. Additionally
while major adverse side effects are not common, probably as a consequence
of the predominant use of topical corticosteroids, such effects are possible with
systemic agents, notably azathioprine. The need for such long-term therapy
together with the requirement to change therapies frequently suggest that there
needs to be a drive to develop more effective therapies and/or adopt new
generation agents such as the anti-TNF-α agents or other newly recombinant
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biologically-active agents for the potential treatment of IMDs that affect the oral
mucosa. However although there have been small numbers of reports of the
use of such agents for the treatment of such disease (Hegarty et al., 2003;
Cardoso et al., 2006; Heffernan and Bentley, 2006) there remain no published
well-designed RCTs for such clinical application. In addition the new biologically
active agents are costly, necessitate detailed clinical monitoring and carry a risk
of significant adverse side effects (e.g. risk of reactivation of tuberculosis with
anti-TNF-α agents). Another potential therapeutic avenue would be to develop
systems that permit delivery of conventional (e.g. corticosteroids) or new (anti-
TNF-α) agents to the site of immunological attack (perhaps particularly for oral
lichen planus and orofacial granulomatosis).
At present there are no studies that definitively demonstrate that adhesive
agents such as carmellose (Orabase®) truly improve the clinical effectiveness of
any corticosteroids used for oral mucosal disease. In the light of the advances in
biomaterials and nanoparticles it would be hoped that formulations be
developed that permit controlled release of immunologically active agents at the
site of oral mucosal disease.
Most of the studies on therapeutic agents used to manage IMDs of the oral
mucosa have comprised small patient groups; as a result, the management of
such diseases is largely based on clinical experience not controlled research.
There is a need for more detailed, well-designed studies to provide high quality
evidence on the efficacy of different treatment plans and different therapeutic
agents. One problem with implementing such research is the limited number of
patients that attend individual clinical units, as well as the high cost of
developing appropriate protocols and trial designs. Nevertheless well-planned
multicentre randomised, double-masked, placebo-controlled clinical trials are
now warranted to evaluate the effect of different agents and therapeutic
protocols used in the management of different IMDs of the oral mucosa.
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The extent of the oral mucosal ulceration/erosions (measured in mm) and pain
levels have been the main outcome measures in most published papers (Nolan
et al., 2009; Mousavi et al., 2009). Measuring disease activity and response to
treatment is one of the most challenging issues in patient management.
However, there is no widely used reproducible and objective scoring system for
recording symptoms or signs of oral mucosal diseases (Piboonniyom et al.,
2005) which can assist practitioners in determining effective patient
management. The importance of developing a reliable scoring measure for
clinical trials of oral mucosal disorders was highlighted in a Cochrane review
(Chan et al., 2000).
It is not difficult to assess the outcome of recurrent aphthous stomatitis in terms
of duration of ulcers, length of interval between episodes and ulcer size.
However, it is more difficult to determine the outcome and estimate the
response to therapy of PV, MMP, OLP and OFG since, as noted above; there
are no widely accepted reliable outcome measures that can capture the
changes in clinical features. There have been some efforts to design tools to
overcome this obstacle. Some of these were clinician-centred (Thongprasom et
al., 1992; Piboonniyom et al., 2005) others were patient-centred (Slade and
Spencer, 1994; McGrath and Bedi, 2001) and some combined both approaches
(Escudier et al. 2007). However, those scoring systems are used mainly in
prospective studies, not in routine patient examinations as clinicians may find it
difficult and time consuming. Hence, there is a need to develop simple and
reliable scoring measure that can be employed in daily clinical practice to record
signs and symptoms of different oral mucosal diseases.
There is an urgent need to establish the effects of oral mucosal diseases upon
the quality of life (QoL) of affected individuals. A number of tools such as the
oral health impact profile (OHIP) (Slade and Spencer, 1994) and the oral health
related quality of life (OHQoL-UK) (McGrath and Bedi, 2001) are available.
However these QoL measures have been used mainly in clinical trials and it will
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take considerable time before they are implemented as part of routine patient
management. A simple scoring system, such as well-known visual analogue
scale (VAS), is a valuable aid to assessing pain if it is recorded at every clinical
examination but it does not provide an indication of how much the patient oral
and systemic health is being affected by the oral disease.
The development and implementation of a universally accepted, simple,
objective, reproducible and reliable scoring system that incorporates aspects of
quality of life is essential to enable clinicians and researchers to compare the
results of different studies, assess the efficacy of different therapeutic agents,
and measure disease activity. In addition this may help to establish guidelines
for follow-up intervals.
Patient education is crucial in the management of IMDs of the oral mucosa as
most of the relevant disorders are chronic, requiring long periods of treatment
and follow-up. Sources include the attending clinician, support groups, internet
sites and brochures. Detailed information on clinical presentation, diagnosis,
treatment options and prognosis should be provided as well as information on
the presumed increased risk of cancer either from the disease (e.g. OLP) or
treatment (e.g. topical tacrolimus and immunosuppressants) and more general
advice on tobacco smoking cessation, alcohol consumption, maintaining a
healthy diet, and regular review by a general dental practitioner. The chronic
nature of IMDs that entitles long-term treatment with a number of different
topical and systemic agents should be emphasized, including the potential
adverse side effects. For example, patients on long-term systemic
corticosteroids should be informed of the small risk of adrenal cortex
hypofunction and the importance of informing always their physicians and
dentists about their medication.
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Limitations of the present study
The main limitation of the present study is its retrospective design and the
associated methodological inadequacies. Hence, the results must be interpreted
with caution. Although retrospective studies are less expensive and time
consuming than prospective studies and can cover extended periods and often
used to report rare diseases they might be limited by bias, lack of agreement on
exclusion and inclusion criteria, incomplete data, differences in reporting clinical
features and outcomes, variations in diagnostic and monitoring procedures and
definition of some terms (e.g. remission, flare up and therapeutic response).
One of the problems in conducting the present study was the diagnostic criteria.
A definitive diagnosis is important in determining patient eligibility for enrolment
in a specific study. However, definitive diagnosis can be difficult for patients as
they may present with some, but not all, of the defined criteria. For example,
some authors (Williams et al., 1991) considered oral Crohn’s disease, as a
component of OFG while others do not (Gibson, 2000; Sanderson et al., 2005).
Missing data are one of the main limitations with reported trials including the
present study. Important information such as treatment dosage, social and/or
drug histories and adverse side effects were not found in all the examined
patients’ notes in the present study. This may be due to recall bias or
incomplete record keeping by the attending clinical team.
A standardized method of reporting signs and symptoms during routine clinical
reviews is important to obtain maximum benefit of a patient’s observations, as
these are a useful source of information when evaluating long-term outcomes
and the efficacy of different therapies. Clinicians should include clear and
complete information on dosage, form and preparation, and duration of the
therapeutic agents provided at every treatment stage in each patient chart.
Patient records should also contain all clinical, histopathological, serological,
and haematological test results. A clear clinical charting of the mucosal lesions
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utilizing one of the available previously published, even invalidated systems,
should be included. The present study demonstrates the need to establish a
simple, widely accepted standardized scoring system to record the oral lesions
of IMDs which will improve patient’s evaluation and to determine the efficacy of
the therapy.
As with other aspects of patient management, there are no guidelines on which
diagnostic test or how regular the monitoring investigation should be undertaken
and these decisions are currently made by the attending clinician. In addition,
laboratory test results, as evident in the present study, vary considerably in
terms of the range of normal values and how they are reported. This is not
unexpected, as these tests are administered over long periods of time and may
be processed by different laboratories. This situation makes it difficult to
compare and interpret data, even within the same patient cohort. It is possible
that all test results could be recorded using computer software which could
automatically be updated as new data is directly uploaded to the patient’s
electronic record and presented as an updated graphic.
Homogeneity of reported data is important for analyses of information from
different studies. Various methods of reporting signs and symptoms and
different follow-up intervals make it difficult to compare studies, even those
describing the same disease or therapeutic agents. As noted above, there is a
need to uniformly define terms such as relapse, flare-up, disease extent,
disease activity and resolution and therapeutic response. Recently a consensus
on pemphigus terminology has been published (Murrell et al., 2008) which could
perhaps be generalized and used in other similar disorders.
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Conclusions
There are many challenges in the management of IMDs of the oral mucosa.
Most of these disorders affect patients in middle to late life and may be
complicated by existence of other diseases which may increase the burden of
overall disease, influence quality of life and increase the risk of drug
interactions. However therapeutic outcomes have improved over the past few
decades due to pharmaceutical advances expanding the armamentarium
available to clinicians. Nonetheless, as this thesis illustrates, there are still
several areas of controversy regarding the diagnosis and management of IMDs.
The results of this present study indicate that the treatment of IMDs of the oral
mucosa is challenging to patients and their attendant clinicians. While many
patients do experience an improvement in their disease status, many do not.
The impact of their oral disease upon their quality of life and activities of their
daily living are not known. There is thus much to be done to improve the
management of immunologically-mediated oral mucosal diseases.
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APPENDIX 1
Demographic/general data
UCL Eastman Dental Institute
Oral Medicine
Outcomes of therapy of immunologically-mediated diseases of the oral mucosa study
Contact No. First visit to OM:
D.O.B Last visit to OM:
Gender: Male Female Provisional diagnosis:
Post Code: Final diagnosis:
Marital Status:
Single
Divorce
Unknown
Married
Widow/Widower
Method of Diagnosis:
Blood Clinical
Histopath. (date):
Occupation: …………………………………
Ethnicity (2001 Census Class): Smoking: Yes No Past smoker
………………………………… Start: Stop:
Chief Complaint Duration of smoking Yrs
Date of first episode Type: Cig. Cigar Chew
Pipe
…………………………………
Cig/ Day:Pt. referred from:
GDP
OMF
Other (specify):
GP
Dermatologist Alcohol: Yes No Past user
Referral date: Start Stop
Cause of referral: Units/week:
Diagnosis (on referral): Other Habits:
Lesions detected by:
Patient GP GDP
Others (Specify):
Pt discharge from OM:
Yes No
Diagnosed by: Reason for discharge:
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APPENDIX 2
Clinical Features:
1. Oral lichen planus:
Extra-oral signs and symptoms:
Are there any lesions other than oral lesions? Yes No In Past
Site: Type: Duration:
Which involved first? Oral Skin (Others)
How long it takes to involve the second site:
Date Yes Note
Right Anterior Triangle
Right Post Triangle
Left Anterior triangle
Left Post Triangle
Tender
Cervical
lymphadenopathy
Not specify
Skin
Nails
Genitals
Other
Intra-oral signs and symptoms:
Type of OLP Reticular Papular Plaque-like
Erosive Bullous Ulcerative
Site Yes Note
Right
Left
General distribution
Bilateral
UpperLips
Lower
Upper labial mucosaLabial mucosa
Lower labial mucosa
Right buccal mucosaBuccal mucosa
Left buccal mucosa
Dorsum
Lateral border
Tongue
Ventral surface
Labial/buccal
Lingual/palatel
Gingival involvement
(Desquamative
gingivitis) Not specify
Alveolar ridge
Soft Palate
Hard Palate
Not specify
Near restoration
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2. Orofacial granulomatosis
Visit 1 2 3 4 5 6 7 8
Date
Cervical
lymphadenopathy
Oral ulcers
Desquamative
gingivitis
White/lichenoid
lesions
Atrophy
Erosion
with
stimuli
Pain
without
stimuli
Soreness/burning/
discomfort
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3. Mucous membrane pemphigoid/pemphigus vulgaris
Date
Cervical lymphadenopathy
U =Ulceration, E =Erosion/Ery., B = Blister U E B U E B U E B U E B U E B
Right
Buccal mucosa Left
Upper
Lips Lower
Upper
Labial mucosa Lower
Dorsum
Lateral bordersTongue
Ventral
Labial/buccal
Lingual/palatelDesquamative
gingivitis
Not specify
Alveolar ridge/other gingival
problems
Soft palate
Hard Palate
Floor of the mouth
O
ra
lU
lc
er
at
io
n/
E
ro
si
on
/B
lis
te
r
Not specify
Asymptomatic/Pain/Soreness/ Burning/
Discomfort/Same/Improved/worse
Others
P = Present I = Improved W = Worse
N = Not recorded A = Absent
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APPENDIX 3
Past medical and social histories
Operations
Serious illnesses
Hospital admissions
Allergies eg: penicillin, aspirin, plaster, other
Medical
Corticosteroids: current or within 1 year
Heart disease
Hypertension
Cardiac surgery
Endocaraditis
Rheumatic carditis
CVS
Other
Asthma
Bronchitis
TB
Resp.
Other
Bleeding disorders
Sickle cell disease
Leukemia
Haem.
Other
Diabetes
Thyroid
Endo.
Other
Hepatitis
Jaundice
Peptic ulcer
Celiac disease
Crohn's disease
Ulcerative colitis
GIT
Other
Sight or hearing problems
Epilepsy
Strokes
Parkinson's
Psychiatric problems
Dementia
Spasticity
Learning disability
CNS
Other
Renal
Urinary
Sexually transmitted disease
HIV
GU/ Immu.
Other
Social Family history
Skin diseaseDerm./other
Other conditions
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APPENDIX 4
Past drug history
Drugs at first visit Date Comments
Therapeutic agents prescribed by other health care professionals to control disease
Drug Specialty Effectiveness Comment
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Therapeutic agents prescribed for present cohort of patients
Fluticasone Propio.
(Cutivate)
Clobetasol (Dermovate)
Fluticasone propionate
400
Fluticasone propio.
(flixonase) 50 mcg
Flixotide Nebules
Betamethasone
Beclomethasone Diprop.
(Bectoide)
Adcortyl
Tri-adcortyl
Hydrocortisone
Intralesional triamcin.
Aceto.
1
Prednsol MW
Tacrolimus 0.03%2
Tacrolimus 0.1%
Pimecrolimus 1%
Ciclosporin
3
TO
P
IC
A
L
M
E
D
IC
A
TI
O
N
S
O
Total Topical Med/Pt
Prednisolone
4
Deflazacort
Azathioprine5
Mycophenolate mofetil
Dapsone6
Sulphamethoxypyridazine
S
YS
TE
M
IC
M
E
D
IC
A
TI
O
N
S
O
Total Systemic Med/Pt
Total Med/Pt
1. Topical corticosteroids 5. Antiproliferative immunosuppressants
2. Aminosalicylates 6. Antileprotic drugs
3. Calcineurin Inhibitors O. Others
4. Systemic corticosteroids
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APPENDIX 5
Investigations
Normal Range
WBC ( 3.0 - 10.0 ) 10^9/l
RBC (3. 95-5.15) 10^12/l
HB M (13.0-17.0) g/dlF (11.5-15.5) g/dlC
B
C
PLAT. (150 - 400 ) 10^9/l
Lympho. Dif. ( 20 – 45 ) %
Lympho. Abs. ( 1.5 - 4.0 ) x10^9/l
Urea ( 1.7 - 8.3 ) mmol/L
Creatinine (66- 112 ) umol/L
Sodium ( 135 -145 ) mmol
Potass. ( 3.5 - 5.1) mmol/L
Tot. Bili ( 0 - 20 ) umol/L
ALT ( 10 - 35 ) IU/L
ALP ( 35 - 104 ) IU/L
Albumin ( 34 - 50 ) g/LR
E
N
A
L
&
LI
V
E
R
P
P
R
O
FI
LE
Globulin
Glucose ( 3.9 - 5.8 ) mmol/L
Tacrolimus < 1.5
O
TH
E
R
S
Normal Range
WBC
RBC ( ) 10^12/l
HBC
B
C
PLAT.
Lympho. Dif.
Lympho. Abs.
Urea ( ) mmol/L
Creat. ( ) umol/L
Sodium ( ) mmol
Potass. ( ) mmol/L
Tot. Bili ( ) umol/L
ALT ( ) U/L
ALP ( ) U/L
Albumin ( ) g/LR
E
N
A
L
&
LI
V
E
R
P
P
R
O
FI
LE
Globulin
Glucose (3. 9- 6 ) mmol/L
Tacro.
O
TH
E
R
S
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APPENDIX 6
Published papers and meeting presentation from this work
Published papers:
Al Johani K, Moles DR, Hodgson T, Porter SR, Fedele S. (2009) Onset and
progression of clinical manifestations of orofacial granulomatosis. Oral Dis.;
15:214-9.
Al Johani KA, Hegarty AM, Porter SR, Fedele S. (2009) Calcineurin inhibitors in
oral medicine. J Am Acad Dermatol.; 61:829-40.
Al Johani KA, Moles DR, Hodgson TA, Porter SR, Fedele S. (2010) Orofacial
granulomatosis: clinical features and long-term outcome of therapy. J Am Acad
Dermatol. 62:611-20.
Meeting presentation:
Clinical features and long-term behaviour of oral pemphigus vulgaris.
Pan European Federation (PEF IADR) - London (2008).
Clinical features and long-term behaviour of orofacial granulomatosis.
International Association for Dental Research- Toronto (2008).
Clinical features and long-term behaviour of oral mucous membrane
pemphigoid. The British Society for oral medicine- Glasgow (2008).
Efficacy and safety of topical tacrolimus in the management of oral lichen
planus. The British Society for oral medicine - London (2007).
The safety of treatment of orofacial granulomatosis and related disorders.
8th Biennial Meeting of the European Association of Oral Medicine- Croatia
(2006).
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